<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults - Stephens, G - 2016 | Cochrane Library</title> <meta content="Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults - Stephens, G - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011889.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults - Stephens, G - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011889.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011889.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults" name="citation_title"/> <meta content="Guy Stephens" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Sheena Derry" name="citation_author"/> <meta content="sheena.derry@retired.ox.ac.uk" name="citation_author_email"/> <meta content="R Andrew Moore" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD011889.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/06/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011889.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011889.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011889.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acetaminophen [adverse effects, *therapeutic use]; Administration, Oral; Analgesics, Non‐Narcotic [adverse effects, *therapeutic use]; Pain Measurement; Randomized Controlled Trials as Topic; Tension‐Type Headache [diagnosis, *drug therapy]; Time Factors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011889.pub2&amp;doi=10.1002/14651858.CD011889.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="xcg9958b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011889\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011889\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011889\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011889\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ru","pt","ms","hr","fr","zh_HANS","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011889.pub2",title:"Paracetamol (acetaminophen) for acute treatment of episodic tension\\u2010type headache in adults",firstPublishedDate:"Jun 16, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011889.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011889.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011889.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011889.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011889.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011889.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011889.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011889.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011889.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011889.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11522 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011889.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/full#CD011889-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/full#CD011889-sec-0146"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/full#CD011889-sec-0043"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/full#CD011889-sec-0044"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/full#CD011889-sec-0052"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/full#CD011889-sec-0053"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/full#CD011889-sec-0078"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/full#CD011889-sec-0140"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/appendices#CD011889-sec-0158"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/table_n/CD011889StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/table_n/CD011889StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/information#CD011889-cr-0002">Guy Stephens</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/information#CD011889-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Sheena Derry</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011889.pub2/information#CD011889-cr-0004">R Andrew Moore</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/information/en#CD011889-sec-0175">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 June 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011889.pub2">https://doi.org/10.1002/14651858.CD011889.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011889-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011889-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011889-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011889-abs-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011889-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011889-abs-0003">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011889-abs-0015">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011889-abs-0002">繁體中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011889-abs-0001" lang="en"> <section id="CD011889-sec-0001"> <h3 class="title" id="CD011889-sec-0001">Background</h3> <p>Tension‐type headache (TTH) affects about 1 person in 5 worldwide. It is divided into infrequent episodic TTH (fewer than one headache per month), frequent episodic TTH (two to 14 headaches per month), and chronic TTH (15 headache days a month or more). Paracetamol (acetaminophen) is one of a number of analgesics suggested for acute treatment of headaches in frequent episodic TTH. </p> </section> <section id="CD011889-sec-0002"> <h3 class="title" id="CD011889-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of paracetamol for the acute treatment of frequent episodic TTH in adults. </p> </section> <section id="CD011889-sec-0003"> <h3 class="title" id="CD011889-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (CRSO), MEDLINE, EMBASE, and the Oxford Pain Relief Database to October 2015, and also reference lists of relevant published studies and reviews. We sought unpublished studies by asking personal contacts and searching online clinical trial registers and manufacturers' websites. </p> </section> <section id="CD011889-sec-0004"> <h3 class="title" id="CD011889-sec-0004">Selection criteria</h3> <p>We included randomised, double‐blind, placebo‐controlled studies (parallel‐group or cross‐over) using oral paracetamol for symptomatic relief of an acute episode of TTH. Studies had to be prospective, with participants aged 18 years or over, and include at least 10 participants per treatment arm. </p> </section> <section id="CD011889-sec-0005"> <h3 class="title" id="CD011889-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed studies for inclusion and extracted data. We used the numbers of participants achieving each outcome to calculate the risk ratio (RR) and number needed to treat for one additional beneficial outcome (NNT) or one additional harmful outcome (NNH) for oral paracetamol compared to placebo or an active intervention for a range of outcomes, predominantly those recommended by the International Headache Society (IHS). </p> <p>We assessed the evidence using GRADE (Grading of Recommendations Assessment, Development and Evaluation) and created 'Summary of findings' tables. </p> </section> <section id="CD011889-sec-0006"> <h3 class="title" id="CD011889-sec-0006">Main results</h3> <p>We included 23 studies, all of which enrolled adults with frequent episodic TTH. Twelve studies used the IHS diagnostic criteria or similar, six used the older classification of the Ad Hoc Committee, and five did not describe specific diagnostic criteria but generally excluded participants with migraines. Participants had moderate or severe pain at the start of treatment. While 8079 people with TTH participated in these studies, the numbers available for any analysis were lower than this because outcomes were inconsistently reported and because many participants received active comparators. </p> <p>None of the included studies were at low risk of bias across all domains considered, although for most studies and domains this was likely to be due to inadequate reporting rather than poor methods. We judged five studies to be at high risk of bias for incomplete outcome reporting, and seven due to small size. </p> <p>For the IHS preferred outcome of being pain free at two hours the NNT for paracetamol 1000 mg compared with placebo was 22 (95% confidence interval (CI) 15 to 40) in eight studies (5890 participants; high quality evidence), with no significant difference from placebo at one hour. The NNT was 10 (7.9 to 14) for pain‐free or mild pain at two hours in five studies (5238 participants; high quality evidence). The use of rescue medication was lower with paracetamol 1000 mg than with placebo, with an NNTp to prevent an event of 7.8 (6.0 to 11) in six studies (1856 participants; moderate quality evidence). On limited data, the efficacy of paracetamol 500 mg to 650 mg was not superior to placebo, and paracetamol 1000 mg was not different from either ketoprofen 25 mg or ibuprofen 400 mg (low quality evidence). </p> <p>Adverse events were not different between paracetamol 1000 mg and placebo (RR 1.1 (0.94 to 1.3); 5605 participants; 11 studies; high quality evidence). Studies reported no serious adverse events. </p> <p>The quality of the evidence using GRADE comparing paracetamol 1000 mg with placebo was moderate to high. Where evidence was downgraded it was because a minority of studies reported the outcome. For comparisons of paracetamol 500 mg to 650 mg with placebo, and of paracetamol 1000 mg with active comparators, we downgraded the evidence to low quality or very low quality because of the small number of studies and events. </p> </section> <section id="CD011889-sec-0007"> <h3 class="title" id="CD011889-sec-0007">Authors' conclusions</h3> <p>Paracetamol 1000 mg provided a small benefit in terms of being pain free at two hours for people with frequent episodic TTH who have an acute headache of moderate or severe intensity. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011889-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011889-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011889-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011889-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011889-abs-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011889-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011889-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011889-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011889-abs-0009">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011889-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011889-abs-0016">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011889-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011889-abs-0005" lang="en"> <h3>Oral paracetamol for treatment of acute episodic tension‐type headache in adults</h3> <p><b>Bottom line</b> </p> <p>This review found that few people with two to 14 tension‐type headaches a month get good pain relief from taking paracetamol 1000 mg. There are questions about how studies of this type of headache are conducted. These questions involve the type of people chosen for the studies, and the types of outcomes reported. This limits the usefulness of the results, especially for people who just have an occasional headache. </p> <p><b>Background</b> </p> <p>People with frequent episodic tension‐type headache have between two and 14 headaches every month. Tension‐type headache stops people concentrating and working properly, and results in much disability. When headaches do occur, they get better over time, even without treatment. </p> <p>Paracetamol is a commonly used painkiller, available without prescription (over the counter) in most parts of the world. The usual dose is 1000 mg (usually two tablets) taken by mouth. </p> <p><b>Study characteristics</b> </p> <p>In October 2015, we searched the medical literature and found 23 studies involving 8079 participants looking at paracetamol for frequent episodic tension‐type headache. About 6000 participants were involved in comparisons between paracetamol 1000 mg and placebo (a dummy tablet). Results were usually reported two hours after taking the medicine or placebo. The International Headache Society recommends the outcome of being pain free two hours after taking a medicine, but other outcomes are also suggested. Few studies reported pain free at two hours or other outcomes, so there was limited information to analyse for some outcomes. </p> <p><b>Key results</b> </p> <p>The outcome of being pain free at two hours was reported by 24 in 100 people taking paracetamol 1000 mg, and in 19 out of 100 people taking placebo, meaning that only 5 in 100 people benefited because of paracetamol 1000 mg (high quality evidence). The outcome of being pain free or having only mild pain at two hours was reported by 59 in 100 people taking paracetamol 1000 mg, and in 49 out of 100 people taking placebo (high quality evidence), meaning that only 10 in 100 people benefited because of paracetamol 1000 mg. </p> <p>About 10 in 100 people taking paracetamol 1000 mg reported having a side effect, which was the same as with placebo (9 in 100 people) (high quality evidence). Most side effects were mild or moderate in intensity. No side effects were serious. </p> <p>We found a very small amount of information comparing paracetamol 500 mg or 650 mg with placebo, and comparing paracetamol 1000 mg with other painkillers. There was no difference between any of these treatments. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence was moderate or high for paracetamol 1000 mg compared with placebo, and low or very low for paracetamol 500 mg to 650 mg compared with placebo, and for paracetamol 1000 mg compared with other painkillers. High quality evidence means that we are very certain about the results. Low quality evidence means that we are very uncertain about the results. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011889-sec-0146" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011889-sec-0146"></div> <h3 class="title" id="CD011889-sec-0147">Implications for practice</h3> <section id="CD011889-sec-0147"> <section id="CD011889-sec-0148"> <h5 class="title">For people with frequent episodic tension‐type headache</h5> <p>Paracetamol 1000 mg may relieve headache pain, but the chance of the pain being relieved entirely by two hours is low, about 2 in 10 (24%), but this is only very slightly greater than the proportion who took placebo (about 1 in 5, or 19%) We do not know how or if these results can be extrapolated to people with an occasional headache. </p> </section> <section id="CD011889-sec-0149"> <h5 class="title">For clinicians</h5> <p>It may be that a different formulation of paracetamol, or a combination with a nonsteroidal anti‐inflammatory drug, or caffeine might be better, but evidence on this is lacking. </p> </section> <section id="CD011889-sec-0150"> <h5 class="title">For policy makers</h5> <p>There is insufficient information on drugs, doses, formulations, or outcomes for policy makers to be able to make strong recommendations. Policy should reflect the finding of no or little clinically useful benefit. </p> </section> <section id="CD011889-sec-0151"> <h5 class="title">For funders</h5> <p>Because of the very limited information and small degree of efficacy found for paracetamol, it is highly unlikely that the treatment could be regarded as cost effective even considering the low price of this drug. </p> </section> </section> <h3 class="title" id="CD011889-sec-0152">Implications for research</h3> <section id="CD011889-sec-0152"> <section id="CD011889-sec-0153"> <h5 class="title">General</h5> <p>Frequent episodic tension‐type headache is common and debilitating. The amount and reporting of evidence was limited by reporting issues, particularly of outcomes; this is a general finding for all TTH studies, not just those involving paracetamol. It is not sufficient just to call for more studies. What is needed is a better understanding of TTH studies, in terms of the outcomes that can be reported from clinical trials, and often are not, and the differential effects of treatments in people with different degrees of headache frequency. This can be done from individual participant‐level analyses. Given that a number of modern studies have been completed or are underway, this would appear to be the research priority before new studies are commissioned. </p> </section> <section id="CD011889-sec-0154"> <h5 class="title">Design</h5> <p>The design of studies was generally good, although some were small. Future studies should be adequately powered to detect the magnitude of any effect, not simply a statistical difference from placebo. </p> </section> <section id="CD011889-sec-0155"> <h5 class="title">Measurement (endpoints)</h5> <p>The measurement of pain is not a major issue as most studies, especially modern studies, have used standard pain intensity and pain relief scales. What is at issue are the outcomes reported using those pain measurements. It is not clear that the International Headache Society‐preferred outcome of being free of pain at two hours is entirely appropriate, and while it is reasonable by analogy with migraine, it requires substantiating. </p> <p><b>Comparison between active treatments</b> </p> <p>No authoritative comparisons between active treatments is possible in the present state of knowledge. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011889-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011889-sec-0043"></div> <div class="table" id="CD011889-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Paracetamol 1000 mg compared with placebo for episodic tension‐type headache</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Paracetamol 1000 mg compared with placebo for episodic tension‐type headache</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with episodic tension‐type headache </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> paracetamol 1000 mg </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> comparator</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> intervention</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>RR<br/> (95% CI)</b> </p> <p><b>NNT or NNH (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No. of studies, attacks, events</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain‐free at 2 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>240 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.3 (1.1 to 1.4)</p> <p>NNT 22 (15 to 40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 studies</p> <p>5890 attacks</p> <p>1285 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and events</p> <p>Consistent direction of results</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain‐free at 1 hour</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.2 (0.90 to 1.5)</p> <p>NNT not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>4717 attacks</p> <p>269 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because few studies reported, and modest number of events</p> <p>Some inconsistency in direction of response</p> <p>Dominated by 1 study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain‐free at 4 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>440 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>560 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.2 (1.16 to 1.3)</p> <p>NNT 8.2 (6.6 to 11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>4909 attacks</p> <p>2577 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because few studies reported, but large number of events, tight CIs</p> <p>Consistent direction of results</p> <p>Dominated by 1 study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of rescue medication</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>170 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.58 (0.50 to 0.69)</p> <p>NNTp 7.7 (6.0 to 11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 studies</p> <p>1856 attacks</p> <p>422 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because few studies reported, and modest number of events</p> <p>Consistent direction of results</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain‐free or mild pain at 2 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>490 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>590 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.2 (1.15 to 1.3)</p> <p>NNT 10 (7.9 to 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 studies</p> <p>5238 attacks</p> <p>2910 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Few studies reported, but large number of events, tight CIs</p> <p>1 small study showed different direction of response</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse event</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.1 (0.94 to 1.3)</p> <p>NNH not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 studies</p> <p>5605 attacks</p> <p>528 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and events</p> <p>Consistent direction of results (no effect)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 studies, estimated 5147 participants in comparisons</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because no events reported in 5147 comparisons</p> <p>Rate of serious adverse events unlikely to be &gt; 1 in 1700 (<a href="./references#CD011889-bbs2-0046" title="EypaschE , LeferingR , KumCK , TroidlH . Probability of adverse events that have not yet occurred: a statistical reminder. BMJ1995;311(7005):619‐20. [DOI: 10.1136/bmj.311.7005.619] ">Eypasch 1995</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>NNTH:</b> number needed to treat for one additional harmful outcome; <b>NNT:</b> number needed to treat for one additional beneficial outcome; <b>NNTp:</b> number needed to treat to prevent one harmful outcome; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011889-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Paracetamol 500 mg to 650 mg compared with placebo for episodic tension‐type headache</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Paracetamol 500 mg to 650 mg compared with placebo for episodic tension‐type headache</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with episodic tension‐type headache </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> paracetamol 500 mg to 650 mg </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> comparator</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> intervention</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>RR<br/> (95% CI)</b> </p> <p><b>NNT or NNH (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No. of studies, attacks, events</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain‐free at 2 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain‐free at 1 hour</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain‐free at 4 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of rescue medication</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.76 (0.55 to 1.1)</p> <p>NNTp not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>301 attacks</p> <p>99 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Few studies and events</p> <p>Consistent direction of results (no effect)</p> <p>1 study had high attrition</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain‐free or mild pain at 2 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>530 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>590 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.1 (0.90 to 1.4)</p> <p>NNT not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>275 attacks</p> <p>154 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Few studies and events</p> <p>Consistent direction of results (no effect)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse event</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>140 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.3 (0.71 to 2.5)</p> <p>NNH not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>301 attacks</p> <p>38 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Few studies and events</p> <p>Consistent direction of results (no effect)</p> <p>1 study had high attrition</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 studies</p> <p>estimated 463 participants in comparisons</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 events reported in only 463 comparisons</p> <p>Rate of serious adverse events unlikely to be &gt; 1 in 155 (<a href="./references#CD011889-bbs2-0046" title="EypaschE , LeferingR , KumCK , TroidlH . Probability of adverse events that have not yet occurred: a statistical reminder. BMJ1995;311(7005):619‐20. [DOI: 10.1136/bmj.311.7005.619] ">Eypasch 1995</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>NNH:</b> number needed to treat for one additional harmful outcome; <b>NNT:</b> number needed to treat for one additional beneficial outcome; <b>NNTp:</b> number needed to treat to prevent one harmful outcome; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011889-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011889-sec-0044"></div> <p>This review is based on a template for reviews of drugs used for acute treatment of frequent episodic tension‐type headache (TTH) in adults. The aim is for all reviews to use the same methods. </p> <p>Headaches are a commonly reported problem in community‐based surveys worldwide. The lifetime prevalence of headache is estimated to be greater than 90% (<a href="./references#CD011889-bbs2-0099" title="SteinerTJ . Lifting the burden: the global campaign against headache. Lancet Neurology2004;3(4):204‐5. [DOI: 10.1016/S1474‐4422(04)00703‐3] ">Steiner 2004</a>), and the annual prevalence rate is estimated to be 46% in the general adult population (<a href="./references#CD011889-bbs2-0101" title="StovnerLJ , HagenK , JensenR , KatsaravaZ , LiptonR , ScherAI , et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia2007;27(3):193‐210. [DOI: 10.1111/j.1468‐2982.2007.01288.x] ">Stovner 2007</a>). Variations in reported prevalence may result from differences in study design, population, inclusion or exclusion of cases of infrequent episodic TTH, overlap with probable migraine, cultural and environmental differences, or even genetic factors (<a href="./references#CD011889-bbs2-0096" title="SahlerK . Epidemiology and cultural differences in tension‐type headache. Current Pain and Headache Research2012;16(6):525‐32. [DOI: 10.1007/s11916‐012‐0296‐5] ">Sahler 2012</a>). TTH is more common than migraine, a finding replicated across the world (<a href="./references#CD011889-bbs2-0089" title="OshinaikeO , OjoO , OkubadejoN , OjelabiO , DadaA . Primary headache disorders at a tertiary health facility in Lagos, Nigeria: prevalence and consultation patterns. Biomedical Research International2014;2014:782915. [DOI: 10.1155/2014/782915] ">Oshinaike 2014</a>; <a href="./references#CD011889-bbs2-0104" title="VosT , FlaxmanAD , NaghaviM , LozanoR , MichaudC , EzzatiM , et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380(9859):2163‐96. [DOI: 10.1016/S0140‐6736(12)61729‐2] ">Vos 2012</a>). </p> <p>The management of people with headaches is largely neglected (<a href="./references#CD011889-bbs2-0093" title="RasmussenBK . Epidemiology of headache. Cephalalgia2001;21(7):774‐7. [PUBMED: 11595011] ">Rasmussen 2001</a>; <a href="./references#CD011889-bbs2-0100" title="SteinerTJ , StovnerLJ , DuaT , BirbeckGL , JensenR , KatsaravaZ , et al. Time to act on headache disorders. Journal of Headache and Pain2011;12(5):501‐3. [DOI: 10.1007/s10194‐011‐0368‐7] ">Steiner 2011</a>), and may be fragmented by the involvement of clinicians from different medical specialities (neurology; ear, nose and throat; ophthalmology; psychiatry). Because headache is rarely life‐threatening and headache pain is generally mild to moderate in intensity, people often self medicate and do not seek formal care from health services (<a href="./references#CD011889-bbs2-0093" title="RasmussenBK . Epidemiology of headache. Cephalalgia2001;21(7):774‐7. [PUBMED: 11595011] ">Rasmussen 2001</a>). </p> <p>Headache can be either primary (no underlying cause) or secondary (due to other systemic or local causes) (<a href="./references#CD011889-bbs2-0053" title="GreenMW . Primary and secondary headaches. In: RowlandLP , PedleyTA editor(s). Merritt's Neurology. 12th Edition. Philadelphia: Lippincott Williams and Wilkins, 2009:951‐60. [ISBN: 9780781791861] ">Green 2009</a>). TTH belongs to the group of primary headaches and is seen in nearly one‐third of people experiencing headaches; the large number of people affected imposes a significant burden on the healthcare system (<a href="./references#CD011889-bbs2-0101" title="StovnerLJ , HagenK , JensenR , KatsaravaZ , LiptonR , ScherAI , et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia2007;27(3):193‐210. [DOI: 10.1111/j.1468‐2982.2007.01288.x] ">Stovner 2007</a>). Generally, episodes of TTH are mild to moderate in intensity, and self limiting, but in a small group of people they may be more severe and disabling (<a href="./references#CD011889-bbs2-0053" title="GreenMW . Primary and secondary headaches. In: RowlandLP , PedleyTA editor(s). Merritt's Neurology. 12th Edition. Philadelphia: Lippincott Williams and Wilkins, 2009:951‐60. [ISBN: 9780781791861] ">Green 2009</a>). People with longer lasting or more severe headaches may seek help in a clinical setting, but the majority of people do not do so, resulting often in inadequate and inappropriate management (<a href="./references#CD011889-bbs2-0069" title="KernickD , StapleyS , HamiltonW . GPs' classification of headache: is primary headache underdiagnosed?. British Journal of General Practice2008;58(547):102‐4. [DOI: 10.3399/bjgp08X264072] ">Kernick 2008</a>). In one community‐based telephone survey to determine medication patterns of 274 people with frequent headache, only 1% used prescription medication. The majority reported using over‐the‐counter (OTC) analgesics (paracetamol (acetaminophen): 56% and aspirin: 15%), and the perceived effectiveness of OTC medication was approximately 7 on a scale of 0 to 10 (<a href="./references#CD011889-bbs2-0049" title="ForwardSP , McGrathPJ , MacKinnonD , BrownTL , SwannJ , CurrieEL . Medication patterns of recurrent headache sufferers: a community study. Cephalalgia1998;18(3):146‐51. [DOI: 10.1046/j.1468‐2982.1998.1803146.x] ">Forward 1998</a>). There is a greater propensity to develop analgesic abuse among people who self medicate with OTC preparations, particularly those with frequent TTH. This calls for developing treatment and management guidelines that bring about substantial and sustained pain relief with minimal adverse effects. </p> <p>Professional strategies for the management of TTH have typically been extrapolated from those used for migraine; the World Health Organization (WHO) essential drug list, for example, does not include indications for the management of TTH (<a href="./references#CD011889-bbs2-0105" title="World Health Organization. WHO model list of essential medicines, 19th List, 2015. www.who.int/medicines/publications/essentialmedicines/en/index.html (accessed 22 December 2015). ">WHO 2015</a>). In 2010, the British Association for the Study of Headache (BASH) and the European Federation of Neurological Societies (EFNS) updated or published guidelines for the management of TTH (<a href="./references#CD011889-bbs2-0030" title="MacGregorEA , SteinerTJ , DaviesPTG , for the British Association for the Study of Headache. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension‐type, cluster, and medication overuse headache. 3rd edition (1st revision), 2010. www.bash.org.uk/wp‐content/uploads/2012/07/10102‐BASH‐Guidelines‐update‐2_v5‐1‐indd.pdf (accessed 22 December 2015). ">BASH 2010</a>; <a href="./references#CD011889-bbs2-0033" title="BendtsenL , EversS , LindeM , MitsikostasDD , SandriniG , SchoenenJ . EFNS guideline on the treatment of tension‐type headache ‐ report of an EFNS taskforce. European Journal of Neurology2010;17(11):1318‐25. [DOI: 10.1111/j.1468‐1331.2010.03070.x] ">Bendtsen 2010</a>); there is also German and Austrian guidance (<a href="./references#CD011889-bbs2-0057" title="HaagG , DienerHC , MayA , MeyerC , MorckH , StraubeA , et al. Self‐medication of migraine and tension‐type headache: summary of the evidence‐based recommendations of the Deutsche Migräne und Kopfschmerzgesellschaft (DMKG), the Deutsche Gesellschaft für Neurologie (DGN), the Österreichische Kopfschmerzgesellschaft (ÖKSG) and the Schweizerische Kopfwehgesellschaft (SKG). Journal of Headache and Pain2011;12(2):201‐17. [DOI: 10.1007/s10194‐010‐0266‐4] ">Haag 2011</a>). The guidelines reflect ongoing systematic efforts to bridge the gap between clinical trial evidence and clinical practice with the aim of improving practice. While these guidelines represent a step forward, there are, nonetheless, issues relating to the quality and methodological limitations of individual studies. </p> <p>People with TTH and migraine have more work absence than people without headaches (<a href="./references#CD011889-bbs2-0073" title="LyngbergAC , RasmussenBK , JørgensenT , JensenR . Secular changes in health care utilization and work absence for migraine and tension‐type headache: a population based study. European Journal of Epidemiology2005;20(12):1007‐14. [DOI: 10.1007/s10654‐005‐3778‐5] ">Lyngberg 2005</a>); there is also considerable loss of productivity (<a href="./references#CD011889-bbs2-0038" title="CristofoliniA , Dalla SerraP , ScherilloG , OrricoD , MiccioloR . The prevalence of headache in a population of health care workers and the effects on productivity costs. La Medicina del Lavoro2008;99(1):8‐15. ">Cristofolini 2008</a>; <a href="./references#CD011889-bbs2-0091" title="PopPH , GierveldCM , KarisHA , TiedinkHG . Epidemiological aspects of headache in a workplace setting and the impact on the economic loss. European Journal of Neurology2002;9(2):171‐4. ">Pop 2002</a>). Headache‐related characteristics include significant problems with headache management, disability, pain, worry, and dissatisfaction with care, as well as greater use of medical services and worse general health (<a href="./references#CD011889-bbs2-0058" title="HarpoleLH , SamsaGP , MatcharDB , SilbersteinSD , BlumenfeldA , JurgelskiAE . Burden of illness and satisfaction with care among patients with headache seen in a primary care setting. Headache2005;45(8):1048‐55. [DOI: 10.1111/j.1526‐4610.2005.05186.x] ">Harpole 2005</a>). </p> <section id="CD011889-sec-0045"> <h3 class="title" id="CD011889-sec-0045">Description of the condition</h3> <p>TTH has been known by several names, including tension headache, muscle contraction headache, psychomyogenic headache, stress headache, ordinary headache, essential headache, idiopathic headache, and psychogenic headache (<a href="./references#CD011889-bbs2-0064" title="Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia2004;24 Suppl 1:1‐160. [DOI: 10.1111/j.1468‐2982.2003.00824.x] ">IHS 2004</a>). TTH is diagnosed mainly by the absence of features found in other headache types, especially migraine. The third edition of the International Classification of Headache Disorders (ICHD‐3 beta) distinguishes between episodic and chronic varieties of TTH (<a href="./references#CD011889-bbs2-0066" title="Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia2013;33(9):629‐808. [DOI: 10.1177/0333102413485658] ">IHS 2013</a>). Chronic TTH is diagnosed when headache occurs on 15 days or more per month on average for three months or more (180 or more days per year); otherwise TTH is considered to be episodic. </p> <p>Acute treatment with analgesics is more appropriate for episodic TTH, while both pharmacological and non‐pharmacological treatments are used for managing chronic TTH. Structural changes in the brain have been reported in people with chronic TTH (<a href="./references#CD011889-bbs2-0050" title="FumalA , SchoenenJ . Tension‐type headache: current research and clinical management. Lancet Neurology2008;7(1):70‐83. [DOI: 10.1016/S1474‐4422(07)70325‐3] ">Fumal 2008</a>). Furthermore, management of TTH in children and adolescents raises diverse clinical issues (establishing diagnoses, dosages, nature of preparation, pharmacodynamics, etc; <a href="./references#CD011889-bbs2-0078" title="MonteithTS , SprengerT . Tension type headache in adolescence and childhood: where are we now?. Current Pain and Headache Reports2010;14(6):424‐30. [DOI: 10.1007/s11916‐010‐0149‐z] ">Monteith 2010</a>). For all of these reasons, the proposed review will focus on the acute treatment of episodic TTH in adults. </p> <section id="CD011889-sec-0046"> <h4 class="title">Diagnosis</h4> <p>Episodic TTH is subdivided into infrequent and frequent types (<a href="./references#CD011889-bbs2-0066" title="Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia2013;33(9):629‐808. [DOI: 10.1177/0333102413485658] ">IHS 2013</a>). </p> <p>Infrequent episodic TTH is diagnosed by the following criteria.</p> <p> <ul id="CD011889-list-0001"> <li> <p>At least 10 episodes occurring on fewer than one day per month (fewer than 12 days per year) and satisfying criteria 2 through 4. </p> </li> <li> <p>Headache lasting from 30 minutes to seven days.</p> </li> <li> <p>Headache has at least two of the following characteristics:</p> <ul id="CD011889-list-0002"> <li> <p>bilateral location;</p> </li> <li> <p>pressing/tightening (non‐pulsating) quality;</p> </li> <li> <p>mild or moderate intensity;</p> </li> <li> <p>not aggravated by routine physical activity such as walking or climbing stairs.</p> </li> </ul> </li> <li> <p>Both of the following:</p> <ul id="CD011889-list-0003"> <li> <p>no nausea or vomiting (anorexia may occur);</p> </li> <li> <p>no more than one of photophobia or phonophobia.</p> </li> </ul> </li> <li> <p>Not attributed to another disorder.</p> </li> </ul> </p> <p>Frequent episodic TTH is defined when at least 10 episodes of headache occur on at least one day but fewer than 15 days per month for at least three months (at least 12 and fewer than 180 days per year), and when criteria 2 to 5, above, are also met. </p> </section> <section id="CD011889-sec-0047"> <h4 class="title">Prevalence</h4> <p>The Global Burden of Diseases Study 2010 found global prevalence of TTH as 21%, making it the second most prevalent condition after dental caries, and slightly more prevalent than migraine (<a href="./references#CD011889-bbs2-0104" title="VosT , FlaxmanAD , NaghaviM , LozanoR , MichaudC , EzzatiM , et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380(9859):2163‐96. [DOI: 10.1016/S0140‐6736(12)61729‐2] ">Vos 2012</a>). </p> <p>In previous studies, the one‐year prevalence of infrequent episodic TTH in one Danish study of 4000 people aged 40 years was 48.2%, while that of frequent episodic TTH was 34% (<a href="./references#CD011889-bbs2-0095" title="RussellMB . Tension‐type headache in 40‐year‐olds: a Danish population‐based sample of 4000. Journal of Headache and Pain2005;6(6):441‐7. [DOI: 10.1007/s10194‐005‐0253‐3] ">Russell 2005</a>). Overall annual prevalence of TTH in the US was estimated to be 38%, with a higher incidence among women (prevalence ratio of 1:1.2; <a href="./references#CD011889-bbs2-0098" title="SchwartzBS , StewartWF , SimonD , LiptonRB . Epidemiology of tension‐type headache. JAMA1998;279(5):381‐3. [DOI: 10.1001/jama.279.5.381] ">Schwartz 1998</a>). In Canada, the estimated prevalence was 29% (<a href="./references#CD011889-bbs2-0044" title="EdmeadsJ , FindlayH , TugwellP , Pryse‐PhillipsW , NelsonRF , MurrayTJ . Impact of migraine and tension‐type headache on life‐style, consulting behaviour, and medication use: a Canadian population survey. Canadian Journal of Neurological Sciences1993;20(2):131‐7. [PUBMED: 8334575] ">Edmeads 1993</a>). One study conducted in Chile reported that TTH constituted 72% of all recurrent headaches, with a total prevalence of 27% (95% confidence interval (CI) 25% to 29%). Nearly 1 in 4 (24%) participants had episodic TTH, and prevalence was greater among women when compared to men (35% for women versus 18% for men; <a href="./references#CD011889-bbs2-0071" title="LavadosPM , TenhammE . Epidemiology of tension‐type headache in Santiago, Chile: a prevalence study. Cephalalgia1998;18(8):552‐8. [DOI: 10.1046/j.1468‐2982.1998.1808552.x] ">Lavados 1998</a>). </p> </section> <section id="CD011889-sec-0048"> <h4 class="title">Causation</h4> <p>The exact pathogenesis of TTH is still unknown and is said to be multifactorial, including central dysfunction of pain processing pathways and peripheral myofascial factors. There is a general agreement that peripheral myofascial nociception disturbances play a greater role in the pathogenesis of both frequent and infrequent episodic TTH (<a href="./references#CD011889-bbs2-0047" title="Fernández‐de‐las‐PeñasC , MadeleineP , CamineroAB , CuadradoML , Arendt‐NielsenL , ParejaJA . Generalized neck‐shoulder hyperalgesia in chronic tension‐type headache and unilateral migraine assessed by pressure pain sensitivity topographical maps of the trapezius muscle. Cephalalgia2010;30(1):77‐86. [DOI: 10.1111/j.1468‐2982.2009.01901.x] ">Fernández‐de‐las‐Peñas 2010</a>; <a href="./references#CD011889-bbs2-0050" title="FumalA , SchoenenJ . Tension‐type headache: current research and clinical management. Lancet Neurology2008;7(1):70‐83. [DOI: 10.1016/S1474‐4422(07)70325‐3] ">Fumal 2008</a>). </p> </section> </section> <section id="CD011889-sec-0049"> <h3 class="title" id="CD011889-sec-0049">Description of the intervention</h3> <p>Paracetamol (acetaminophen) was first identified as the active metabolite of two older antipyretic drugs, acetanilide and phenacetin, in the late nineteenth century. It became available in the UK on prescription in 1956, and without prescription (OTC) in 1963 (<a href="./references#CD011889-bbs2-0090" title="PharmWeb . Paracetamol Information Centre. www2.pharmweb.net/pwmirror/pwy/paracetamol/pharmwebpic.html (accessed 22 December 2015). ">PIC 2015</a>). Since then, it has become one of the most popular antipyretic and analgesic drugs worldwide, and is often also used in combination with other drugs. OTC medications are less expensive, more accessible, and have favourable safety profiles relative to many prescription treatments. </p> <p>Despite a low incidence of adverse effects, paracetamol has a recognised potential for hepatotoxicity and is thought to be responsible for approximately half of all cases of liver failure in the UK (<a href="./references#CD011889-bbs2-0060" title="HawtonK , TownsendE , DeeksJ , ApplebyL , GunnellD , BennewithO , et al. Effects of legislation restricting pack sizes of paracetamol and salicylate on self poisoning in the United Kingdom: before and after study. BMJ2001;322(7296):1203‐7. [DOI: 10.1136/bmj.322.7296.1203] ">Hawton 2001</a>), and about 40% in the US (<a href="./references#CD011889-bbs2-0087" title="NorrisW , ParedesAH , LewisJH . Drug‐induced liver injury in 2007. Current Opinion in Gastroenterology2008;24(3):287‐97. [DOI: 10.1097/MOG.0b013e3282f9764b] ">Norris 2008</a>). One study evaluating all cases of acute liver failure leading to registration for transplantation (ALFT) across seven European countries for a three‐year period showed that paracetamol overdose was responsible for one sixth of cases of ALFT; however, this varied considerably between each country (<a href="./references#CD011889-bbs2-0055" title="GulmezSE , LarreyD , PageauxGP , BernuauJ , BissoliF , HorsmansY , et al. Liver transplant associated with paracetamol overdose: results from the seven‐country SALT study. British Journal of Clinical Pharmacology2015;80(3):599‐606. [DOI: 10.1111/bcp.12635] ">Gulmez 2015</a>). Acute paracetamol hepatotoxicity at therapeutic doses has been judged to be extremely unlikely, despite reports of so‐called 'therapeutic misadventure' (<a href="./references#CD011889-bbs2-0092" title="PrescottLF . Therapeutic misadventure with paracetamol: fact or fiction?. American Journal of Therapeutics2000;7(2):99‐114. [PUBMED: 11319578] ">Prescott 2000</a>). It has been observed that non‐overdose ALFT is more likely to follow therapeutic‐dose paracetamol exposure than similar nonsteroidal anti‐inflammatory drug (NSAID) exposure (<a href="./references#CD011889-bbs2-0054" title="GulmezSE , LarreyD , PageauxGP , LignotS , LassalleR , JovéJ , et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case‐population SALT study. Drug Safety2013;36(2):135‐44. [DOI: 10.1007/s40264‐012‐0013‐7] ">Gulmez 2013</a>). Legislative changes were introduced in the UK to restrict pack sizes and the maximum number of tablets permitted in OTC sales (<a href="./references#CD011889-bbs2-0039" title="Committee on Safety of Medicines. Medicines Control Agency. Paracetamol and aspirin. Current Problems in Pharmacovigilance1997;23:9. ">CSM 1997</a>) on the basis of evidence that poisoning was lower in countries that restrict availability (<a href="./references#CD011889-bbs2-0056" title="GunnellD , HawtonK , GarnierV , BismuthC , FaggJ . Use of paracetamol for suicide and non‐fatal poisoning in the UK and France: are restrictions on availability justified?. Journal of Epidemiology and Community Health1997;51(2):175‐9. [PUBMED: 9196648] ">Gunnell 1997</a>; <a href="./references#CD011889-bbs2-0060" title="HawtonK , TownsendE , DeeksJ , ApplebyL , GunnellD , BennewithO , et al. Effects of legislation restricting pack sizes of paracetamol and salicylate on self poisoning in the United Kingdom: before and after study. BMJ2001;322(7296):1203‐7. [DOI: 10.1136/bmj.322.7296.1203] ">Hawton 2001</a>). The contribution of these changes, which are inconvenient and costly (particularly to people with chronic pain), to any observed reductions in incidence of liver failure or death, remains uncertain (<a href="./references#CD011889-bbs2-0031" title="BatemanDN , CarrollR , PettieJ , YamamotoT , ElaminME , PeartL , et al. Effect of the UK's revised paracetamol poisoning management guidelines on admissions, adverse reactions, and costs of treatment. British Journal of Clinical Pharmacology2014;78(3):610‐8. [DOI: 10.1111/bcp.12362] ">Bateman 2014a</a>; <a href="./references#CD011889-bbs2-0032" title="BatemanDN . Pack size and paracetamol overdose: 16 years later. Clinical Toxicology2014;52:821‐3. [DOI: 10.3109/15563650.2014.952432] ">Bateman 2014b</a>; <a href="./references#CD011889-bbs2-0059" title="HawkinsLC , EdwardsJN , DarganPI . Impact of restricting paracetamol pack sizes on paracetamol poisoning in the United Kingdom: a review of the literature. Drug Safety2007;30(6):465‐79. [PUBMED: 17536874] ">Hawkins 2007</a>; <a href="./references#CD011889-bbs2-0061" title="HawtonK , BergenH , SimkinS , DoddS , PocockP , BernalW , et al. Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: interrupted time series analyses. BMJ2013;346:f403. [DOI: 10.1136/bmj.f403] ">Hawton 2013</a>). There have been concerns over the safety of paracetamol in people with compromised hepatic function (people with severe alcoholism, cirrhosis, or hepatitis), but these have not been substantiated (<a href="./references#CD011889-bbs2-0040" title="DartRC , KuffnerEK , RumackBH . Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review. American Journal of Medicine2000;7(2):123‐34. [PUBMED: 11319580] ">Dart 2000</a>; <a href="./references#CD011889-bbs2-0090" title="PharmWeb . Paracetamol Information Centre. www2.pharmweb.net/pwmirror/pwy/paracetamol/pharmwebpic.html (accessed 22 December 2015). ">PIC 2015</a>). </p> <p>The use of paracetamol during pregnancy has been questioned following reports that it is linked to behavioural problems and hyperkinetic disorders in children whose mothers took it during pregnancy (<a href="./references#CD011889-bbs2-0072" title="LiewZ , RitzB , RebordosaC , LeePC , OlsenJ . Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disorders. JAMA Pediatrics2014;168(4):313‐20. [DOI: 10.1001/jamapediatrics.2013.4914] ">Liew 2014</a>), and suggestions that it can interfere with sex hormones (<a href="./references#CD011889-bbs2-0076" title="Mazaud‐GuittotS , Nicolas NicolazC , Desdoits‐LethimonierC , CoiffecI , Ben MaamarM , BalaguerP , et al. Paracetamol, aspirin, and indomethacin induce endocrine disturbances in the human fetal testis capable of interfering with testicular descent. Journal of Clinical Endocrinology and Metabolism2013;98(11):1757‐67. [DOI: 10.1210/jc.2013‐2531] ">Mazaud‐Guittot 2013</a>). </p> <p>In one analysis of single dose studies in migraine, there was no evidence that adverse events were more common with paracetamol 1000 mg than with placebo, and no serious adverse events occurred with paracetamol alone (<a href="./references#CD011889-bbs2-0042" title="DerryS , MooreRA . Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD008040.pub3] ">Derry 2013</a>). </p> <p>Oral paracetamol has long been used as a first‐line analgesic for a variety of acute and chronic conditions, although some systematic reviews and meta‐analyses have suggested that there is no good evidence for a clinically relevant benefit of paracetamol (as monotherapy) in many of these pain conditions (<a href="./references#CD011889-bbs2-0074" title="MachadoGC , MaherCG , FerreiraPH , PinheiroMB , LinCW , DayRO , et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta‐analysis of randomised placebo controlled trials. BMJ2015;350:h1225. [DOI: 10.1136/bmj.h1225] ">Machado 2015</a>; <a href="./references#CD011889-bbs2-0082" title="MooreRA , DerryS , WiffenPJ , StraubeS , AldingtonDJ . Overview review: comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions. European Journal of Pain2014;19(9):1213‐23. [DOI: 10.1002/ejp.649] ">Moore 2014a</a>). The benefit risk of paracetamol has been called into question, especially in view of limited or absent evidence of efficacy, and growing evidence about risk (<a href="./references#CD011889-bbs2-0085" title="MooreRA , MooreN . Paracetamol and pain: the kiloton problem. European Journal of Hospital Pharmacy2016;April. [DOI: 10.1136/ejhpharm‐2016‐000952] ">Moore 2016</a>). </p> </section> <section id="CD011889-sec-0050"> <h3 class="title" id="CD011889-sec-0050">How the intervention might work</h3> <p>The lack of significant anti‐inflammatory activity of paracetamol implies a mode of action distinct from that of NSAIDs; yet, despite years of use and research, the mechanisms of action of paracetamol are not fully understood. NSAIDs act by inhibiting the activity of cyclooxygenase (COX), now recognised to consist of two isoforms (COX‐1 and COX‐2), which catalyses the production of prostaglandins responsible for pain and inflammation. Paracetamol has previously been shown to have no significant effects on COX‐1 or COX‐2 (<a href="./references#CD011889-bbs2-0097" title="SchwabJM , SchluesenerHJ , LauferS . COX‐3: just another COX or the solitary elusive target of paracetamol?. Lancet2003;361(9362):981‐2. [DOI: 10.1016/S0140‐6736(03)12841‐3] ">Schwab 2003</a>), but is now being considered as a selective COX‐2 inhibitor (<a href="./references#CD011889-bbs2-0063" title="HinzB , ChereminaO , BruneK . Acetaminophen (paracetamol) is a selective cyclooxygenase‐2 inhibitor in man. Federation of American Societies for Experimental Biology Journal2008;22(2):383‐90. [DOI: 10.1096/fj.07‐8506com] ">Hinz 2008</a>). Significant paracetamol‐induced inhibition of prostaglandin production has been demonstrated in tissues in the brain, spleen, and lung (<a href="./references#CD011889-bbs2-0034" title="BottingRM . Mechanism of action of acetaminophen: is there a cyclooxygenase 3?. Clinical Infectious Diseases2000;31(5):S203‐10. [DOI: 10.1086/317520] ">Botting 2000</a>; <a href="./references#CD011889-bbs2-0048" title="FlowerRJ , VaneJR . Inhibition of prostaglandin synthetase in brain explains the anti‐pyretic activity of paracetamol (4‐acetamidophenol). Nature1972;240(5381):410‐1. [PUBMED: 4564318] ">Flower 1972</a>). A 'COX‐3 hypothesis', wherein the efficacy of paracetamol is attributed to its specific inhibition of a third COX isoform enzyme, COX‐3 (<a href="./references#CD011889-bbs2-0034" title="BottingRM . Mechanism of action of acetaminophen: is there a cyclooxygenase 3?. Clinical Infectious Diseases2000;31(5):S203‐10. [DOI: 10.1086/317520] ">Botting 2000</a>; <a href="./references#CD011889-bbs2-0036" title="ChandrasekharanNV , DaiH , RoosKL , EvansonNK , TomsikJ , EltonTS , et al. COX‐3, a cyclooxygenase‐1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proceedings of the National Academy of Sciences of the United States of America2002;99(21):13926‐31. [DOI: 10.1073/pnas.162468699] ">Chandrasekharan 2002</a>), has little credibility, and a central mode action of paracetamol is thought to be likely (<a href="./references#CD011889-bbs2-0052" title="GrahamGG , ScottKF . Mechanism of action of paracetamol. American Journal of Therapeutics2005;12(1):46‐55. [DOI: 10.1097/00045391‐200501000‐00008] ">Graham 2005</a>). </p> </section> <section id="CD011889-sec-0051"> <h3 class="title" id="CD011889-sec-0051">Why it is important to do this review</h3> <p>Episodic TTH is ubiquitous, affecting a large proportion of adults. Despite being generally mild to moderate in intensity, headache results in considerable suffering to the affected person and contributes overall to a significant loss of productivity to society (<a href="./references#CD011889-bbs2-0075" title="MannixLK . Epidemiology and impact of primary headache disorders. Medical Clinics of North America2001;85(4):887‐95. [DOI: 10.1016/S0025‐7125(05)70349‐7] ">Mannix 2001</a>; <a href="./references#CD011889-bbs2-0093" title="RasmussenBK . Epidemiology of headache. Cephalalgia2001;21(7):774‐7. [PUBMED: 11595011] ">Rasmussen 2001</a>; <a href="./references#CD011889-bbs2-0099" title="SteinerTJ . Lifting the burden: the global campaign against headache. Lancet Neurology2004;3(4):204‐5. [DOI: 10.1016/S1474‐4422(04)00703‐3] ">Steiner 2004</a>; <a href="./references#CD011889-bbs2-0101" title="StovnerLJ , HagenK , JensenR , KatsaravaZ , LiptonR , ScherAI , et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia2007;27(3):193‐210. [DOI: 10.1111/j.1468‐2982.2007.01288.x] ">Stovner 2007</a>). Seeking relief, people generally self medicate with one or more medicines, and OTC medicines are often used (<a href="./references#CD011889-bbs2-0049" title="ForwardSP , McGrathPJ , MacKinnonD , BrownTL , SwannJ , CurrieEL . Medication patterns of recurrent headache sufferers: a community study. Cephalalgia1998;18(3):146‐51. [DOI: 10.1046/j.1468‐2982.1998.1803146.x] ">Forward 1998</a>). Paracetamol is a readily accessible OTC analgesic. As a generic drug, paracetamol could be a drug of choice for management of TTH, particularly in low‐resource settings. It has some efficacy in individual studies and one systematic review (<a href="./references#CD011889-bbs2-0083" title="MooreRA , DerryS , WiffenPJ , StraubeS , BendtsenL . Evidence for efficacy of acute treatment of episodic tension‐type headache: methodological critique of randomised trials for oral treatments. Pain2014;155(11):2220‐8. [DOI: 10.1016/j.pain.2014.08.009] ">Moore 2014b</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>). </p> <p>Two guidelines on the management of TTH have reviewed the effectiveness of different treatments, both using a consensus methodology because the amount of randomised trial evidence is limited (<a href="./references#CD011889-bbs2-0083" title="MooreRA , DerryS , WiffenPJ , StraubeS , BendtsenL . Evidence for efficacy of acute treatment of episodic tension‐type headache: methodological critique of randomised trials for oral treatments. Pain2014;155(11):2220‐8. [DOI: 10.1016/j.pain.2014.08.009] ">Moore 2014b</a>). The BASH guidelines are based on a limited review of studies (<a href="./references#CD011889-bbs2-0030" title="MacGregorEA , SteinerTJ , DaviesPTG , for the British Association for the Study of Headache. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension‐type, cluster, and medication overuse headache. 3rd edition (1st revision), 2010. www.bash.org.uk/wp‐content/uploads/2012/07/10102‐BASH‐Guidelines‐update‐2_v5‐1‐indd.pdf (accessed 22 December 2015). ">BASH 2010</a>), and the EFNS guidelines are based on a more detailed and thorough literature search (<a href="./references#CD011889-bbs2-0033" title="BendtsenL , EversS , LindeM , MitsikostasDD , SandriniG , SchoenenJ . EFNS guideline on the treatment of tension‐type headache ‐ report of an EFNS taskforce. European Journal of Neurology2010;17(11):1318‐25. [DOI: 10.1111/j.1468‐1331.2010.03070.x] ">Bendtsen 2010</a>). The EFNS guidelines represent an improvement over the BASH guidelines in that they used a standard published protocol for developing management guidelines (<a href="./references#CD011889-bbs2-0035" title="BraininM , BarnesM , BaronJC , GilhusNE , HughesR , SelmajK , et al. for the Guideline Standards Subcommittee of the EFNS Scientific Committee. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces‐revised recommendations 2004. European Journal of Neurology2004;11(9):577‐81. [DOI: 10.1111/j.1468‐1331.2004.00867.x] ">Brainin 2004</a>). That protocol strongly recommends active and frequent consultation of <i>The Cochrane Library</i>. However, there were no published Cochrane reviews on the acute management of frequent episodic TTH until the publication of a review of ibuprofen for this indication (<a href="./references#CD011889-bbs2-0043" title="DerryS , WiffenPJ , MooreRA , BendtsenL . Ibuprofen for acute treatment of episodic tension‐type headache in adults. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD011474.pub2] ">Derry 2015</a>). One non‐Cochrane systematic review by Verhagen and others followed methods similar to those used in Cochrane reviews and evaluated the efficacy and tolerability of analgesics for the acute treatment of episodes of TTH in adults (<a href="./references#CD011889-bbs2-0103" title="VerhagenAP , DamenL , BergerMY , PasschierJ , MerlinV , KoesBW . Is any one analgesic superior for episodic tension‐type headache?. Journal of Family Practice2006;55(12):1064‐72. [PUBMED: 17137543] ">Verhagen 2006</a>), but the authors analysed a non‐standard outcome of "pain relief or recovery over 2 to 6 hours" as the main efficacy outcome. </p> <p>Reviews explicitly adopting Cochrane methods and evaluating the more focused outcomes recommended in the updated guidelines of the IHS for controlled trials of drugs in TTH are clearly important (<a href="./references#CD011889-bbs2-0065" title="BendtsenL , BigalME , CerboR , DienerHC , HolroydK , LamplC , et al. on behalf of the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in tension‐type headache: second edition. Cephalalgia2010;30(1):1‐16. [DOI: 10.1111/j.1468‐2982.2009.01948.x] ">IHS 2010</a>). One survey of TTH study methods and reporting demonstrated that these are seldom adhered to in clinical trials, and studies of aspirin, ibuprofen, ketoprofen, and paracetamol used a variety of outcomes including, occasionally, IHS‐preferred outcomes (<a href="./references#CD011889-bbs2-0083" title="MooreRA , DerryS , WiffenPJ , StraubeS , BendtsenL . Evidence for efficacy of acute treatment of episodic tension‐type headache: methodological critique of randomised trials for oral treatments. Pain2014;155(11):2220‐8. [DOI: 10.1016/j.pain.2014.08.009] ">Moore 2014b</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011889-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011889-sec-0052"></div> <p>To assess the efficacy and safety of paracetamol for the acute treatment of frequent episodic TTH in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011889-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011889-sec-0053"></div> <section id="CD011889-sec-0054"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011889-sec-0055"> <h4 class="title">Types of studies</h4> <p>We included randomised, double‐blind, placebo‐controlled studies (parallel‐group or cross‐over) in any setting using paracetamol for symptomatic relief of an acute episode of TTH. Studies had to be prospective. We accepted studies reporting treatment of consecutive headache episodes if they reported outcomes for the first, or each, episode separately. We included trials regardless of publication status or language of publication. We included studies conducted in any setting (home, clinic, doctor's surgery, community centre, etc) as long as it was clear that treatment was for an acute episode of TTH. </p> <p>Cross‐over studies are well‐suited to study acute episodic TTH and eliminate within‐person variation; however, they pose challenges during analysis related to drop‐outs, inadequate reporting (reporting only the first period), and inappropriate reporting (reporting as parallel‐group trials instead of paired observations). We included cross‐over trials only if there was adequate washout (at least 48 hours) between treatments and after ascertaining that the participants were adequately randomised to the first treatment period. </p> <p>We excluded trials using alternation, date of birth, hospital record number, or other 'quasi‐random' methods of allocation of treatment. </p> </section> <section id="CD011889-sec-0056"> <h4 class="title">Types of participants</h4> <p>Study participants were adults (at least 18 years of age) with frequent episodic TTH. We excluded studies involving participants with chronic TTH. </p> <p>The diagnosis of episodic TTH ideally conformed to IHS criteria (<a href="./references#CD011889-bbs2-0066" title="Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia2013;33(9):629‐808. [DOI: 10.1177/0333102413485658] ">IHS 2013</a>). We considered other definitions if they conformed in general to IHS diagnostic criteria and reasonably distinguished TTH from other headache types by specifying distinctive features of TTH; for example, absence of nausea or vomiting, mild to moderate head pain, character and location of pain, absence of obvious phonophobia or photophobia and aura, and differentiated from chronic daily headache. </p> <p>We analysed data only for people with acute TTH episodes. Studies including people with 'mixed' migraine and TTH or 'combination' headaches would have posed problems, as these terms may refer to people with discrete episodes of migraine and discrete episodes of TTH, or to people with headaches that (in the view of the investigators) combined features of migraine and TTH. The IHS criteria assign a dual diagnosis of migraine and TTH or 'probable migraine', respectively, to such people. Where participants experienced both migraine and TTH, they were required to be able to distinguish between them and to treat only TTH. We excluded secondary headache disorders using criteria based on ICHD (<a href="./references#CD011889-bbs2-0066" title="Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia2013;33(9):629‐808. [DOI: 10.1177/0333102413485658] ">IHS 2013</a>). </p> </section> <section id="CD011889-sec-0057"> <h4 class="title">Types of interventions</h4> <p>Included studies had to have at least one arm in which paracetamol was given orally for acute treatment of an episode of TTH. There was no restriction on dose. Included studies could use either a single dose to treat a discrete headache episode or investigate different dosing strategies. We looked primarily for studies using paracetamol alone, but also for studies that used paracetamol in combination with another active oral treatment. </p> <p>A placebo comparator is essential to demonstrate that paracetamol is effective in this condition. The placebo used had to be identical to paracetamol in appearance (size, colour, etc) and the number of tablets, or a double‐dummy technique should be used. All the active‐controlled trials also included a placebo treatment arm. </p> </section> <section id="CD011889-sec-0058"> <h4 class="title">Types of outcome measures</h4> <p>Primary and secondary outcomes selected for analysis reflected the most recent guidelines for controlled trials of drugs in TTH issued by the IHS (<a href="./references#CD011889-bbs2-0065" title="BendtsenL , BigalME , CerboR , DienerHC , HolroydK , LamplC , et al. on behalf of the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in tension‐type headache: second edition. Cephalalgia2010;30(1):1‐16. [DOI: 10.1111/j.1468‐2982.2009.01948.x] ">IHS 2010</a>). </p> <section id="CD011889-sec-0059"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011889-list-0004"> <li> <p>Pain‐free rate at two hours using any standard method of pain assessment and without the use of rescue medication. </p> </li> </ul> </p> </section> <section id="CD011889-sec-0060"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011889-list-0005"> <li> <p>Pain‐free rate at different time points, without the use of rescue medication. We used one hour, four hours, and 24 hours as clinically important endpoints and analysed them separately. </p> </li> <li> <p>Pain Intensity Difference (PID) and Sum of Pain Intensity Difference (SPID), at two hours, without the use of rescue medication. </p> </li> <li> <p>Pain‐free or mild pain at two hours (equivalent to headache response in migraine trials); this is an outcome regarded as useful by most people with acute or chronic pain (<a href="./references#CD011889-bbs2-0081" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013</a>). </p> </li> <li> <p>Use of rescue medication. When participants use rescue medication they are considered to have withdrawn from the study because of a lack of efficacy. </p> </li> <li> <p>Adverse events: number of participants with any adverse event, identity and rates (if data permitted) of specific adverse events, serious adverse events, and number of withdrawals due to adverse events. </p> </li> </ul> </p> </section> </section> </section> <section id="CD011889-sec-0061"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011889-sec-0062"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases.</p> <p> <ul id="CD011889-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (via CRSO) on 14 October 2015. </p> </li> <li> <p>MEDLINE (via Ovid, 1946 to 14 October 2015).</p> </li> <li> <p>EMBASE (via Ovid, 1974 to 14 October 2015).</p> </li> <li> <p>Oxford Pain Relief Database (<a href="./references#CD011889-bbs2-0067" title="JadadAR , CarrollD , MooreA , McQuayH . Developing a database of published reports of randomised clinical trials in pain research. Pain1996;66(2‐3):239‐46. [DOI: 10.1016/0304‐3959(96)03033‐3] ">Jadad 1996a</a>) on 14 October 2015. </p> </li> </ul> </p> <p><a href="./appendices#CD011889-sec-0159">Appendix 1</a> shows the search strategy for CENTRAL, <a href="./appendices#CD011889-sec-0160">Appendix 2</a> for MEDLINE, and <a href="./appendices#CD011889-sec-0161">Appendix 3</a> for EMBASE. </p> </section> <section id="CD011889-sec-0063"> <h4 class="title">Searching other resources</h4> <p>We searched the International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) and ClinicalTrials.gov (<a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>) for completed or ongoing trials using the key words 'headache' or 'cephalalgia' or their variations (using wildcards). We also examined web‐based clinical trials registries of relevant manufacturers and drug companies including GlaxoSmithKline, Novartis, Bayer, and Reckitt Benckiser. </p> <p>We searched the reference lists of all eligible trials and previous systematic reviews for additional studies, and asked personal contacts for information about any unpublished and ongoing studies known to them. </p> </section> </section> <section id="CD011889-sec-0064"> <h3 class="title" id="CD011889-sec-0064">Data collection and analysis</h3> <section id="CD011889-sec-0065"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently reviewed the titles and abstracts of all studies identified through searching to exclude any that clearly did not satisfy inclusion criteria, and read full copies of the remaining studies to identify those suitable for inclusion. We resolved disagreements by discussion or by referral to a third review author for independent review and a final decision. </p> </section> <section id="CD011889-sec-0066"> <h4 class="title">Data extraction and management</h4> <p>We adapted the Cochrane Pain, Palliative and Supportive Care Review Group's (PaPaS) data extraction form to suit the requirements of this review. Two review authors independently extracted data from each study using the form. We resolved disagreements and uncertainties by discussion. It was not necessary to involve a third review author. One review author entered data into Review Manager 5 (<a href="./references#CD011889-bbs2-0094" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD011889-sec-0067"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the Oxford Quality Score (<a href="./references#CD011889-bbs2-0068" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJM , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials1996;17(1):1‐12. [DOI: 10.1016/0197‐2456(95)00134‐4] ">Jadad 1996b</a>) as the basis for inclusion, limiting inclusion to studies that were randomised and double‐blind as a minimum. We reported the scores for each study in the <a href="./references#CD011889-sec-0182" title="">Characteristics of included studies</a> table. </p> <p>Two review authors independently assessed the risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, Chapter 8 (<a href="./references#CD011889-bbs2-0062" title="Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), and adapted from those used by the Cochrane Pregnancy and Childbirth Group, with any disagreements resolved by discussion. We assessed the following for each study. </p> <p> <ul id="CD011889-list-0007"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies using a non‐random process (odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions before assignment determines whether intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. We assessed the methods as: low risk of bias (telephone or central randomisation; consecutively numbered sealed opaque envelopes); unclear risk of bias (method not clearly stated). We excluded studies that did not conceal allocation (open list). </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received as: low risk of bias (study stated that it was blinded and described the method used to achieve blinding, identical tablets, matched in appearance and smell); unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved). We excluded studies that were not double‐blind. </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk (fewer than 10% of participants did not complete the study or the study used 'baseline observation carried forward' analysis, or both); unclear risk of bias (used 'last observation carried forward' analysis); high risk of bias (used 'completer' analysis). </p> </li> <li> <p>Size of study (checking for possible biases confounded by small size). Small studies have been shown to overestimate treatment effects, probably because the conduct of small studies is more likely to be less rigorous, allowing critical criteria to be compromised (<a href="./references#CD011889-bbs2-0041" title="DechartresA , TrinquartL , BoutronI , RavaudP . Influence of trial sample size on treatment effect estimates: meta‐epidemiological study. BMJ2013;346:f2304. [DOI: 10.1136/bmj.f2304] ">Dechartres 2013</a>; <a href="./references#CD011889-bbs2-0088" title="NüeschE , TrelleS , ReichenbachS , RutjesAW , TschannenB , AltmanDG , et al. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJ2010;341:c3515. [DOI: 10.1136/bmj.c3515] ">Nüesch 2010</a>). We assessed studies as being at low risk of bias (200 participants or greater per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (fewer than 50 participants per treatment arm). </p> </li> </ul> </p> </section> <section id="CD011889-sec-0068"> <h4 class="title">Measures of treatment effect</h4> <p>We used risk ratio (RR) to establish statistical difference, and the numbers needed to treat for an additional beneficial outcome (NNT) and pooled percentages as absolute measures of benefit or harm. </p> <p>We used the following terms to describe adverse outcomes in terms of harm or prevention of harm. </p> <p> <ul id="CD011889-list-0008"> <li> <p>When significantly fewer adverse outcomes occurred with paracetamol than with control (placebo or active), we used the term the number needed to treat to prevent one event (NNTp). </p> </li> <li> <p>When significantly more adverse outcomes occurred with paracetamol compared with control (placebo or active), we used the term the number needed to treat for an additional harmful outcome or to cause one event (NNH). </p> </li> </ul> </p> <p>We have reported continuous data as the mean difference, with 95% confidence intervals (CIs), where appropriate. As anticipated, we did not carry out any analysis of continuous data. </p> </section> <section id="CD011889-sec-0069"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant.</p> </section> <section id="CD011889-sec-0070"> <h4 class="title">Dealing with missing data</h4> <p>The most likely source of missing data was expected to be cross‐over studies; we planned to use only first‐period data where possible, but where those data were not provided, we treated the results as if they were parallel group results, and commented on this. </p> <p>For all outcomes, we carried out analyses, as far as possible, on a modified intention‐to‐treat basis in which we included all participants who were randomised and received an intervention. Where studies reported sufficient information, we re‐included missing data in the analyses undertaken. We noted where there were substantial amounts of missing data in any study, and planned to perform sensitivity analyses to investigate their effect in any analyses. </p> </section> <section id="CD011889-sec-0071"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity of response rates using L'Abbé plots, a visual method for assessing differences in results of individual studies (<a href="./references#CD011889-bbs2-0070" title="L'AbbéKA , DetskyAS , O'RourkeK . Meta‐analysis in clinical research. Annals of Internal Medicine1987;107(2):224‐33. [DOI: 10.7326/0003‐4819‐107‐2‐224] ">L'Abbé 1987</a>). Where we pooled data, we reported the I<sup>2</sup> statistic. </p> </section> <section id="CD011889-sec-0072"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess publication bias by examining the number of participants in trials with zero effect (RR = 1.0) needed for the point estimate of the NNT to increase beyond a clinically useful level (<a href="./references#CD011889-bbs2-0080" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978‐0‐931092‐69‐5] ">Moore 2008</a>). In this case, we specified a clinically useful level as an NNT of 10 or greater for the outcome 'pain‐free at two hours', and NNT of 8 or greater for 'pain‐free or mild pain at two hours'. In the event, the NNTs were higher than these pre‐specified levels, so this was not possible. </p> </section> <section id="CD011889-sec-0073"> <h4 class="title">Data synthesis</h4> <p>We planned to analyse studies using a single dose of paracetamol in established pain of at least moderate intensity separately from studies in which medication was taken before pain was well established, or in which a second dose of medication was permitted. In the event, all the studies treated established headaches and almost all reported a mean baseline pain of moderate intensity. None specifically treated early, or when pain was mild. Only one study allowed a second dose of study medication, and that study did not contribute data for analysis. </p> <p>We carried out all analyses according to dose (1000 mg or 500 mg to 650 mg) and compared paracetamol with placebo or an active comparator. We combined data for analysis only for comparisons and outcomes where there were at least two studies and 200 participants (<a href="./references#CD011889-bbs2-0079" title="MooreRA , GavaghanD , TramerMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>). We calculated the RRs for benefit or harm with 95% CIs using a fixed‐effect model (<a href="./references#CD011889-bbs2-0086" title="MorrisJA , GardnerMJ . Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: GardnerMJ , AltmanDG editor(s). Statistics with Confidence ‐ Confidence Intervals and Statistical Guidelines. London: British Medical Journal, 1995:50‐63. [ISBN: 0‐7279‐0222‐0] ">Morris 1995</a>). We calculated NNT, NNTp, and NNH with 95% CIs using the pooled number of events by the method of Cook and Sackett (<a href="./references#CD011889-bbs2-0037" title="CookRJ , SackettDL . The number needed to treat: a clinically useful measure of treatment effect. BMJ1995;310(6977):452‐4. [DOI: 10.1136/bmj.310.6977.452] ">Cook 1995</a>). We assumed a statistically significant difference from control when the 95% CI of the RR for benefit or harm included the number one. </p> <p>We used the Z test to determine significant differences between the two doses of paracetamol (<a href="./references#CD011889-bbs2-0102" title="TramèrMR , ReynoldsDJM , MooreRA , McQuayHJ . Impact of covert duplicate results on meta‐analysis: a case study. BMJ1997;315(7109):635‐9. [DOI: 10.1136/bmj.315.7109.635] ">Tramèr 1997</a>). </p> <p>We have described data from comparisons and outcomes with only one study or fewer than 200 participants in the text and summary tables where appropriate for information and comparison, but did not analyse them quantitatively. </p> <section id="CD011889-sec-0074"> <h5 class="title">Quality of the evidence</h5> <p>Two review authors independently rated the quality of each outcome. We used the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) system to assess the quality of the evidence related to the key outcomes listed in <a href="#CD011889-sec-0058">Types of outcome measures</a> (<a href="./appendices#CD011889-sec-0162">Appendix 4</a>; Chapter 12, <a href="./references#CD011889-bbs2-0062" title="Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD011889-sec-0075"> <h5 class="title">'Summary of findings' tables</h5> <p>We included 'Summary of findings' tables to present the main findings in a transparent and simple tabular format. In particular, we included key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the outcomes of pain‐free at two hours, pain‐free at one and four hours, pain‐free or mild pain at two hours, participants with any adverse event, and participants with serious adverse events. </p> </section> </section> <section id="CD011889-sec-0076"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Possible issues for subgroup analysis were dose, formulation, and route of administration. A minimum of two studies and 200 participants had to be available for any subgroup analysis. </p> </section> <section id="CD011889-sec-0077"> <h4 class="title">Sensitivity analysis</h4> <p>We planned sensitivity analysis for study quality (Oxford Quality Score of 2 versus 3 or more). A minimum of two studies and 200 participants had to be available for any sensitivity analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011889-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011889-sec-0078"></div> <section id="CD011889-sec-0079"> <h3 class="title">Description of studies</h3> <section id="CD011889-sec-0080"> <h4 class="title">Results of the search</h4> <p>Our searches identified 532 potentially relevant reports in CENTRAL, 540 in MEDLINE, 1748 in EMBASE, and three in clinical trial registries. After removing duplicates and screening titles and abstracts, we obtained and read 27 full reports. Of these, we included 23 of these reports (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a>; <a href="./references#CD011889-bbs2-0003" title="FriedmanAP , DiSerioF . Symptomatic treatment of chronically recurring tension headache: a placebo‐controlled, multicenter investigation of Fioricet® and acetaminophen with codeine. Clinical Therapeutics1987;10(1):69‐81. [PUBMED: 3329967] ">Friedman 1987</a>; <a href="./references#CD011889-bbs2-0004" title="GatoulisSC , VoelkerM , FisherM . Assessment of the efficacy and safety profiles of aspirin and acetaminophen with codeine: results from 2 randomized, controlled trials in individuals with tension‐type headache and postoperative dental pain. Clinical Therapeutics2012;34(1):138‐48. [PUBMED: 22169050] ">Gatoulis 2012</a>; <a href="./references#CD011889-bbs2-0005" title="GilbertMM , DeSola PoolN , SchecterC . Analgesic/calmative effects of acetaminophen and phenyltoloxamine in treatment of simple nervous tension accompanied by headache. Current Therapeutic Research, Clinical and Experimental1976;20(1):53‐8. [PUBMED: 821705] ">Gilbert 1976</a>; <a href="./references#CD011889-bbs2-0006" title="GöbelH , FreseniusJ , HeinzeA , DworschakM , SoykaD . Effectiveness of oleum menthae piperitae and paracetamol in therapy of headache of the tension type [in German] [Effektivität von oleum menthae piperitae und von Paracetamol in der Therapie des Kopfschmerzes vom Spannungstyp]. Nervenarzt1996;67(8):672‐81. [PUBMED: 8805113] ">Göbel 1996</a>; <a href="./references#CD011889-bbs2-0007" title="GöbelH , HeinzeA , LurchA , DworschakM . Essential oils in the therapy of tension headache [in German]. Zeitschrift fur Allgemeinmedizin1998;74(4):223‐8. ">Göbel 1998</a>; <a href="./references#CD011889-bbs2-0008" title="GöbelH , HeinzeA , DworschakM , Heinze‐KuhnK , StolzeH . Analgesic efficacy and tolerability of locally applied Oleum menthae piperitae preparation LI 170 in patients with migraine or tension‐type headache [German] [Wirksamkeit und verträglichkeit von oleum‐menthaepiperitae‐lösung LI 170 bei kopfschmerz vom spannungstyp und migräne]. Zeitschrift fur Allgemeinmedizin2001;77(6):287‐295. ">Göbel 2001</a>; <a href="./references#CD011889-bbs2-0009" title="MehlischDR , WeaverM , FladungB . Ketoprofen, acetaminophen, and placebo in the treatment of tension headache. Headache1998;38(8):576‐89. [DOI: 10.1046/j.1526‐4610.1998.3808579.x] ">Mehlisch 1998</a>; <a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a>; <a href="./references#CD011889-bbs2-0011" title="MillerDS , TalbotCA , SimpsonW , KoreyA . A comparison of naproxen sodium, acetaminophen and placebo in the treatment of muscle contraction headache. Headache1987;27(7):392‐6. [DOI: 0.1111/j.1526‐4610.1987.hed2707392.x] ">Miller 1987</a>; <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a>; <a href="./references#CD011889-bbs2-0013" title="Daniels SE (Study investigator). A randomised, double‐blind, placebo‐controlled, double‐dummy, parallel group comparison of commercial ibuprofen (single dose of 400 mg) versus commercial paracetamol (single dose of 1000 mg) in patients with tension type headache. Supplied by Reckitt Benckiser2001. ">NL9701</a>; <a href="./references#CD011889-bbs2-0014" title="PackmanB , PackmanE , DoyleG , CooperS , AshrafE , KoronkiewiczK , et al. Solubilized ibuprofen: evaluation of onset, relief, and safety of a novel formulation in the treatment of episodic tension‐type headache. Headache2000;40(7):561‐7. [DOI: 10.1046/j.1526‐4610.2000.00087.x] ">Packman 2000</a>; <a href="./references#CD011889-bbs2-0015" title="PetersBH , FraimCJ , MaselBE . Comparison of 650 mg aspirin and 1,000 mg acetaminophen with each other, and with placebo in moderately severe headache. American Journal of Medicine1983;74(6):36‐42. [DOI: 10.1016/0002‐9343(83)90526‐0] ">Peters 1983</a>; <a href="./references#CD011889-bbs2-0016" title="PiniLA , DelBeneE , ZanchinG , SarchielliP , DiTrapaniG , PrudenzanoMP , et al. Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension‐type headache: a randomised, double‐blind, double‐dummy, cross‐over study versus placebo and naproxen sodium. Journal of Headache and Pain2008;9(6):367‐73. [PUBMED: 18815727] ">Pini 2008</a>; <a href="./references#CD011889-bbs2-0017" title="PriorMJ , CooperKM , MayLG , BowenDL . Efficacy and safety of acetaminophen and naproxen in the treatment of tension‐type headache. A randomised, double‐blind, placebo‐controlled trial. Cephalgia2002;20(9):740‐8. [PUBMED: 12421160 ] ">Prior 2002</a>; <a href="./references#CD011889-bbs2-0018" title="SchachtelBP , ThodenWR , KonermanJP , BrownA , ChaingDS . Headache pain model for assessing and comparing the efficacy of over‐the‐counter analgesic agents. Clinical Pharmacology &amp; Therapeutics1991;50(3):322‐9. [DOI: 10.1038/clpt.1991.143] ">Schachtel 1991</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>; <a href="./references#CD011889-bbs2-0022" title='ThorpeP . Controlled and uncontrolled studies on "Fiorinal‐PA" for symptomatic relief in tension headache. Medical Journal of Australia1970;2(4):180‐1. [PUBMED: 4917129] '>Thorpe 1970</a>; <a href="./references#CD011889-bbs2-0023" title="WardN , WhitneyC , AveryD , DunnerD . The analgesic effects of caffeine in headache. Pain1991;44(2):151‐5. [DOI: 10.1016/0304‐3959(91)90129‐L] ">Ward 1991</a>) and excluded four (<a href="./references#CD011889-bbs2-0024" title="deSouza CarvalhoD , BareaLM , KowacsPA , FragosoYD . Efficacy and tolerability of combined dipyrone, isometheptene and caffeine in the treatment of mild‐to‐moderate primary headache episodes. Expert Review of Neurotherapeutics2012;12(2):159‐67. [DOI: 10.1586/ern.11.193] ">de Souza Carvalho 2012</a>; <a href="./references#CD011889-bbs2-0025" title="DienerHC , PeilH , AicherB . The efficacy and tolerability of a fixed combination of acetylsalicylic acid, paracetamol, and caffeine in patients with severe headache: a post‐hoc subgroup analysis from a multicentre, randomized, double‐blind, single‐dose, placebo‐controlled parallel group study. Cephalalgia2011;31(14):1466‐76. [DOI: 10.1177/0333102411419682] DienerHC , PfaffenrathV , PagelerL , PeilH , AicherB . The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double‐blind, single‐dose, placebo‐controlled parallel group study. Cephalalgia2005;25(10):776‐87. [DOI: 10.1111/j.1468‐2982.2005.00948.x] ">Diener 2005</a>; <a href="./references#CD011889-bbs2-0026" title="Bayer . A double‐blind, randomized, parallel, placebo‐controlled trial assessing the analgesic efficacy of a single dose of fast release aspirin 1000 mg and acetaminophen 1000 mg in tension type headache pain, 2014. www.clinicaltrials.gov/ct2/show/NCT01552798 (accessed 22 December 2015). ">NCT01552798</a>; <a href="./references#CD011889-bbs2-0027" title="WójcickiJ , SamochowiecL , LawczyńskiL , SzwedG , OlszewskaM . A double‐blind comparative evaluation of aspirin, paracetamol and paracetamol + caffeine (Finimal) for their analgesic effectiveness. Archivum Immunologiae et Therapiae Experimentalis (Warsz)1977;25(2):175‐9. [PUBMED: 326219] ">Wójcicki 1977</a>). In addition, RB provided the clinical trial report for one unpublished study that satisfied our inclusion criteria (<a href="./references#CD011889-bbs2-0013" title="Daniels SE (Study investigator). A randomised, double‐blind, placebo‐controlled, double‐dummy, parallel group comparison of commercial ibuprofen (single dose of 400 mg) versus commercial paracetamol (single dose of 1000 mg) in patients with tension type headache. Supplied by Reckitt Benckiser2001. ">NL9701</a>) (<a href="#CD011889-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011889-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011889-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>One ongoing study is testing paracetamol 1000 mg plus caffeine 130 mg compared with placebo and ibuprofen 400 mg (<a href="./references#CD011889-bbs2-0028" title="GlaxoSmithKline . A study to assess efficacy over placebo and speed of onset of pain relief of new paracetamol and caffeine tablets as compared to ibuprofen in episodic tension type headache, 2014. www.clinicaltrials.gov/ct2/show/record/NCT01842633 (accessed 22 December 2015). ">NCT01842633</a>) (see <a href="./references#CD011889-sec-0184" title="">Characteristics of ongoing studies</a>). </p> </section> <section id="CD011889-sec-0081"> <h4 class="title">Included studies</h4> <p>One article reported on six individual studies with similar methods, but combined the results (<a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a>). Another article subsequently reported combined results for four of these studies, providing additional efficacy data (<a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a>). For the purposes of this review, we refer to studies 1 to 4 as <a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a> and studies 5 and 6 as <a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a>, and count them as two included studies. We included 23 studies (8079 participants; 7701 in efficacy analyses), all of which enrolled adult participants with frequent episodic TTH (see <a href="./references#CD011889-sec-0182" title="">Characteristics of included studies</a> table). </p> <p>Eleven studies specified using the IHS diagnostic criteria (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0004" title="GatoulisSC , VoelkerM , FisherM . Assessment of the efficacy and safety profiles of aspirin and acetaminophen with codeine: results from 2 randomized, controlled trials in individuals with tension‐type headache and postoperative dental pain. Clinical Therapeutics2012;34(1):138‐48. [PUBMED: 22169050] ">Gatoulis 2012</a>; <a href="./references#CD011889-bbs2-0006" title="GöbelH , FreseniusJ , HeinzeA , DworschakM , SoykaD . Effectiveness of oleum menthae piperitae and paracetamol in therapy of headache of the tension type [in German] [Effektivität von oleum menthae piperitae und von Paracetamol in der Therapie des Kopfschmerzes vom Spannungstyp]. Nervenarzt1996;67(8):672‐81. [PUBMED: 8805113] ">Göbel 1996</a>; <a href="./references#CD011889-bbs2-0007" title="GöbelH , HeinzeA , LurchA , DworschakM . Essential oils in the therapy of tension headache [in German]. Zeitschrift fur Allgemeinmedizin1998;74(4):223‐8. ">Göbel 1998</a>; <a href="./references#CD011889-bbs2-0009" title="MehlischDR , WeaverM , FladungB . Ketoprofen, acetaminophen, and placebo in the treatment of tension headache. Headache1998;38(8):576‐89. [DOI: 10.1046/j.1526‐4610.1998.3808579.x] ">Mehlisch 1998</a>; <a href="./references#CD011889-bbs2-0013" title="Daniels SE (Study investigator). A randomised, double‐blind, placebo‐controlled, double‐dummy, parallel group comparison of commercial ibuprofen (single dose of 400 mg) versus commercial paracetamol (single dose of 1000 mg) in patients with tension type headache. Supplied by Reckitt Benckiser2001. ">NL9701</a>; <a href="./references#CD011889-bbs2-0014" title="PackmanB , PackmanE , DoyleG , CooperS , AshrafE , KoronkiewiczK , et al. Solubilized ibuprofen: evaluation of onset, relief, and safety of a novel formulation in the treatment of episodic tension‐type headache. Headache2000;40(7):561‐7. [DOI: 10.1046/j.1526‐4610.2000.00087.x] ">Packman 2000</a>; <a href="./references#CD011889-bbs2-0016" title="PiniLA , DelBeneE , ZanchinG , SarchielliP , DiTrapaniG , PrudenzanoMP , et al. Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension‐type headache: a randomised, double‐blind, double‐dummy, cross‐over study versus placebo and naproxen sodium. Journal of Headache and Pain2008;9(6):367‐73. [PUBMED: 18815727] ">Pini 2008</a>; <a href="./references#CD011889-bbs2-0017" title="PriorMJ , CooperKM , MayLG , BowenDL . Efficacy and safety of acetaminophen and naproxen in the treatment of tension‐type headache. A randomised, double‐blind, placebo‐controlled trial. Cephalgia2002;20(9):740‐8. [PUBMED: 12421160 ] ">Prior 2002</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>), and one other reported criteria in line with those of the IHS (<a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a>). Six studies used the older classification of the Ad Hoc Committee (<a href="./references#CD011889-bbs2-0029" title="Ad Hoc Committee on Classification of Headache. Classification of headache. JAMA1962;179:717‐8. ">Ad Hoc Committee 1962</a>), (<a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a>; <a href="./references#CD011889-bbs2-0003" title="FriedmanAP , DiSerioF . Symptomatic treatment of chronically recurring tension headache: a placebo‐controlled, multicenter investigation of Fioricet® and acetaminophen with codeine. Clinical Therapeutics1987;10(1):69‐81. [PUBMED: 3329967] ">Friedman 1987</a>; <a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a>; <a href="./references#CD011889-bbs2-0011" title="MillerDS , TalbotCA , SimpsonW , KoreyA . A comparison of naproxen sodium, acetaminophen and placebo in the treatment of muscle contraction headache. Headache1987;27(7):392‐6. [DOI: 0.1111/j.1526‐4610.1987.hed2707392.x] ">Miller 1987</a>; <a href="./references#CD011889-bbs2-0018" title="SchachtelBP , ThodenWR , KonermanJP , BrownA , ChaingDS . Headache pain model for assessing and comparing the efficacy of over‐the‐counter analgesic agents. Clinical Pharmacology &amp; Therapeutics1991;50(3):322‐9. [DOI: 10.1038/clpt.1991.143] ">Schachtel 1991</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>). Five studies did not describe specific diagnostic criteria (<a href="./references#CD011889-bbs2-0005" title="GilbertMM , DeSola PoolN , SchecterC . Analgesic/calmative effects of acetaminophen and phenyltoloxamine in treatment of simple nervous tension accompanied by headache. Current Therapeutic Research, Clinical and Experimental1976;20(1):53‐8. [PUBMED: 821705] ">Gilbert 1976</a>; <a href="./references#CD011889-bbs2-0008" title="GöbelH , HeinzeA , DworschakM , Heinze‐KuhnK , StolzeH . Analgesic efficacy and tolerability of locally applied Oleum menthae piperitae preparation LI 170 in patients with migraine or tension‐type headache [German] [Wirksamkeit und verträglichkeit von oleum‐menthaepiperitae‐lösung LI 170 bei kopfschmerz vom spannungstyp und migräne]. Zeitschrift fur Allgemeinmedizin2001;77(6):287‐295. ">Göbel 2001</a>; <a href="./references#CD011889-bbs2-0015" title="PetersBH , FraimCJ , MaselBE . Comparison of 650 mg aspirin and 1,000 mg acetaminophen with each other, and with placebo in moderately severe headache. American Journal of Medicine1983;74(6):36‐42. [DOI: 10.1016/0002‐9343(83)90526‐0] ">Peters 1983</a>; <a href="./references#CD011889-bbs2-0022" title='ThorpeP . Controlled and uncontrolled studies on "Fiorinal‐PA" for symptomatic relief in tension headache. Medical Journal of Australia1970;2(4):180‐1. [PUBMED: 4917129] '>Thorpe 1970</a>; <a href="./references#CD011889-bbs2-0023" title="WardN , WhitneyC , AveryD , DunnerD . The analgesic effects of caffeine in headache. Pain1991;44(2):151‐5. [DOI: 10.1016/0304‐3959(91)90129‐L] ">Ward 1991</a>). Of these, the investigators of one study (<a href="./references#CD011889-bbs2-0008" title="GöbelH , HeinzeA , DworschakM , Heinze‐KuhnK , StolzeH . Analgesic efficacy and tolerability of locally applied Oleum menthae piperitae preparation LI 170 in patients with migraine or tension‐type headache [German] [Wirksamkeit und verträglichkeit von oleum‐menthaepiperitae‐lösung LI 170 bei kopfschmerz vom spannungstyp und migräne]. Zeitschrift fur Allgemeinmedizin2001;77(6):287‐295. ">Göbel 2001</a>) had previously described using IHS criteria in other studies. Two studies described excluding headaches of other origin including migraine (<a href="./references#CD011889-bbs2-0015" title="PetersBH , FraimCJ , MaselBE . Comparison of 650 mg aspirin and 1,000 mg acetaminophen with each other, and with placebo in moderately severe headache. American Journal of Medicine1983;74(6):36‐42. [DOI: 10.1016/0002‐9343(83)90526‐0] ">Peters 1983</a>; <a href="./references#CD011889-bbs2-0023" title="WardN , WhitneyC , AveryD , DunnerD . The analgesic effects of caffeine in headache. Pain1991;44(2):151‐5. [DOI: 10.1016/0304‐3959(91)90129‐L] ">Ward 1991</a>), and one study described a typical TTH history without other causes (<a href="./references#CD011889-bbs2-0022" title='ThorpeP . Controlled and uncontrolled studies on "Fiorinal‐PA" for symptomatic relief in tension headache. Medical Journal of Australia1970;2(4):180‐1. [PUBMED: 4917129] '>Thorpe 1970</a>). We included these six studies in the review, with the intention to carry out sensitivity analyses if any of them contributed to analyses. </p> <p>All studies reported mean baseline pain of at least moderate intensity, except one in which it was not reported (<a href="./references#CD011889-bbs2-0022" title='ThorpeP . Controlled and uncontrolled studies on "Fiorinal‐PA" for symptomatic relief in tension headache. Medical Journal of Australia1970;2(4):180‐1. [PUBMED: 4917129] '>Thorpe 1970</a>). None of the studies reported the average headache frequency of participants. </p> <p>Ten studies used a cross‐over design (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a>; <a href="./references#CD011889-bbs2-0005" title="GilbertMM , DeSola PoolN , SchecterC . Analgesic/calmative effects of acetaminophen and phenyltoloxamine in treatment of simple nervous tension accompanied by headache. Current Therapeutic Research, Clinical and Experimental1976;20(1):53‐8. [PUBMED: 821705] ">Gilbert 1976</a>; <a href="./references#CD011889-bbs2-0006" title="GöbelH , FreseniusJ , HeinzeA , DworschakM , SoykaD . Effectiveness of oleum menthae piperitae and paracetamol in therapy of headache of the tension type [in German] [Effektivität von oleum menthae piperitae und von Paracetamol in der Therapie des Kopfschmerzes vom Spannungstyp]. Nervenarzt1996;67(8):672‐81. [PUBMED: 8805113] ">Göbel 1996</a>; <a href="./references#CD011889-bbs2-0007" title="GöbelH , HeinzeA , LurchA , DworschakM . Essential oils in the therapy of tension headache [in German]. Zeitschrift fur Allgemeinmedizin1998;74(4):223‐8. ">Göbel 1998</a>; <a href="./references#CD011889-bbs2-0008" title="GöbelH , HeinzeA , DworschakM , Heinze‐KuhnK , StolzeH . Analgesic efficacy and tolerability of locally applied Oleum menthae piperitae preparation LI 170 in patients with migraine or tension‐type headache [German] [Wirksamkeit und verträglichkeit von oleum‐menthaepiperitae‐lösung LI 170 bei kopfschmerz vom spannungstyp und migräne]. Zeitschrift fur Allgemeinmedizin2001;77(6):287‐295. ">Göbel 2001</a>; <a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a>; <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a>; <a href="./references#CD011889-bbs2-0016" title="PiniLA , DelBeneE , ZanchinG , SarchielliP , DiTrapaniG , PrudenzanoMP , et al. Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension‐type headache: a randomised, double‐blind, double‐dummy, cross‐over study versus placebo and naproxen sodium. Journal of Headache and Pain2008;9(6):367‐73. [PUBMED: 18815727] ">Pini 2008</a>; <a href="./references#CD011889-bbs2-0023" title="WardN , WhitneyC , AveryD , DunnerD . The analgesic effects of caffeine in headache. Pain1991;44(2):151‐5. [DOI: 10.1016/0304‐3959(91)90129‐L] ">Ward 1991</a>), and 13 used a parallel‐group design (<a href="./references#CD011889-bbs2-0003" title="FriedmanAP , DiSerioF . Symptomatic treatment of chronically recurring tension headache: a placebo‐controlled, multicenter investigation of Fioricet® and acetaminophen with codeine. Clinical Therapeutics1987;10(1):69‐81. [PUBMED: 3329967] ">Friedman 1987</a>; <a href="./references#CD011889-bbs2-0004" title="GatoulisSC , VoelkerM , FisherM . Assessment of the efficacy and safety profiles of aspirin and acetaminophen with codeine: results from 2 randomized, controlled trials in individuals with tension‐type headache and postoperative dental pain. Clinical Therapeutics2012;34(1):138‐48. [PUBMED: 22169050] ">Gatoulis 2012</a>; <a href="./references#CD011889-bbs2-0009" title="MehlischDR , WeaverM , FladungB . Ketoprofen, acetaminophen, and placebo in the treatment of tension headache. Headache1998;38(8):576‐89. [DOI: 10.1046/j.1526‐4610.1998.3808579.x] ">Mehlisch 1998</a>; <a href="./references#CD011889-bbs2-0011" title="MillerDS , TalbotCA , SimpsonW , KoreyA . A comparison of naproxen sodium, acetaminophen and placebo in the treatment of muscle contraction headache. Headache1987;27(7):392‐6. [DOI: 0.1111/j.1526‐4610.1987.hed2707392.x] ">Miller 1987</a>; <a href="./references#CD011889-bbs2-0013" title="Daniels SE (Study investigator). A randomised, double‐blind, placebo‐controlled, double‐dummy, parallel group comparison of commercial ibuprofen (single dose of 400 mg) versus commercial paracetamol (single dose of 1000 mg) in patients with tension type headache. Supplied by Reckitt Benckiser2001. ">NL9701</a>; <a href="./references#CD011889-bbs2-0014" title="PackmanB , PackmanE , DoyleG , CooperS , AshrafE , KoronkiewiczK , et al. Solubilized ibuprofen: evaluation of onset, relief, and safety of a novel formulation in the treatment of episodic tension‐type headache. Headache2000;40(7):561‐7. [DOI: 10.1046/j.1526‐4610.2000.00087.x] ">Packman 2000</a>; <a href="./references#CD011889-bbs2-0015" title="PetersBH , FraimCJ , MaselBE . Comparison of 650 mg aspirin and 1,000 mg acetaminophen with each other, and with placebo in moderately severe headache. American Journal of Medicine1983;74(6):36‐42. [DOI: 10.1016/0002‐9343(83)90526‐0] ">Peters 1983</a>; <a href="./references#CD011889-bbs2-0017" title="PriorMJ , CooperKM , MayLG , BowenDL . Efficacy and safety of acetaminophen and naproxen in the treatment of tension‐type headache. A randomised, double‐blind, placebo‐controlled trial. Cephalgia2002;20(9):740‐8. [PUBMED: 12421160 ] ">Prior 2002</a>; <a href="./references#CD011889-bbs2-0018" title="SchachtelBP , ThodenWR , KonermanJP , BrownA , ChaingDS . Headache pain model for assessing and comparing the efficacy of over‐the‐counter analgesic agents. Clinical Pharmacology &amp; Therapeutics1991;50(3):322‐9. [DOI: 10.1038/clpt.1991.143] ">Schachtel 1991</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>; <a href="./references#CD011889-bbs2-0022" title='ThorpeP . Controlled and uncontrolled studies on "Fiorinal‐PA" for symptomatic relief in tension headache. Medical Journal of Australia1970;2(4):180‐1. [PUBMED: 4917129] '>Thorpe 1970</a>). All but one study used a single dose of medication to treat a discrete headache episode. The one exception to this was <a href="./references#CD011889-bbs2-0022" title='ThorpeP . Controlled and uncontrolled studies on "Fiorinal‐PA" for symptomatic relief in tension headache. Medical Journal of Australia1970;2(4):180‐1. [PUBMED: 4917129] '>Thorpe 1970</a>, which permitted the use of a second dose. None of the cross‐over studies reported first period data separately. In most of the studies, participants treated a single episode with any one intervention, but in <a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a> and <a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a> participants treated two episodes with each intervention. Four cross‐over studies specified a washout of at least 48 hours between doses (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a>; <a href="./references#CD011889-bbs2-0005" title="GilbertMM , DeSola PoolN , SchecterC . Analgesic/calmative effects of acetaminophen and phenyltoloxamine in treatment of simple nervous tension accompanied by headache. Current Therapeutic Research, Clinical and Experimental1976;20(1):53‐8. [PUBMED: 821705] ">Gilbert 1976</a>; <a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a>), whereas the others did not specify periods between treatments. We included these six other studies in the review, with the intention to carry out sensitivity analyses if any of them contributed to analyses (<a href="./references#CD011889-bbs2-0006" title="GöbelH , FreseniusJ , HeinzeA , DworschakM , SoykaD . Effectiveness of oleum menthae piperitae and paracetamol in therapy of headache of the tension type [in German] [Effektivität von oleum menthae piperitae und von Paracetamol in der Therapie des Kopfschmerzes vom Spannungstyp]. Nervenarzt1996;67(8):672‐81. [PUBMED: 8805113] ">Göbel 1996</a>; <a href="./references#CD011889-bbs2-0007" title="GöbelH , HeinzeA , LurchA , DworschakM . Essential oils in the therapy of tension headache [in German]. Zeitschrift fur Allgemeinmedizin1998;74(4):223‐8. ">Göbel 1998</a>; <a href="./references#CD011889-bbs2-0008" title="GöbelH , HeinzeA , DworschakM , Heinze‐KuhnK , StolzeH . Analgesic efficacy and tolerability of locally applied Oleum menthae piperitae preparation LI 170 in patients with migraine or tension‐type headache [German] [Wirksamkeit und verträglichkeit von oleum‐menthaepiperitae‐lösung LI 170 bei kopfschmerz vom spannungstyp und migräne]. Zeitschrift fur Allgemeinmedizin2001;77(6):287‐295. ">Göbel 2001</a>; <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a>; <a href="./references#CD011889-bbs2-0016" title="PiniLA , DelBeneE , ZanchinG , SarchielliP , DiTrapaniG , PrudenzanoMP , et al. Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension‐type headache: a randomised, double‐blind, double‐dummy, cross‐over study versus placebo and naproxen sodium. Journal of Headache and Pain2008;9(6):367‐73. [PUBMED: 18815727] ">Pini 2008</a>; <a href="./references#CD011889-bbs2-0023" title="WardN , WhitneyC , AveryD , DunnerD . The analgesic effects of caffeine in headache. Pain1991;44(2):151‐5. [DOI: 10.1016/0304‐3959(91)90129‐L] ">Ward 1991</a>). </p> <p>The studies did not consistently report the outcomes of interest. Eight studies reported pain‐free at two hours, four studies reported pain‐free at one hour, and three studies reported pain‐free at four hours. Five studies reported pain‐free or mild pain at two hours (including "total or worthwhile effect at two hours"), and 15 studies reported some measure of PID. Seventeen studies reported on adverse events, and eight studies reported on the use of rescue medication. </p> <p>Sixteen studies used paracetamol 1000 mg (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a>; <a href="./references#CD011889-bbs2-0006" title="GöbelH , FreseniusJ , HeinzeA , DworschakM , SoykaD . Effectiveness of oleum menthae piperitae and paracetamol in therapy of headache of the tension type [in German] [Effektivität von oleum menthae piperitae und von Paracetamol in der Therapie des Kopfschmerzes vom Spannungstyp]. Nervenarzt1996;67(8):672‐81. [PUBMED: 8805113] ">Göbel 1996</a>; <a href="./references#CD011889-bbs2-0007" title="GöbelH , HeinzeA , LurchA , DworschakM . Essential oils in the therapy of tension headache [in German]. Zeitschrift fur Allgemeinmedizin1998;74(4):223‐8. ">Göbel 1998</a>; <a href="./references#CD011889-bbs2-0008" title="GöbelH , HeinzeA , DworschakM , Heinze‐KuhnK , StolzeH . Analgesic efficacy and tolerability of locally applied Oleum menthae piperitae preparation LI 170 in patients with migraine or tension‐type headache [German] [Wirksamkeit und verträglichkeit von oleum‐menthaepiperitae‐lösung LI 170 bei kopfschmerz vom spannungstyp und migräne]. Zeitschrift fur Allgemeinmedizin2001;77(6):287‐295. ">Göbel 2001</a>; <a href="./references#CD011889-bbs2-0009" title="MehlischDR , WeaverM , FladungB . Ketoprofen, acetaminophen, and placebo in the treatment of tension headache. Headache1998;38(8):576‐89. [DOI: 10.1046/j.1526‐4610.1998.3808579.x] ">Mehlisch 1998</a>; <a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a>; <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a>; <a href="./references#CD011889-bbs2-0013" title="Daniels SE (Study investigator). A randomised, double‐blind, placebo‐controlled, double‐dummy, parallel group comparison of commercial ibuprofen (single dose of 400 mg) versus commercial paracetamol (single dose of 1000 mg) in patients with tension type headache. Supplied by Reckitt Benckiser2001. ">NL9701</a>; <a href="./references#CD011889-bbs2-0014" title="PackmanB , PackmanE , DoyleG , CooperS , AshrafE , KoronkiewiczK , et al. Solubilized ibuprofen: evaluation of onset, relief, and safety of a novel formulation in the treatment of episodic tension‐type headache. Headache2000;40(7):561‐7. [DOI: 10.1046/j.1526‐4610.2000.00087.x] ">Packman 2000</a>; <a href="./references#CD011889-bbs2-0015" title="PetersBH , FraimCJ , MaselBE . Comparison of 650 mg aspirin and 1,000 mg acetaminophen with each other, and with placebo in moderately severe headache. American Journal of Medicine1983;74(6):36‐42. [DOI: 10.1016/0002‐9343(83)90526‐0] ">Peters 1983</a>; <a href="./references#CD011889-bbs2-0017" title="PriorMJ , CooperKM , MayLG , BowenDL . Efficacy and safety of acetaminophen and naproxen in the treatment of tension‐type headache. A randomised, double‐blind, placebo‐controlled trial. Cephalgia2002;20(9):740‐8. [PUBMED: 12421160 ] ">Prior 2002</a>; <a href="./references#CD011889-bbs2-0018" title="SchachtelBP , ThodenWR , KonermanJP , BrownA , ChaingDS . Headache pain model for assessing and comparing the efficacy of over‐the‐counter analgesic agents. Clinical Pharmacology &amp; Therapeutics1991;50(3):322‐9. [DOI: 10.1038/clpt.1991.143] ">Schachtel 1991</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>). Two studies used paracetamol 500 mg (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>). Two studies used paracetamol 650 mg (<a href="./references#CD011889-bbs2-0005" title="GilbertMM , DeSola PoolN , SchecterC . Analgesic/calmative effects of acetaminophen and phenyltoloxamine in treatment of simple nervous tension accompanied by headache. Current Therapeutic Research, Clinical and Experimental1976;20(1):53‐8. [PUBMED: 821705] ">Gilbert 1976</a>; <a href="./references#CD011889-bbs2-0011" title="MillerDS , TalbotCA , SimpsonW , KoreyA . A comparison of naproxen sodium, acetaminophen and placebo in the treatment of muscle contraction headache. Headache1987;27(7):392‐6. [DOI: 0.1111/j.1526‐4610.1987.hed2707392.x] ">Miller 1987</a>). One used paracetamol 648 mg (<a href="./references#CD011889-bbs2-0023" title="WardN , WhitneyC , AveryD , DunnerD . The analgesic effects of caffeine in headache. Pain1991;44(2):151‐5. [DOI: 10.1016/0304‐3959(91)90129‐L] ">Ward 1991</a>). Nine studies used paracetamol given in combination with other medications. One study used paracetamol 600 mg plus codeine 60 mg (<a href="./references#CD011889-bbs2-0003" title="FriedmanAP , DiSerioF . Symptomatic treatment of chronically recurring tension headache: a placebo‐controlled, multicenter investigation of Fioricet® and acetaminophen with codeine. Clinical Therapeutics1987;10(1):69‐81. [PUBMED: 3329967] ">Friedman 1987</a>). One study used paracetamol 300 mg plus codeine 30 mg (<a href="./references#CD011889-bbs2-0004" title="GatoulisSC , VoelkerM , FisherM . Assessment of the efficacy and safety profiles of aspirin and acetaminophen with codeine: results from 2 randomized, controlled trials in individuals with tension‐type headache and postoperative dental pain. Clinical Therapeutics2012;34(1):138‐48. [PUBMED: 22169050] ">Gatoulis 2012</a>). One study used paracetamol 650 mg plus phenyltoloxamine citrate 60 mg (Percogesic) (<a href="./references#CD011889-bbs2-0005" title="GilbertMM , DeSola PoolN , SchecterC . Analgesic/calmative effects of acetaminophen and phenyltoloxamine in treatment of simple nervous tension accompanied by headache. Current Therapeutic Research, Clinical and Experimental1976;20(1):53‐8. [PUBMED: 821705] ">Gilbert 1976</a>). Two studies used paracetamol 1000 mg plus peppermint oil 10 mg (<a href="./references#CD011889-bbs2-0006" title="GöbelH , FreseniusJ , HeinzeA , DworschakM , SoykaD . Effectiveness of oleum menthae piperitae and paracetamol in therapy of headache of the tension type [in German] [Effektivität von oleum menthae piperitae und von Paracetamol in der Therapie des Kopfschmerzes vom Spannungstyp]. Nervenarzt1996;67(8):672‐81. [PUBMED: 8805113] ">Göbel 1996</a>; <a href="./references#CD011889-bbs2-0008" title="GöbelH , HeinzeA , DworschakM , Heinze‐KuhnK , StolzeH . Analgesic efficacy and tolerability of locally applied Oleum menthae piperitae preparation LI 170 in patients with migraine or tension‐type headache [German] [Wirksamkeit und verträglichkeit von oleum‐menthaepiperitae‐lösung LI 170 bei kopfschmerz vom spannungstyp und migräne]. Zeitschrift fur Allgemeinmedizin2001;77(6):287‐295. ">Göbel 2001</a>). One study used paracetamol 500 mg plus aspirin 500 mg plus caffeine 130 mg (<a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a>). Three studies used paracetamol 1000 mg plus caffeine 130 mg (<a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a>; <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a>; <a href="./references#CD011889-bbs2-0016" title="PiniLA , DelBeneE , ZanchinG , SarchielliP , DiTrapaniG , PrudenzanoMP , et al. Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension‐type headache: a randomised, double‐blind, double‐dummy, cross‐over study versus placebo and naproxen sodium. Journal of Headache and Pain2008;9(6):367‐73. [PUBMED: 18815727] ">Pini 2008</a>). One study used both paracetamol 648 mg plus caffeine 65 mg, and paracetamol 648 mg plus caffeine 130 mg (<a href="./references#CD011889-bbs2-0023" title="WardN , WhitneyC , AveryD , DunnerD . The analgesic effects of caffeine in headache. Pain1991;44(2):151‐5. [DOI: 10.1016/0304‐3959(91)90129‐L] ">Ward 1991</a>). One study used paracetamol 650 mg plus butalbital 100 mg plus caffeine 80 mg (Fioricet) (<a href="./references#CD011889-bbs2-0003" title="FriedmanAP , DiSerioF . Symptomatic treatment of chronically recurring tension headache: a placebo‐controlled, multicenter investigation of Fioricet® and acetaminophen with codeine. Clinical Therapeutics1987;10(1):69‐81. [PUBMED: 3329967] ">Friedman 1987</a>). One used paracetamol plus aspirin plus caffeine plus isobutylallylbarbituric acid; Fiorinal‐Pa) (<a href="./references#CD011889-bbs2-0022" title='ThorpeP . Controlled and uncontrolled studies on "Fiorinal‐PA" for symptomatic relief in tension headache. Medical Journal of Australia1970;2(4):180‐1. [PUBMED: 4917129] '>Thorpe 1970</a>). </p> <p>Active comparators were:</p> <p> <ul id="CD011889-list-0009"> <li> <p>ketoprofen 12.5 mg, 25 mg, and 50 mg (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0009" title="MehlischDR , WeaverM , FladungB . Ketoprofen, acetaminophen, and placebo in the treatment of tension headache. Headache1998;38(8):576‐89. [DOI: 10.1046/j.1526‐4610.1998.3808579.x] ">Mehlisch 1998</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>); </p> </li> <li> <p>phenyltoloxamine 60 mg (<a href="./references#CD011889-bbs2-0005" title="GilbertMM , DeSola PoolN , SchecterC . Analgesic/calmative effects of acetaminophen and phenyltoloxamine in treatment of simple nervous tension accompanied by headache. Current Therapeutic Research, Clinical and Experimental1976;20(1):53‐8. [PUBMED: 821705] ">Gilbert 1976</a>); </p> </li> <li> <p>peppermint oil 10 g (<a href="./references#CD011889-bbs2-0006" title="GöbelH , FreseniusJ , HeinzeA , DworschakM , SoykaD . Effectiveness of oleum menthae piperitae and paracetamol in therapy of headache of the tension type [in German] [Effektivität von oleum menthae piperitae und von Paracetamol in der Therapie des Kopfschmerzes vom Spannungstyp]. Nervenarzt1996;67(8):672‐81. [PUBMED: 8805113] ">Göbel 1996</a>; <a href="./references#CD011889-bbs2-0007" title="GöbelH , HeinzeA , LurchA , DworschakM . Essential oils in the therapy of tension headache [in German]. Zeitschrift fur Allgemeinmedizin1998;74(4):223‐8. ">Göbel 1998</a>; <a href="./references#CD011889-bbs2-0008" title="GöbelH , HeinzeA , DworschakM , Heinze‐KuhnK , StolzeH . Analgesic efficacy and tolerability of locally applied Oleum menthae piperitae preparation LI 170 in patients with migraine or tension‐type headache [German] [Wirksamkeit und verträglichkeit von oleum‐menthaepiperitae‐lösung LI 170 bei kopfschmerz vom spannungstyp und migräne]. Zeitschrift fur Allgemeinmedizin2001;77(6):287‐295. ">Göbel 2001</a>); </p> </li> <li> <p>aspirin 500 mg (<a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>); </p> </li> <li> <p>aspirin 650 mg (<a href="./references#CD011889-bbs2-0015" title="PetersBH , FraimCJ , MaselBE . Comparison of 650 mg aspirin and 1,000 mg acetaminophen with each other, and with placebo in moderately severe headache. American Journal of Medicine1983;74(6):36‐42. [DOI: 10.1016/0002‐9343(83)90526‐0] ">Peters 1983</a>); </p> </li> <li> <p>aspirin 1000 mg (<a href="./references#CD011889-bbs2-0004" title="GatoulisSC , VoelkerM , FisherM . Assessment of the efficacy and safety profiles of aspirin and acetaminophen with codeine: results from 2 randomized, controlled trials in individuals with tension‐type headache and postoperative dental pain. Clinical Therapeutics2012;34(1):138‐48. [PUBMED: 22169050] ">Gatoulis 2012</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>); </p> </li> <li> <p>aspirin 1000 mg plus caffeine 64 mg (<a href="./references#CD011889-bbs2-0018" title="SchachtelBP , ThodenWR , KonermanJP , BrownA , ChaingDS . Headache pain model for assessing and comparing the efficacy of over‐the‐counter analgesic agents. Clinical Pharmacology &amp; Therapeutics1991;50(3):322‐9. [DOI: 10.1038/clpt.1991.143] ">Schachtel 1991</a>); </p> </li> <li> <p>naproxen 375 mg (<a href="./references#CD011889-bbs2-0017" title="PriorMJ , CooperKM , MayLG , BowenDL . Efficacy and safety of acetaminophen and naproxen in the treatment of tension‐type headache. A randomised, double‐blind, placebo‐controlled trial. Cephalgia2002;20(9):740‐8. [PUBMED: 12421160 ] ">Prior 2002</a>); </p> </li> <li> <p>naproxen sodium 550 mg (<a href="./references#CD011889-bbs2-0011" title="MillerDS , TalbotCA , SimpsonW , KoreyA . A comparison of naproxen sodium, acetaminophen and placebo in the treatment of muscle contraction headache. Headache1987;27(7):392‐6. [DOI: 0.1111/j.1526‐4610.1987.hed2707392.x] ">Miller 1987</a>; <a href="./references#CD011889-bbs2-0016" title="PiniLA , DelBeneE , ZanchinG , SarchielliP , DiTrapaniG , PrudenzanoMP , et al. Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension‐type headache: a randomised, double‐blind, double‐dummy, cross‐over study versus placebo and naproxen sodium. Journal of Headache and Pain2008;9(6):367‐73. [PUBMED: 18815727] ">Pini 2008</a>); </p> </li> <li> <p>ibuprofen 400 mg (<a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a>; <a href="./references#CD011889-bbs2-0014" title="PackmanB , PackmanE , DoyleG , CooperS , AshrafE , KoronkiewiczK , et al. Solubilized ibuprofen: evaluation of onset, relief, and safety of a novel formulation in the treatment of episodic tension‐type headache. Headache2000;40(7):561‐7. [DOI: 10.1046/j.1526‐4610.2000.00087.x] ">Packman 2000</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>), presumably as ibuprofen acid. </p> </li> </ul> </p> <p>The total number of participants in the 23 studies was 7164, with 5141 in 13 parallel‐group studies and 2023 in 10 cross‐over studies (though some of these participants contributed more than one headache episode). Because outcomes were inconsistently reported and because many participants received active comparators, the number of participants with data for analyses for paracetamol was therefore much smaller than the total number. </p> </section> <section id="CD011889-sec-0082"> <h4 class="title">Excluded studies</h4> <p>We excluded four studies (see <a href="./references#CD011889-sec-0183" title="">Characteristics of excluded studies</a> table). Two studies treated participants with either TTHs or migraine headaches, and did not report results separately (<a href="./references#CD011889-bbs2-0024" title="deSouza CarvalhoD , BareaLM , KowacsPA , FragosoYD . Efficacy and tolerability of combined dipyrone, isometheptene and caffeine in the treatment of mild‐to‐moderate primary headache episodes. Expert Review of Neurotherapeutics2012;12(2):159‐67. [DOI: 10.1586/ern.11.193] ">de Souza Carvalho 2012</a>; <a href="./references#CD011889-bbs2-0025" title="DienerHC , PeilH , AicherB . The efficacy and tolerability of a fixed combination of acetylsalicylic acid, paracetamol, and caffeine in patients with severe headache: a post‐hoc subgroup analysis from a multicentre, randomized, double‐blind, single‐dose, placebo‐controlled parallel group study. Cephalalgia2011;31(14):1466‐76. [DOI: 10.1177/0333102411419682] DienerHC , PfaffenrathV , PagelerL , PeilH , AicherB . The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double‐blind, single‐dose, placebo‐controlled parallel group study. Cephalalgia2005;25(10):776‐87. [DOI: 10.1111/j.1468‐2982.2005.00948.x] ">Diener 2005</a>). One study treated "common idiopathic headache", which we considered insufficiently classified, and it was not clearly randomised (<a href="./references#CD011889-bbs2-0027" title="WójcickiJ , SamochowiecL , LawczyńskiL , SzwedG , OlszewskaM . A double‐blind comparative evaluation of aspirin, paracetamol and paracetamol + caffeine (Finimal) for their analgesic effectiveness. Archivum Immunologiae et Therapiae Experimentalis (Warsz)1977;25(2):175‐9. [PUBMED: 326219] ">Wójcicki 1977</a>). The fourth study was terminated early, with only nine participants enrolled, and had no results (<a href="./references#CD011889-bbs2-0026" title="Bayer . A double‐blind, randomized, parallel, placebo‐controlled trial assessing the analgesic efficacy of a single dose of fast release aspirin 1000 mg and acetaminophen 1000 mg in tension type headache pain, 2014. www.clinicaltrials.gov/ct2/show/NCT01552798 (accessed 22 December 2015). ">NCT01552798</a>). </p> </section> </section> <section id="CD011889-sec-0083"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD011889-fig-0002">Figure 2</a> presents a summary of the risk of bias assessment. </p> <div class="figure" id="CD011889-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011889-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011889-sec-0084"> <h4 class="title">Allocation</h4> <p>All studies were randomised, but only eight adequately described the methods used to generate the random sequence (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0014" title="PackmanB , PackmanE , DoyleG , CooperS , AshrafE , KoronkiewiczK , et al. Solubilized ibuprofen: evaluation of onset, relief, and safety of a novel formulation in the treatment of episodic tension‐type headache. Headache2000;40(7):561‐7. [DOI: 10.1046/j.1526‐4610.2000.00087.x] ">Packman 2000</a>; <a href="./references#CD011889-bbs2-0016" title="PiniLA , DelBeneE , ZanchinG , SarchielliP , DiTrapaniG , PrudenzanoMP , et al. Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension‐type headache: a randomised, double‐blind, double‐dummy, cross‐over study versus placebo and naproxen sodium. Journal of Headache and Pain2008;9(6):367‐73. [PUBMED: 18815727] ">Pini 2008</a>; <a href="./references#CD011889-bbs2-0017" title="PriorMJ , CooperKM , MayLG , BowenDL . Efficacy and safety of acetaminophen and naproxen in the treatment of tension‐type headache. A randomised, double‐blind, placebo‐controlled trial. Cephalgia2002;20(9):740‐8. [PUBMED: 12421160 ] ">Prior 2002</a>; <a href="./references#CD011889-bbs2-0018" title="SchachtelBP , ThodenWR , KonermanJP , BrownA , ChaingDS . Headache pain model for assessing and comparing the efficacy of over‐the‐counter analgesic agents. Clinical Pharmacology &amp; Therapeutics1991;50(3):322‐9. [DOI: 10.1038/clpt.1991.143] ">Schachtel 1991</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>; <a href="./references#CD011889-bbs2-0022" title='ThorpeP . Controlled and uncontrolled studies on "Fiorinal‐PA" for symptomatic relief in tension headache. Medical Journal of Australia1970;2(4):180‐1. [PUBMED: 4917129] '>Thorpe 1970</a>). Three studies adequately described the method used to conceal the random allocation (<a href="./references#CD011889-bbs2-0013" title="Daniels SE (Study investigator). A randomised, double‐blind, placebo‐controlled, double‐dummy, parallel group comparison of commercial ibuprofen (single dose of 400 mg) versus commercial paracetamol (single dose of 1000 mg) in patients with tension type headache. Supplied by Reckitt Benckiser2001. ">NL9701</a>; <a href="./references#CD011889-bbs2-0016" title="PiniLA , DelBeneE , ZanchinG , SarchielliP , DiTrapaniG , PrudenzanoMP , et al. Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension‐type headache: a randomised, double‐blind, double‐dummy, cross‐over study versus placebo and naproxen sodium. Journal of Headache and Pain2008;9(6):367‐73. [PUBMED: 18815727] ">Pini 2008</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>). </p> </section> <section id="CD011889-sec-0085"> <h4 class="title">Blinding</h4> <p>All studies were double blind, and 19 adequately described the methods used to conceal the intervention from participants and personnel (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a>; <a href="./references#CD011889-bbs2-0003" title="FriedmanAP , DiSerioF . Symptomatic treatment of chronically recurring tension headache: a placebo‐controlled, multicenter investigation of Fioricet® and acetaminophen with codeine. Clinical Therapeutics1987;10(1):69‐81. [PUBMED: 3329967] ">Friedman 1987</a>; <a href="./references#CD011889-bbs2-0004" title="GatoulisSC , VoelkerM , FisherM . Assessment of the efficacy and safety profiles of aspirin and acetaminophen with codeine: results from 2 randomized, controlled trials in individuals with tension‐type headache and postoperative dental pain. Clinical Therapeutics2012;34(1):138‐48. [PUBMED: 22169050] ">Gatoulis 2012</a>; <a href="./references#CD011889-bbs2-0005" title="GilbertMM , DeSola PoolN , SchecterC . Analgesic/calmative effects of acetaminophen and phenyltoloxamine in treatment of simple nervous tension accompanied by headache. Current Therapeutic Research, Clinical and Experimental1976;20(1):53‐8. [PUBMED: 821705] ">Gilbert 1976</a>; <a href="./references#CD011889-bbs2-0006" title="GöbelH , FreseniusJ , HeinzeA , DworschakM , SoykaD . Effectiveness of oleum menthae piperitae and paracetamol in therapy of headache of the tension type [in German] [Effektivität von oleum menthae piperitae und von Paracetamol in der Therapie des Kopfschmerzes vom Spannungstyp]. Nervenarzt1996;67(8):672‐81. [PUBMED: 8805113] ">Göbel 1996</a>; <a href="./references#CD011889-bbs2-0007" title="GöbelH , HeinzeA , LurchA , DworschakM . Essential oils in the therapy of tension headache [in German]. Zeitschrift fur Allgemeinmedizin1998;74(4):223‐8. ">Göbel 1998</a>; <a href="./references#CD011889-bbs2-0008" title="GöbelH , HeinzeA , DworschakM , Heinze‐KuhnK , StolzeH . Analgesic efficacy and tolerability of locally applied Oleum menthae piperitae preparation LI 170 in patients with migraine or tension‐type headache [German] [Wirksamkeit und verträglichkeit von oleum‐menthaepiperitae‐lösung LI 170 bei kopfschmerz vom spannungstyp und migräne]. Zeitschrift fur Allgemeinmedizin2001;77(6):287‐295. ">Göbel 2001</a>; <a href="./references#CD011889-bbs2-0009" title="MehlischDR , WeaverM , FladungB . Ketoprofen, acetaminophen, and placebo in the treatment of tension headache. Headache1998;38(8):576‐89. [DOI: 10.1046/j.1526‐4610.1998.3808579.x] ">Mehlisch 1998</a>; <a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a>; <a href="./references#CD011889-bbs2-0011" title="MillerDS , TalbotCA , SimpsonW , KoreyA . A comparison of naproxen sodium, acetaminophen and placebo in the treatment of muscle contraction headache. Headache1987;27(7):392‐6. [DOI: 0.1111/j.1526‐4610.1987.hed2707392.x] ">Miller 1987</a>; <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a>; <a href="./references#CD011889-bbs2-0013" title="Daniels SE (Study investigator). A randomised, double‐blind, placebo‐controlled, double‐dummy, parallel group comparison of commercial ibuprofen (single dose of 400 mg) versus commercial paracetamol (single dose of 1000 mg) in patients with tension type headache. Supplied by Reckitt Benckiser2001. ">NL9701</a>; <a href="./references#CD011889-bbs2-0015" title="PetersBH , FraimCJ , MaselBE . Comparison of 650 mg aspirin and 1,000 mg acetaminophen with each other, and with placebo in moderately severe headache. American Journal of Medicine1983;74(6):36‐42. [DOI: 10.1016/0002‐9343(83)90526‐0] ">Peters 1983</a>; <a href="./references#CD011889-bbs2-0016" title="PiniLA , DelBeneE , ZanchinG , SarchielliP , DiTrapaniG , PrudenzanoMP , et al. Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension‐type headache: a randomised, double‐blind, double‐dummy, cross‐over study versus placebo and naproxen sodium. Journal of Headache and Pain2008;9(6):367‐73. [PUBMED: 18815727] ">Pini 2008</a>; <a href="./references#CD011889-bbs2-0017" title="PriorMJ , CooperKM , MayLG , BowenDL . Efficacy and safety of acetaminophen and naproxen in the treatment of tension‐type headache. A randomised, double‐blind, placebo‐controlled trial. Cephalgia2002;20(9):740‐8. [PUBMED: 12421160 ] ">Prior 2002</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>). </p> </section> <section id="CD011889-sec-0086"> <h4 class="title">Incomplete outcome data</h4> <p>Seven studies convincingly accounted for all participants in the primary outcome (<a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a>; <a href="./references#CD011889-bbs2-0003" title="FriedmanAP , DiSerioF . Symptomatic treatment of chronically recurring tension headache: a placebo‐controlled, multicenter investigation of Fioricet® and acetaminophen with codeine. Clinical Therapeutics1987;10(1):69‐81. [PUBMED: 3329967] ">Friedman 1987</a>; <a href="./references#CD011889-bbs2-0009" title="MehlischDR , WeaverM , FladungB . Ketoprofen, acetaminophen, and placebo in the treatment of tension headache. Headache1998;38(8):576‐89. [DOI: 10.1046/j.1526‐4610.1998.3808579.x] ">Mehlisch 1998</a>; <a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a>; <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a>; <a href="./references#CD011889-bbs2-0013" title="Daniels SE (Study investigator). A randomised, double‐blind, placebo‐controlled, double‐dummy, parallel group comparison of commercial ibuprofen (single dose of 400 mg) versus commercial paracetamol (single dose of 1000 mg) in patients with tension type headache. Supplied by Reckitt Benckiser2001. ">NL9701</a>; <a href="./references#CD011889-bbs2-0018" title="SchachtelBP , ThodenWR , KonermanJP , BrownA , ChaingDS . Headache pain model for assessing and comparing the efficacy of over‐the‐counter analgesic agents. Clinical Pharmacology &amp; Therapeutics1991;50(3):322‐9. [DOI: 10.1038/clpt.1991.143] ">Schachtel 1991</a>). Three studies were at high risk of bias due to their use of completer analysis (<a href="./references#CD011889-bbs2-0007" title="GöbelH , HeinzeA , LurchA , DworschakM . Essential oils in the therapy of tension headache [in German]. Zeitschrift fur Allgemeinmedizin1998;74(4):223‐8. ">Göbel 1998</a>; <a href="./references#CD011889-bbs2-0008" title="GöbelH , HeinzeA , DworschakM , Heinze‐KuhnK , StolzeH . Analgesic efficacy and tolerability of locally applied Oleum menthae piperitae preparation LI 170 in patients with migraine or tension‐type headache [German] [Wirksamkeit und verträglichkeit von oleum‐menthaepiperitae‐lösung LI 170 bei kopfschmerz vom spannungstyp und migräne]. Zeitschrift fur Allgemeinmedizin2001;77(6):287‐295. ">Göbel 2001</a>; <a href="./references#CD011889-bbs2-0023" title="WardN , WhitneyC , AveryD , DunnerD . The analgesic effects of caffeine in headache. Pain1991;44(2):151‐5. [DOI: 10.1016/0304‐3959(91)90129‐L] ">Ward 1991</a>). We judged the remaining studies to be at unclear risk of bias due to a lack of information. </p> </section> <section id="CD011889-sec-0087"> <h4 class="title">Other potential sources of bias</h4> <p>Two studies enrolled 200 or more participants per treatment arm (low risk of bias; <a href="./references#CD011889-bbs2-0005" title="GilbertMM , DeSola PoolN , SchecterC . Analgesic/calmative effects of acetaminophen and phenyltoloxamine in treatment of simple nervous tension accompanied by headache. Current Therapeutic Research, Clinical and Experimental1976;20(1):53‐8. [PUBMED: 821705] ">Gilbert 1976</a>; <a href="./references#CD011889-bbs2-0017" title="PriorMJ , CooperKM , MayLG , BowenDL . Efficacy and safety of acetaminophen and naproxen in the treatment of tension‐type headache. A randomised, double‐blind, placebo‐controlled trial. Cephalgia2002;20(9):740‐8. [PUBMED: 12421160 ] ">Prior 2002</a>). Seven studies all included at least one treatment arm with fewer than 50 participants (high risk of bias: <a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0006" title="GöbelH , FreseniusJ , HeinzeA , DworschakM , SoykaD . Effectiveness of oleum menthae piperitae and paracetamol in therapy of headache of the tension type [in German] [Effektivität von oleum menthae piperitae und von Paracetamol in der Therapie des Kopfschmerzes vom Spannungstyp]. Nervenarzt1996;67(8):672‐81. [PUBMED: 8805113] ">Göbel 1996</a>; <a href="./references#CD011889-bbs2-0007" title="GöbelH , HeinzeA , LurchA , DworschakM . Essential oils in the therapy of tension headache [in German]. Zeitschrift fur Allgemeinmedizin1998;74(4):223‐8. ">Göbel 1998</a>; <a href="./references#CD011889-bbs2-0011" title="MillerDS , TalbotCA , SimpsonW , KoreyA . A comparison of naproxen sodium, acetaminophen and placebo in the treatment of muscle contraction headache. Headache1987;27(7):392‐6. [DOI: 0.1111/j.1526‐4610.1987.hed2707392.x] ">Miller 1987</a>; <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a>; <a href="./references#CD011889-bbs2-0014" title="PackmanB , PackmanE , DoyleG , CooperS , AshrafE , KoronkiewiczK , et al. Solubilized ibuprofen: evaluation of onset, relief, and safety of a novel formulation in the treatment of episodic tension‐type headache. Headache2000;40(7):561‐7. [DOI: 10.1046/j.1526‐4610.2000.00087.x] ">Packman 2000</a>; <a href="./references#CD011889-bbs2-0022" title='ThorpeP . Controlled and uncontrolled studies on "Fiorinal‐PA" for symptomatic relief in tension headache. Medical Journal of Australia1970;2(4):180‐1. [PUBMED: 4917129] '>Thorpe 1970</a>). The remaining 14 studies had a minimum of between 50 and 199 per treatment arm (unclear risk of bias; <a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a> (in individual studies); <a href="./references#CD011889-bbs2-0003" title="FriedmanAP , DiSerioF . Symptomatic treatment of chronically recurring tension headache: a placebo‐controlled, multicenter investigation of Fioricet® and acetaminophen with codeine. Clinical Therapeutics1987;10(1):69‐81. [PUBMED: 3329967] ">Friedman 1987</a>; <a href="./references#CD011889-bbs2-0004" title="GatoulisSC , VoelkerM , FisherM . Assessment of the efficacy and safety profiles of aspirin and acetaminophen with codeine: results from 2 randomized, controlled trials in individuals with tension‐type headache and postoperative dental pain. Clinical Therapeutics2012;34(1):138‐48. [PUBMED: 22169050] ">Gatoulis 2012</a>; <a href="./references#CD011889-bbs2-0008" title="GöbelH , HeinzeA , DworschakM , Heinze‐KuhnK , StolzeH . Analgesic efficacy and tolerability of locally applied Oleum menthae piperitae preparation LI 170 in patients with migraine or tension‐type headache [German] [Wirksamkeit und verträglichkeit von oleum‐menthaepiperitae‐lösung LI 170 bei kopfschmerz vom spannungstyp und migräne]. Zeitschrift fur Allgemeinmedizin2001;77(6):287‐295. ">Göbel 2001</a>; <a href="./references#CD011889-bbs2-0009" title="MehlischDR , WeaverM , FladungB . Ketoprofen, acetaminophen, and placebo in the treatment of tension headache. Headache1998;38(8):576‐89. [DOI: 10.1046/j.1526‐4610.1998.3808579.x] ">Mehlisch 1998</a>; <a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a> (in individual studies); <a href="./references#CD011889-bbs2-0013" title="Daniels SE (Study investigator). A randomised, double‐blind, placebo‐controlled, double‐dummy, parallel group comparison of commercial ibuprofen (single dose of 400 mg) versus commercial paracetamol (single dose of 1000 mg) in patients with tension type headache. Supplied by Reckitt Benckiser2001. ">NL9701</a>; <a href="./references#CD011889-bbs2-0015" title="PetersBH , FraimCJ , MaselBE . Comparison of 650 mg aspirin and 1,000 mg acetaminophen with each other, and with placebo in moderately severe headache. American Journal of Medicine1983;74(6):36‐42. [DOI: 10.1016/0002‐9343(83)90526‐0] ">Peters 1983</a>; <a href="./references#CD011889-bbs2-0016" title="PiniLA , DelBeneE , ZanchinG , SarchielliP , DiTrapaniG , PrudenzanoMP , et al. Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension‐type headache: a randomised, double‐blind, double‐dummy, cross‐over study versus placebo and naproxen sodium. Journal of Headache and Pain2008;9(6):367‐73. [PUBMED: 18815727] ">Pini 2008</a>; <a href="./references#CD011889-bbs2-0018" title="SchachtelBP , ThodenWR , KonermanJP , BrownA , ChaingDS . Headache pain model for assessing and comparing the efficacy of over‐the‐counter analgesic agents. Clinical Pharmacology &amp; Therapeutics1991;50(3):322‐9. [DOI: 10.1038/clpt.1991.143] ">Schachtel 1991</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>; <a href="./references#CD011889-bbs2-0023" title="WardN , WhitneyC , AveryD , DunnerD . The analgesic effects of caffeine in headache. Pain1991;44(2):151‐5. [DOI: 10.1016/0304‐3959(91)90129‐L] ">Ward 1991</a>). </p> </section> </section> <section id="CD011889-sec-0088"> <h3 class="title" id="CD011889-sec-0088">Effects of interventions</h3> <p>See: <a href="./full#CD011889-tbl-0001"><b>Summary of findings for the main comparison</b> Paracetamol 1000 mg compared with placebo for episodic tension‐type headache</a>; <a href="./full#CD011889-tbl-0002"><b>Summary of findings 2</b> Paracetamol 500 mg to 650 mg compared with placebo for episodic tension‐type headache</a> </p> <p><a href="./appendices#CD011889-sec-0163">Appendix 5</a> (efficacy) and <a href="./appendices#CD011889-sec-0164">Appendix 6</a> (adverse events and withdrawals) show the results for individual studies. A summary of results for comparisons of paracetamol with placebo is presented in a summary table at the end of this section. </p> <section id="CD011889-sec-0089"> <h4 class="title">Paracetamol 1000 mg versus placebo</h4> <p>Sixteen studies compared paracetamol 1000 mg with placebo.</p> <section id="CD011889-sec-0090"> <h5 class="title">Pain‐free at two hours</h5> <p>Eight studies (5890 attacks or participants) contributed data for pain‐free at two hours (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a>; <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a>; <a href="./references#CD011889-bbs2-0013" title="Daniels SE (Study investigator). A randomised, double‐blind, placebo‐controlled, double‐dummy, parallel group comparison of commercial ibuprofen (single dose of 400 mg) versus commercial paracetamol (single dose of 1000 mg) in patients with tension type headache. Supplied by Reckitt Benckiser2001. ">NL9701</a>; <a href="./references#CD011889-bbs2-0017" title="PriorMJ , CooperKM , MayLG , BowenDL . Efficacy and safety of acetaminophen and naproxen in the treatment of tension‐type headache. A randomised, double‐blind, placebo‐controlled trial. Cephalgia2002;20(9):740‐8. [PUBMED: 12421160 ] ">Prior 2002</a>; <a href="./references#CD011889-bbs2-0018" title="SchachtelBP , ThodenWR , KonermanJP , BrownA , ChaingDS . Headache pain model for assessing and comparing the efficacy of over‐the‐counter analgesic agents. Clinical Pharmacology &amp; Therapeutics1991;50(3):322‐9. [DOI: 10.1038/clpt.1991.143] ">Schachtel 1991</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>). </p> <p> <ul id="CD011889-list-0010"> <li> <p>The proportion of attacks/participants who were pain‐free at two hours with paracetamol was 24% (867/3681, range 8.6% to 56%). </p> </li> <li> <p>The proportion of attacks/participants who were pain‐free at two hours with placebo was 19% (418/2209, range 1.3% to 53%). </p> </li> <li> <p>The RR for paracetamol 1000 mg compared with placebo was 1.3 (95% CI 1.1 to 1.4); the NNT was 22 (15 to 40) (<a href="#CD011889-fig-0003">Figure 3</a>). </p> </li> </ul> </p> <div class="figure" id="CD011889-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Paracetamol 1000 mg versus placebo, outcome: 1.1 Pain‐free at 2 hours." data-id="CD011889-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Paracetamol 1000 mg versus placebo, outcome: 1.1 Pain‐free at 2 hours. </p> </div> </div> </div> <p>We assessed the evidence for this outcome to be of high quality according to GRADE because there were adequate numbers of studies and events and the direction of results was consistent. </p> </section> <section id="CD011889-sec-0091"> <h5 class="title">Pain‐free at one hour</h5> <p>Four studies (4717 attacks or participants) contributed data for pain‐free at one hour (<a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a>; <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a>; <a href="./references#CD011889-bbs2-0018" title="SchachtelBP , ThodenWR , KonermanJP , BrownA , ChaingDS . Headache pain model for assessing and comparing the efficacy of over‐the‐counter analgesic agents. Clinical Pharmacology &amp; Therapeutics1991;50(3):322‐9. [DOI: 10.1038/clpt.1991.143] ">Schachtel 1991</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>). </p> <p> <ul id="CD011889-list-0011"> <li> <p>The proportion of attacks/participants who were pain‐free or had only mild pain at one hour with paracetamol was 6.0% (183/3044; range 0% to 11%). </p> </li> <li> <p>The proportion of attacks/participants who were pain‐free or had only mild pain at one hour with placebo was 5.1% (86/1673; range 0% to 16%). </p> </li> <li> <p>The RR for paracetamol 1000 mg compared with placebo was 1.2 (95% CI 0.90 to 1.5); the NNT was not calculated (<a href="./references#CD011889-fig-0006" title="">Analysis 1.2</a>). </p> </li> </ul> </p> <p>We downgraded the evidence for this outcome from high to moderate quality because few studies reported it and there was a modest number of events. There was some inconsistency in the direction of response, and the results were dominated by one study. </p> </section> <section id="CD011889-sec-0092"> <h5 class="title">Pain‐free at four hours</h5> <p>Four studies (4909 attacks or participants) contributed data for pain‐free at four hours (<a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a>; <a href="./references#CD011889-bbs2-0013" title="Daniels SE (Study investigator). A randomised, double‐blind, placebo‐controlled, double‐dummy, parallel group comparison of commercial ibuprofen (single dose of 400 mg) versus commercial paracetamol (single dose of 1000 mg) in patients with tension type headache. Supplied by Reckitt Benckiser2001. ">NL9701</a>; <a href="./references#CD011889-bbs2-0018" title="SchachtelBP , ThodenWR , KonermanJP , BrownA , ChaingDS . Headache pain model for assessing and comparing the efficacy of over‐the‐counter analgesic agents. Clinical Pharmacology &amp; Therapeutics1991;50(3):322‐9. [DOI: 10.1038/clpt.1991.143] ">Schachtel 1991</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>). </p> <p> <ul id="CD011889-list-0012"> <li> <p>The proportion of attacks/participants who were pain‐free at four hours with paracetamol was 57% (1810/3187, range 34% to 77%). </p> </li> <li> <p>The proportion of attacks/participants who were pain‐free at four hours with placebo was 45% (767/1722, range 7.3% to 59%). </p> </li> <li> <p>The RR for paracetamol 1000 mg compared with placebo was 1.2 (95% CI 1.16 to 1.3); the NNT was 8.2 (6.6 to 11) (<a href="./references#CD011889-fig-0007" title="">Analysis 1.3</a>). </p> </li> </ul> </p> <p>We downgraded the evidence for this outcome from high to moderate quality because few studies reported it and, although there was a large number of events, the direction of results was consistent, and the confidence intervals were tight, the analysis was dominated by one study (<a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a>, 84% of participants) and the I<sup>2</sup> statistic was 86%. One of the smaller studies had a particularly low placebo event rate, which probably accounts for the high I<sup>2</sup> statistic. It had almost identical inclusion criteria and methods to the other small study, and the low placebo event rate could well be due to random chance, given its small size. </p> </section> <section id="CD011889-sec-0093"> <h5 class="title">Pain‐free at 24 hours</h5> <p>No studies reported pain‐free at 24 hours.</p> </section> <section id="CD011889-sec-0094"> <h5 class="title">Pain intensity difference at two hours</h5> <p>Eleven studies reported some measure of PID, but no analysis was possible because they used different scales and recorded at different time points. Eight studies reported a statistically significant difference between paracetamol and placebo (<a href="./references#CD011889-bbs2-0006" title="GöbelH , FreseniusJ , HeinzeA , DworschakM , SoykaD . Effectiveness of oleum menthae piperitae and paracetamol in therapy of headache of the tension type [in German] [Effektivität von oleum menthae piperitae und von Paracetamol in der Therapie des Kopfschmerzes vom Spannungstyp]. Nervenarzt1996;67(8):672‐81. [PUBMED: 8805113] ">Göbel 1996</a>; <a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a>; <a href="./references#CD011889-bbs2-0013" title="Daniels SE (Study investigator). A randomised, double‐blind, placebo‐controlled, double‐dummy, parallel group comparison of commercial ibuprofen (single dose of 400 mg) versus commercial paracetamol (single dose of 1000 mg) in patients with tension type headache. Supplied by Reckitt Benckiser2001. ">NL9701</a>; <a href="./references#CD011889-bbs2-0017" title="PriorMJ , CooperKM , MayLG , BowenDL . Efficacy and safety of acetaminophen and naproxen in the treatment of tension‐type headache. A randomised, double‐blind, placebo‐controlled trial. Cephalgia2002;20(9):740‐8. [PUBMED: 12421160 ] ">Prior 2002</a>; <a href="./references#CD011889-bbs2-0018" title="SchachtelBP , ThodenWR , KonermanJP , BrownA , ChaingDS . Headache pain model for assessing and comparing the efficacy of over‐the‐counter analgesic agents. Clinical Pharmacology &amp; Therapeutics1991;50(3):322‐9. [DOI: 10.1038/clpt.1991.143] ">Schachtel 1991</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>), and three no significant difference (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0009" title="MehlischDR , WeaverM , FladungB . Ketoprofen, acetaminophen, and placebo in the treatment of tension headache. Headache1998;38(8):576‐89. [DOI: 10.1046/j.1526‐4610.1998.3808579.x] ">Mehlisch 1998</a>; <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a>). None commented on the clinical significance of the findings. </p> </section> <section id="CD011889-sec-0095"> <h5 class="title">Pain‐free or mild pain at two hours</h5> <p>Five studies (5238 attacks or participants) contributed data for pain‐free or mild pain at two hours (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a>; <a href="./references#CD011889-bbs2-0017" title="PriorMJ , CooperKM , MayLG , BowenDL . Efficacy and safety of acetaminophen and naproxen in the treatment of tension‐type headache. A randomised, double‐blind, placebo‐controlled trial. Cephalgia2002;20(9):740‐8. [PUBMED: 12421160 ] ">Prior 2002</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>). </p> <p> <ul id="CD011889-list-0013"> <li> <p>The proportion of attacks/participants who were pain‐free or had only mild pain at two hours with paracetamol was 59% (1958/3308, range 38% to 71%). </p> </li> <li> <p>The proportion of attacks/participants who were pain‐free or had only mild pain at two hours with placebo was 49% (952/1930, range 36% to 55%). </p> </li> <li> <p>The RR for paracetamol 1000 mg compared with placebo was 1.2 (95% CI 1.15 to 1.3); the NNT was 10 (7.9 to 14) (<a href="#CD011889-fig-0004">Figure 4</a>). </p> </li> </ul> </p> <div class="figure" id="CD011889-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Paracetamol 1000 mg versus placebo, outcome: 1.4 Pain‐free or mild pain at 2 hours." data-id="CD011889-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Paracetamol 1000 mg versus placebo, outcome: 1.4 Pain‐free or mild pain at 2 hours. </p> </div> </div> </div> <p>We assessed the evidence for this outcome to be of high quality because, although few studies reported it, there was a large number of events and the CIs were tight. One very small study showed a different direction of response, which is likely to be due to random chance. </p> </section> <section id="CD011889-sec-0096"> <h5 class="title">Use of rescue medication</h5> <p>Six studies (1856 attacks or participants) provided data for the use of rescue medication with paracetamol 1000 mg versus placebo (<a href="./references#CD011889-bbs2-0009" title="MehlischDR , WeaverM , FladungB . Ketoprofen, acetaminophen, and placebo in the treatment of tension headache. Headache1998;38(8):576‐89. [DOI: 10.1046/j.1526‐4610.1998.3808579.x] ">Mehlisch 1998</a>; <a href="./references#CD011889-bbs2-0013" title="Daniels SE (Study investigator). A randomised, double‐blind, placebo‐controlled, double‐dummy, parallel group comparison of commercial ibuprofen (single dose of 400 mg) versus commercial paracetamol (single dose of 1000 mg) in patients with tension type headache. Supplied by Reckitt Benckiser2001. ">NL9701</a>; <a href="./references#CD011889-bbs2-0017" title="PriorMJ , CooperKM , MayLG , BowenDL . Efficacy and safety of acetaminophen and naproxen in the treatment of tension‐type headache. A randomised, double‐blind, placebo‐controlled trial. Cephalgia2002;20(9):740‐8. [PUBMED: 12421160 ] ">Prior 2002</a>; <a href="./references#CD011889-bbs2-0018" title="SchachtelBP , ThodenWR , KonermanJP , BrownA , ChaingDS . Headache pain model for assessing and comparing the efficacy of over‐the‐counter analgesic agents. Clinical Pharmacology &amp; Therapeutics1991;50(3):322‐9. [DOI: 10.1038/clpt.1991.143] ">Schachtel 1991</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>). The time frames over which these were reported varied from two hours to 24 hours, but it seems likely that participants with an inadequate response would have taken rescue medication soon after it was allowed, and due to the limited amount of data available we have combined these for the analysis. There was no obvious heterogeneity (I<sup>2</sup> = 8%). </p> <p> <ul id="CD011889-list-0014"> <li> <p>The proportion of participants who used rescue medication with paracetamol was 17% (164/985; range 2.0% to 46%). </p> </li> <li> <p>The proportion of participants who used rescue medication with placebo was 30% (258/871; range 13% to 72%). </p> </li> <li> <p>The RR for paracetamol 1000 mg compared with placebo was 0.58 (95% CI 0.50 to 0.69); the NNTp was 7.7 (6.0 to 11) (<a href="./references#CD011889-fig-0009" title="">Analysis 1.5</a>). </p> </li> </ul> </p> <p>Nine studies did not report use of rescue medication (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a>; <a href="./references#CD011889-bbs2-0006" title="GöbelH , FreseniusJ , HeinzeA , DworschakM , SoykaD . Effectiveness of oleum menthae piperitae and paracetamol in therapy of headache of the tension type [in German] [Effektivität von oleum menthae piperitae und von Paracetamol in der Therapie des Kopfschmerzes vom Spannungstyp]. Nervenarzt1996;67(8):672‐81. [PUBMED: 8805113] ">Göbel 1996</a>; <a href="./references#CD011889-bbs2-0007" title="GöbelH , HeinzeA , LurchA , DworschakM . Essential oils in the therapy of tension headache [in German]. Zeitschrift fur Allgemeinmedizin1998;74(4):223‐8. ">Göbel 1998</a>; <a href="./references#CD011889-bbs2-0008" title="GöbelH , HeinzeA , DworschakM , Heinze‐KuhnK , StolzeH . Analgesic efficacy and tolerability of locally applied Oleum menthae piperitae preparation LI 170 in patients with migraine or tension‐type headache [German] [Wirksamkeit und verträglichkeit von oleum‐menthaepiperitae‐lösung LI 170 bei kopfschmerz vom spannungstyp und migräne]. Zeitschrift fur Allgemeinmedizin2001;77(6):287‐295. ">Göbel 2001</a>; <a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a>; <a href="./references#CD011889-bbs2-0014" title="PackmanB , PackmanE , DoyleG , CooperS , AshrafE , KoronkiewiczK , et al. Solubilized ibuprofen: evaluation of onset, relief, and safety of a novel formulation in the treatment of episodic tension‐type headache. Headache2000;40(7):561‐7. [DOI: 10.1046/j.1526‐4610.2000.00087.x] ">Packman 2000</a>; <a href="./references#CD011889-bbs2-0015" title="PetersBH , FraimCJ , MaselBE . Comparison of 650 mg aspirin and 1,000 mg acetaminophen with each other, and with placebo in moderately severe headache. American Journal of Medicine1983;74(6):36‐42. [DOI: 10.1016/0002‐9343(83)90526‐0] ">Peters 1983</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>), while <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a> reported that the median time to use of rescue medication was 130 minutes with paracetamol 1000 mg compared with 62 minutes with placebo. </p> <p>We downgraded the evidence for this outcome from high to moderate quality because few studies reported it and there was a modest number of events. There was consistency in the direction of response. </p> </section> <section id="CD011889-sec-0097"> <h5 class="title">Adverse events</h5> <section id="CD011889-sec-0098"> <h6 class="title">Any adverse events</h6> <p>Eleven studies (5605 attacks or participants) contributed data for any adverse events (<a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a>; <a href="./references#CD011889-bbs2-0009" title="MehlischDR , WeaverM , FladungB . Ketoprofen, acetaminophen, and placebo in the treatment of tension headache. Headache1998;38(8):576‐89. [DOI: 10.1046/j.1526‐4610.1998.3808579.x] ">Mehlisch 1998</a>; <a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a>; <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a>; <a href="./references#CD011889-bbs2-0013" title="Daniels SE (Study investigator). A randomised, double‐blind, placebo‐controlled, double‐dummy, parallel group comparison of commercial ibuprofen (single dose of 400 mg) versus commercial paracetamol (single dose of 1000 mg) in patients with tension type headache. Supplied by Reckitt Benckiser2001. ">NL9701</a>; <a href="./references#CD011889-bbs2-0015" title="PetersBH , FraimCJ , MaselBE . Comparison of 650 mg aspirin and 1,000 mg acetaminophen with each other, and with placebo in moderately severe headache. American Journal of Medicine1983;74(6):36‐42. [DOI: 10.1016/0002‐9343(83)90526‐0] ">Peters 1983</a>; <a href="./references#CD011889-bbs2-0017" title="PriorMJ , CooperKM , MayLG , BowenDL . Efficacy and safety of acetaminophen and naproxen in the treatment of tension‐type headache. A randomised, double‐blind, placebo‐controlled trial. Cephalgia2002;20(9):740‐8. [PUBMED: 12421160 ] ">Prior 2002</a>; <a href="./references#CD011889-bbs2-0018" title="SchachtelBP , ThodenWR , KonermanJP , BrownA , ChaingDS . Headache pain model for assessing and comparing the efficacy of over‐the‐counter analgesic agents. Clinical Pharmacology &amp; Therapeutics1991;50(3):322‐9. [DOI: 10.1038/clpt.1991.143] ">Schachtel 1991</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>). </p> <p> <ul id="CD011889-list-0015"> <li> <p>The proportion of attacks/participants who experienced any adverse event with paracetamol was 10% (337/3373; range 0% to 17%). </p> </li> <li> <p>The proportion of attacks/participants who experienced any adverse event with placebo was 8.6% (191/2232; range 0.66% to 13%). </p> </li> <li> <p>The RR for paracetamol 1000 mg compared with placebo was 1.1 (95% CI 0.94 to 1.3); the NNH was not calculated (<a href="./references#CD011889-fig-0010" title="">Analysis 1.6</a>). </p> </li> </ul> </p> <p>We assessed the evidence for this outcome to be of high quality because there were adequate numbers of studies and events and the direction of results was consistent (no effect). </p> </section> <section id="CD011889-sec-0099"> <h6 class="title">Gastrointestinal adverse events</h6> <p>Ten studies (5526 attacks or participants) contributed data for gastrointestinal adverse events (<a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a>; <a href="./references#CD011889-bbs2-0009" title="MehlischDR , WeaverM , FladungB . Ketoprofen, acetaminophen, and placebo in the treatment of tension headache. Headache1998;38(8):576‐89. [DOI: 10.1046/j.1526‐4610.1998.3808579.x] ">Mehlisch 1998</a>; <a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a>; <a href="./references#CD011889-bbs2-0013" title="Daniels SE (Study investigator). A randomised, double‐blind, placebo‐controlled, double‐dummy, parallel group comparison of commercial ibuprofen (single dose of 400 mg) versus commercial paracetamol (single dose of 1000 mg) in patients with tension type headache. Supplied by Reckitt Benckiser2001. ">NL9701</a>; <a href="./references#CD011889-bbs2-0015" title="PetersBH , FraimCJ , MaselBE . Comparison of 650 mg aspirin and 1,000 mg acetaminophen with each other, and with placebo in moderately severe headache. American Journal of Medicine1983;74(6):36‐42. [DOI: 10.1016/0002‐9343(83)90526‐0] ">Peters 1983</a>; <a href="./references#CD011889-bbs2-0017" title="PriorMJ , CooperKM , MayLG , BowenDL . Efficacy and safety of acetaminophen and naproxen in the treatment of tension‐type headache. A randomised, double‐blind, placebo‐controlled trial. Cephalgia2002;20(9):740‐8. [PUBMED: 12421160 ] ">Prior 2002</a>; <a href="./references#CD011889-bbs2-0018" title="SchachtelBP , ThodenWR , KonermanJP , BrownA , ChaingDS . Headache pain model for assessing and comparing the efficacy of over‐the‐counter analgesic agents. Clinical Pharmacology &amp; Therapeutics1991;50(3):322‐9. [DOI: 10.1038/clpt.1991.143] ">Schachtel 1991</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>). One of these studies reported only nausea as a subgroup of adverse events, and gave no indication as to other gastrointestinal events; therefore, we included nausea figures in this analysis (<a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>). </p> <p> <ul id="CD011889-list-0016"> <li> <p>The proportion of attacks/participants who experienced any gastrointestinal adverse event with paracetamol was 4.6% (155/3335; range 0% to 8.0%). </p> </li> <li> <p>The proportion of attacks/participants who experienced any gastrointestinal adverse event with placebo was 3.8% (84/2191; range 0.66% to 5.6%). </p> </li> <li> <p>The RR for paracetamol 1000 mg compared with placebo was 1.1 (95% CI 0.86 to 1.5); the NNH was not calculated (<a href="./references#CD011889-fig-0011" title="">Analysis 1.7</a>). </p> </li> </ul> </p> <p>Removing <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a> (which reported only nausea as a subgroup of adverse events) from the analysis did not change the result. </p> <p>We downgraded the evidence for this outcome from high to moderate quality because, although there was an adequate number of studies and the direction of results was consistent (no effect), there was a moderate number of events. </p> </section> <section id="CD011889-sec-0100"> <h6 class="title">Dizziness adverse events</h6> <p>Four studies (4036 attacks or participants) contributed data for dizziness adverse events (<a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a>; <a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a>; <a href="./references#CD011889-bbs2-0013" title="Daniels SE (Study investigator). A randomised, double‐blind, placebo‐controlled, double‐dummy, parallel group comparison of commercial ibuprofen (single dose of 400 mg) versus commercial paracetamol (single dose of 1000 mg) in patients with tension type headache. Supplied by Reckitt Benckiser2001. ">NL9701</a>; <a href="./references#CD011889-bbs2-0017" title="PriorMJ , CooperKM , MayLG , BowenDL . Efficacy and safety of acetaminophen and naproxen in the treatment of tension‐type headache. A randomised, double‐blind, placebo‐controlled trial. Cephalgia2002;20(9):740‐8. [PUBMED: 12421160 ] ">Prior 2002</a>). </p> <p> <ul id="CD011889-list-0017"> <li> <p>The proportion of attacks/participants who experienced any dizziness adverse events with paracetamol was 1.6% (42/2589; range 1.6% to 1.9%). </p> </li> <li> <p>The proportion of attacks/participants who experienced any dizziness adverse events with placebo was 1.1% (16/1447; range 0.98% to 1.2%). </p> </li> <li> <p>The RR for paracetamol compared with placebo was 1.5 (95% CI 0.83 to 2.6); the NNH was not calculated (<a href="./references#CD011889-fig-0012" title="">Analysis 1.8</a>). </p> </li> </ul> </p> <p>We downgraded the evidence for this outcome from high to low quality because there were few studies and events. The direction of results was consistent (no effect). </p> </section> <section id="CD011889-sec-0101"> <h6 class="title">Serious adverse events</h6> <p>There were no serious adverse events in comparisons using paracetamol 1000 mg (15 studies, estimated 5147 participants). We estimated that the rate of serious adverse events is unlikely to be greater than 1 in 1700 people (<a href="./references#CD011889-bbs2-0046" title="EypaschE , LeferingR , KumCK , TroidlH . Probability of adverse events that have not yet occurred: a statistical reminder. BMJ1995;311(7005):619‐20. [DOI: 10.1136/bmj.311.7005.619] ">Eypasch 1995</a>). </p> <p>We judged the evidence for this outcome to be moderate quality because, although there were no events reported, there were large numbers of studies and participants. </p> </section> <section id="CD011889-sec-0102"> <h6 class="title">Adverse event withdrawals</h6> <p>One study reported an adverse event withdrawal (for tinnitus and indigestion) in a participant taking paracetamol 1000 mg (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>). Eleven studies reported no adverse event withdrawals (<a href="./references#CD011889-bbs2-0002" title="DienerHC , GoldM , HagenM . Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension‐type headache: meta‐analysis of four randomized, double‐blind, placebo‐controlled, crossover studies. Journal of Headache and Pain2014;15:76. [DOI: 10.1186/1129‐2377‐15‐76] MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 1‐4). Clinical Pharmacology and Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Diener 2014</a>; <a href="./references#CD011889-bbs2-0006" title="GöbelH , FreseniusJ , HeinzeA , DworschakM , SoykaD . Effectiveness of oleum menthae piperitae and paracetamol in therapy of headache of the tension type [in German] [Effektivität von oleum menthae piperitae und von Paracetamol in der Therapie des Kopfschmerzes vom Spannungstyp]. Nervenarzt1996;67(8):672‐81. [PUBMED: 8805113] ">Göbel 1996</a>; <a href="./references#CD011889-bbs2-0007" title="GöbelH , HeinzeA , LurchA , DworschakM . Essential oils in the therapy of tension headache [in German]. Zeitschrift fur Allgemeinmedizin1998;74(4):223‐8. ">Göbel 1998</a>; <a href="./references#CD011889-bbs2-0008" title="GöbelH , HeinzeA , DworschakM , Heinze‐KuhnK , StolzeH . Analgesic efficacy and tolerability of locally applied Oleum menthae piperitae preparation LI 170 in patients with migraine or tension‐type headache [German] [Wirksamkeit und verträglichkeit von oleum‐menthaepiperitae‐lösung LI 170 bei kopfschmerz vom spannungstyp und migräne]. Zeitschrift fur Allgemeinmedizin2001;77(6):287‐295. ">Göbel 2001</a>; <a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a>; <a href="./references#CD011889-bbs2-0014" title="PackmanB , PackmanE , DoyleG , CooperS , AshrafE , KoronkiewiczK , et al. Solubilized ibuprofen: evaluation of onset, relief, and safety of a novel formulation in the treatment of episodic tension‐type headache. Headache2000;40(7):561‐7. [DOI: 10.1046/j.1526‐4610.2000.00087.x] ">Packman 2000</a>; <a href="./references#CD011889-bbs2-0018" title="SchachtelBP , ThodenWR , KonermanJP , BrownA , ChaingDS . Headache pain model for assessing and comparing the efficacy of over‐the‐counter analgesic agents. Clinical Pharmacology &amp; Therapeutics1991;50(3):322‐9. [DOI: 10.1038/clpt.1991.143] ">Schachtel 1991</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>), and one did not specifically report this outcome (<a href="./references#CD011889-bbs2-0015" title="PetersBH , FraimCJ , MaselBE . Comparison of 650 mg aspirin and 1,000 mg acetaminophen with each other, and with placebo in moderately severe headache. American Journal of Medicine1983;74(6):36‐42. [DOI: 10.1016/0002‐9343(83)90526‐0] ">Peters 1983</a>). <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a> reported no withdrawals during treatment periods, but there were three during the first washout period, and five during the second washout period. The reasons for withdrawal and the active treatment given before the washout were not reported. </p> <p>We downgraded the evidence for this outcome from high to low quality because of poor reporting and small numbers of events. </p> </section> </section> </section> <section id="CD011889-sec-0103"> <h4 class="title">Paracetamol 500 mg to 650 mg versus placebo</h4> <p>Five studies compared paracetamol 500 mg to 650 mg with placebo (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0005" title="GilbertMM , DeSola PoolN , SchecterC . Analgesic/calmative effects of acetaminophen and phenyltoloxamine in treatment of simple nervous tension accompanied by headache. Current Therapeutic Research, Clinical and Experimental1976;20(1):53‐8. [PUBMED: 821705] ">Gilbert 1976</a>; <a href="./references#CD011889-bbs2-0011" title="MillerDS , TalbotCA , SimpsonW , KoreyA . A comparison of naproxen sodium, acetaminophen and placebo in the treatment of muscle contraction headache. Headache1987;27(7):392‐6. [DOI: 0.1111/j.1526‐4610.1987.hed2707392.x] ">Miller 1987</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>; <a href="./references#CD011889-bbs2-0023" title="WardN , WhitneyC , AveryD , DunnerD . The analgesic effects of caffeine in headache. Pain1991;44(2):151‐5. [DOI: 10.1016/0304‐3959(91)90129‐L] ">Ward 1991</a>). Due to the small amount of data available, we pooled studies in this dose range. </p> <section id="CD011889-sec-0104"> <h5 class="title">Pain‐free at two hours</h5> <p>Only one study reported pain‐free at two hours; 17% (5/29) of participants were pain‐free at two hours with both paracetamol 500 mg and placebo (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>). </p> </section> <section id="CD011889-sec-0105"> <h5 class="title">Pain‐free at other time points</h5> <p>No studies reported pain‐free outcomes at one, four, or 24 hours.</p> </section> <section id="CD011889-sec-0106"> <h5 class="title">Pain intensity difference at two hours</h5> <p>Four studies reported some information about PIDs at two hours. <a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a> reported a group mean difference between paracetamol and placebo of about 15/100 participants, <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a> a difference of about 0.3/10 participants, and <a href="./references#CD011889-bbs2-0023" title="WardN , WhitneyC , AveryD , DunnerD . The analgesic effects of caffeine in headache. Pain1991;44(2):151‐5. [DOI: 10.1016/0304‐3959(91)90129‐L] ">Ward 1991</a> a difference of 10/100 participants, while <a href="./references#CD011889-bbs2-0011" title="MillerDS , TalbotCA , SimpsonW , KoreyA . A comparison of naproxen sodium, acetaminophen and placebo in the treatment of muscle contraction headache. Headache1987;27(7):392‐6. [DOI: 0.1111/j.1526‐4610.1987.hed2707392.x] ">Miller 1987</a> reported that the mean SPID was not significantly different at any time point. <a href="./references#CD011889-bbs2-0005" title="GilbertMM , DeSola PoolN , SchecterC . Analgesic/calmative effects of acetaminophen and phenyltoloxamine in treatment of simple nervous tension accompanied by headache. Current Therapeutic Research, Clinical and Experimental1976;20(1):53‐8. [PUBMED: 821705] ">Gilbert 1976</a> did not report PID at two hours. None of the studies commented on the clinical significance of the findings. </p> </section> <section id="CD011889-sec-0107"> <h5 class="title">Pain‐free or mild pain at two hours</h5> <p>Two studies (275 attacks or participants) contributed data for pain‐free or mild pain at two hours (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>). </p> <p> <ul id="CD011889-list-0018"> <li> <p>The proportion of attacks/participants who were pain‐free or had only mild pain at two hours with paracetamol was 59% (79/134; range 41% to 64%). </p> </li> <li> <p>The proportion of attacks/participants who were pain‐free or had only mild pain at two hours with placebo was 53% (67/105; range 48% to 54%). </p> </li> <li> <p>The RR for paracetamol 500 mg to 650 mg compared with placebo was 1.1 (95% CI 0.90 to 1.4); the NNT was not calculated (<a href="./references#CD011889-fig-0013" title="">Analysis 2.1</a>). </p> </li> </ul> </p> <p>We downgraded the evidence for this outcome from high to low quality because there were few studies and events. The direction of effect was consistent (no effect). </p> </section> <section id="CD011889-sec-0108"> <h5 class="title">Use of rescue medication</h5> <p>Two studies (301 participants) reported on use of rescue medication, one within six hours (<a href="./references#CD011889-bbs2-0011" title="MillerDS , TalbotCA , SimpsonW , KoreyA . A comparison of naproxen sodium, acetaminophen and placebo in the treatment of muscle contraction headache. Headache1987;27(7):392‐6. [DOI: 0.1111/j.1526‐4610.1987.hed2707392.x] ">Miller 1987</a>), and one at two hours (<a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>). </p> <p> <ul id="CD011889-list-0019"> <li> <p>The proportion of participants who used rescue medication with paracetamol was 28% (42/148; range 26% to 35%). </p> </li> <li> <p>The proportion of participants who used rescue medication with placebo was 37% (57/153; range 34% to 46%). </p> </li> <li> <p>The RR for paracetamol 500 mg to 650 mg compared with placebo was 0.76 (95% CI 0.55 to 1.1). The NNTp was not calculated (<a href="./references#CD011889-fig-0014" title="">Analysis 2.2</a>). </p> </li> </ul> </p> <p>We downgraded the evidence for this outcome from high to low quality because there were few studies and events, and one study had a high attrition rate. The direction of effect was consistent (no effect). </p> </section> <section id="CD011889-sec-0109"> <h5 class="title">Adverse events</h5> <section id="CD011889-sec-0110"> <h6 class="title">Any adverse events</h6> <p>Two studies (301 participants) contributed data for any adverse events (<a href="./references#CD011889-bbs2-0011" title="MillerDS , TalbotCA , SimpsonW , KoreyA . A comparison of naproxen sodium, acetaminophen and placebo in the treatment of muscle contraction headache. Headache1987;27(7):392‐6. [DOI: 0.1111/j.1526‐4610.1987.hed2707392.x] ">Miller 1987</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>). </p> <p> <ul id="CD011889-list-0020"> <li> <p>The proportion of participants who experienced any adverse event with paracetamol was 14% (21/148; range 9.3% to 16%). </p> </li> <li> <p>The proportion of participants who experienced any adverse event with placebo was 11% (17/153; range 4.9% to 13%). </p> </li> <li> <p>The RR for paracetamol 500 mg to 650 mg compared with placebo was 1.3 (95% CI 0.71 to 2.4). The NNT was not calculated (<a href="./references#CD011889-fig-0015" title="">Analysis 2.3</a>). </p> </li> </ul> </p> <p>The number of participants in this comparison only just reached our threshold for carrying out the analysis. We downgraded the evidence for this outcome from high to low quality because there were few studies and events, and one study had a high attrition rate. The direction of effect was consistent (no effect). </p> <p>There were insufficient data for analysis of any specific adverse events.</p> </section> <section id="CD011889-sec-0111"> <h6 class="title">Serious adverse events</h6> <p>There were no serious adverse events in comparisons using paracetamol 500 mg or 650 mg (five studies, estimated 463 participants). We estimated that the rate of serious adverse events is unlikely to be greater than 1 in 155 participants (<a href="./references#CD011889-bbs2-0046" title="EypaschE , LeferingR , KumCK , TroidlH . Probability of adverse events that have not yet occurred: a statistical reminder. BMJ1995;311(7005):619‐20. [DOI: 10.1136/bmj.311.7005.619] ">Eypasch 1995</a>). </p> <p>We judged the evidence for this outcome to be of very low quality because there were few studies and participants on which to base our estimate. </p> </section> <section id="CD011889-sec-0112"> <h6 class="title">Adverse event withdrawals</h6> <p>One study did not provide any information about adverse event withdrawals (<a href="./references#CD011889-bbs2-0023" title="WardN , WhitneyC , AveryD , DunnerD . The analgesic effects of caffeine in headache. Pain1991;44(2):151‐5. [DOI: 10.1016/0304‐3959(91)90129‐L] ">Ward 1991</a>), and three studies reported no adverse event withdrawals in comparisons of paracetamol 500 mg to 650 mg with placebo (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0011" title="MillerDS , TalbotCA , SimpsonW , KoreyA . A comparison of naproxen sodium, acetaminophen and placebo in the treatment of muscle contraction headache. Headache1987;27(7):392‐6. [DOI: 0.1111/j.1526‐4610.1987.hed2707392.x] ">Miller 1987</a>; <a href="./references#CD011889-bbs2-0021" title="SteinerTJ , LangeR , VoelkerM . Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalgia2003;23(1):59‐66. [PUBMED: 12534583] ">Steiner 2003</a>). The remaining study reported that two participants dropped out after the first treatment period because of adverse events, but did not specify which of the four treatments they had received (<a href="./references#CD011889-bbs2-0005" title="GilbertMM , DeSola PoolN , SchecterC . Analgesic/calmative effects of acetaminophen and phenyltoloxamine in treatment of simple nervous tension accompanied by headache. Current Therapeutic Research, Clinical and Experimental1976;20(1):53‐8. [PUBMED: 821705] ">Gilbert 1976</a>). </p> <p>We downgraded the evidence for this outcome from high to very low quality because of poor reporting and small numbers of studies and events. </p> </section> </section> <section id="CD011889-sec-0113"> <h5 class="title">Subgroup analyses</h5> <p>We planned subgroup analysis for dose, route of administration, and formulation. We carried out all analyses by dose (1000 mg or 500 mg to 650 mg), but all studies used the oral route of administration, and only one study reported on formulation (<a href="./references#CD011889-bbs2-0014" title="PackmanB , PackmanE , DoyleG , CooperS , AshrafE , KoronkiewiczK , et al. Solubilized ibuprofen: evaluation of onset, relief, and safety of a novel formulation in the treatment of episodic tension‐type headache. Headache2000;40(7):561‐7. [DOI: 10.1046/j.1526‐4610.2000.00087.x] ">Packman 2000</a>, which used ibuprofen liquigel), so no further subgroup analysis was possible. </p> </section> <section id="CD011889-sec-0114"> <h5 class="title">Sensitivity analyses</h5> <p>We planned to carry out sensitivity analysis for study quality (Oxford Quality Score of 2/5 versus 3/5 or more), but only one study scored 2/5 (<a href="./references#CD011889-bbs2-0023" title="WardN , WhitneyC , AveryD , DunnerD . The analgesic effects of caffeine in headache. Pain1991;44(2):151‐5. [DOI: 10.1016/0304‐3959(91)90129‐L] ">Ward 1991</a>), and it did not contribute to any analyses. </p> <p>We carried out post‐hoc sensitivity analyses for studies that did not report clear diagnostic criteria (<a href="./references#CD011889-bbs2-0005" title="GilbertMM , DeSola PoolN , SchecterC . Analgesic/calmative effects of acetaminophen and phenyltoloxamine in treatment of simple nervous tension accompanied by headache. Current Therapeutic Research, Clinical and Experimental1976;20(1):53‐8. [PUBMED: 821705] ">Gilbert 1976</a>; <a href="./references#CD011889-bbs2-0008" title="GöbelH , HeinzeA , DworschakM , Heinze‐KuhnK , StolzeH . Analgesic efficacy and tolerability of locally applied Oleum menthae piperitae preparation LI 170 in patients with migraine or tension‐type headache [German] [Wirksamkeit und verträglichkeit von oleum‐menthaepiperitae‐lösung LI 170 bei kopfschmerz vom spannungstyp und migräne]. Zeitschrift fur Allgemeinmedizin2001;77(6):287‐295. ">Göbel 2001</a>; <a href="./references#CD011889-bbs2-0015" title="PetersBH , FraimCJ , MaselBE . Comparison of 650 mg aspirin and 1,000 mg acetaminophen with each other, and with placebo in moderately severe headache. American Journal of Medicine1983;74(6):36‐42. [DOI: 10.1016/0002‐9343(83)90526‐0] ">Peters 1983</a>; <a href="./references#CD011889-bbs2-0022" title='ThorpeP . Controlled and uncontrolled studies on "Fiorinal‐PA" for symptomatic relief in tension headache. Medical Journal of Australia1970;2(4):180‐1. [PUBMED: 4917129] '>Thorpe 1970</a>; <a href="./references#CD011889-bbs2-0023" title="WardN , WhitneyC , AveryD , DunnerD . The analgesic effects of caffeine in headache. Pain1991;44(2):151‐5. [DOI: 10.1016/0304‐3959(91)90129‐L] ">Ward 1991</a>), or did not specify a washout period between treatments in cross‐over studies (<a href="./references#CD011889-bbs2-0006" title="GöbelH , FreseniusJ , HeinzeA , DworschakM , SoykaD . Effectiveness of oleum menthae piperitae and paracetamol in therapy of headache of the tension type [in German] [Effektivität von oleum menthae piperitae und von Paracetamol in der Therapie des Kopfschmerzes vom Spannungstyp]. Nervenarzt1996;67(8):672‐81. [PUBMED: 8805113] ">Göbel 1996</a>; <a href="./references#CD011889-bbs2-0007" title="GöbelH , HeinzeA , LurchA , DworschakM . Essential oils in the therapy of tension headache [in German]. Zeitschrift fur Allgemeinmedizin1998;74(4):223‐8. ">Göbel 1998</a>; <a href="./references#CD011889-bbs2-0008" title="GöbelH , HeinzeA , DworschakM , Heinze‐KuhnK , StolzeH . Analgesic efficacy and tolerability of locally applied Oleum menthae piperitae preparation LI 170 in patients with migraine or tension‐type headache [German] [Wirksamkeit und verträglichkeit von oleum‐menthaepiperitae‐lösung LI 170 bei kopfschmerz vom spannungstyp und migräne]. Zeitschrift fur Allgemeinmedizin2001;77(6):287‐295. ">Göbel 2001</a>; <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a>; <a href="./references#CD011889-bbs2-0016" title="PiniLA , DelBeneE , ZanchinG , SarchielliP , DiTrapaniG , PrudenzanoMP , et al. Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension‐type headache: a randomised, double‐blind, double‐dummy, cross‐over study versus placebo and naproxen sodium. Journal of Headache and Pain2008;9(6):367‐73. [PUBMED: 18815727] ">Pini 2008</a>; <a href="./references#CD011889-bbs2-0023" title="WardN , WhitneyC , AveryD , DunnerD . The analgesic effects of caffeine in headache. Pain1991;44(2):151‐5. [DOI: 10.1016/0304‐3959(91)90129‐L] ">Ward 1991</a>). Of these studies, only <a href="./references#CD011889-bbs2-0005" title="GilbertMM , DeSola PoolN , SchecterC . Analgesic/calmative effects of acetaminophen and phenyltoloxamine in treatment of simple nervous tension accompanied by headache. Current Therapeutic Research, Clinical and Experimental1976;20(1):53‐8. [PUBMED: 821705] ">Gilbert 1976</a> and <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a> contributed data for analyses, and removing them did not change the results. </p> <p> <div class="table" id="CD011889-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Summary of results for paracetamol versus placebo</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome/intervention</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants/attacks</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNT (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Pain‐free at 2 hours</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5890</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3 (1.1 to 1.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (15 to 40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Pain‐free at 1 hours</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4717</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 (0.90 to 1.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Pain‐free at 4 hours</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4909</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 (1.15 to 1.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2 (6.6 to 11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Pain‐free or mild pain at 2 hours</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5238</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 (1.15 to 1.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (7.9 to 14)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 500‐650 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>275</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1 (0.90 to 1.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNTp (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Use of rescue medication</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1856</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58 (0.50 to 0.69)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7 (6.0 to 11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 500‐650 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.76 (0.55 to 1.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNH (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse event</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5605</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1 (0.94 to 1.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 500‐650 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3 (0.71 to 2.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Gastrointestinal adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5526</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1 (0.86 to 1.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Dizziness</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paracetamol 1000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4036</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5 (0.83 to 2.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>NNH: number needed to treat for an additional harmful event; NNT: number needed to treat for an additional beneficial event; NNTp: number needed to treat to prevent an event. </p> </td> </tr> </tbody> </table> </div> </p> </section> </section> <section id="CD011889-sec-0115"> <h4 class="title">Paracetamol 1000 mg versus paracetamol 500 mg</h4> <p>Two studies (274 attacks or participants) included both 500 mg and 1000 mg treatment arms (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>), but the only outcome that could be compared was pain‐free or no pain at two hours. </p> <p> <ul id="CD011889-list-0021"> <li> <p>The proportion of attacks/participants who were pain‐free or had only mild pain at two hours with paracetamol 1000 mg was 64% (90/140; range 38% to 71%). </p> </li> <li> <p>The proportion of attacks/participants who were pain‐free or had only mild pain at two hours with paracetamol 500 mg was 59% (79/134; range 41% to 64%). </p> </li> <li> <p>The RR for paracetamol 1000 mg compared with 500 mg was 1.1 (95% CI 0.91 to 1.3) (<a href="./references#CD011889-fig-0016" title="">Analysis 3.1</a>). The NNT was not calculated. </p> </li> </ul> </p> <p>Indirect comparison with placebo also showed no significant difference between the doses (Z = 0.6673, P value = 0.43). </p> <p>We downgraded the evidence for this comparison from high to very low quality because of small numbers of studies and events. </p> </section> <section id="CD011889-sec-0116"> <h4 class="title">Paracetamol 1000 mg versus other active comparators</h4> <p>Three studies compared paracetamol 1000 mg with ketoprofen 25 mg (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0009" title="MehlischDR , WeaverM , FladungB . Ketoprofen, acetaminophen, and placebo in the treatment of tension headache. Headache1998;38(8):576‐89. [DOI: 10.1046/j.1526‐4610.1998.3808579.x] ">Mehlisch 1998</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>). Two studies compared paracetamol 1000 mg with ibuprofen 400 mg (<a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>). Only single studies provided usable data for comparing paracetamol 1000 mg with other active comparators, so no other analyses were done. </p> <p><a href="./appendices#CD011889-sec-0163">Appendix 5</a> and <a href="./appendices#CD011889-sec-0164">Appendix 6</a> show results for individual studies. </p> </section> <section id="CD011889-sec-0117"> <h4 class="title">Paracetamol 1000 mg versus ketoprofen 25 mg</h4> <p>Three studies compared paracetamol 1000 mg with ketoprofen 25 mg (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0009" title="MehlischDR , WeaverM , FladungB . Ketoprofen, acetaminophen, and placebo in the treatment of tension headache. Headache1998;38(8):576‐89. [DOI: 10.1046/j.1526‐4610.1998.3808579.x] ">Mehlisch 1998</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>). </p> <section id="CD011889-sec-0118"> <h5 class="title">Pain‐free at two hours</h5> <p>Two studies (276 attacks or participants) contributed data for pain‐free at two hours (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>). </p> <p> <ul id="CD011889-list-0022"> <li> <p>The proportion of attacks/participants who were pain‐free at two hours with paracetamol was 21% (30/145; range 17% to 22%). </p> </li> <li> <p>The proportion of attacks/participants who were pain‐free at two hours with ketoprofen was 27% (36/131; range 27% to 28%). </p> </li> <li> <p>The RR for paracetamol 1000 mg compared with ketoprofen 25 mg was 0.75 (95% CI 0.49 to 1.2). The NNT was not calculated (<a href="./references#CD011889-fig-0017" title="">Analysis 4.1</a>). </p> </li> </ul> </p> <p>We downgraded the evidence for this outcome from high to very low quality because of small numbers of studies and events. </p> </section> <section id="CD011889-sec-0119"> <h5 class="title">Pain‐free at one, four, and 24 hours</h5> <p>No studies reported pain‐free at one, four, and 24 hours.</p> </section> <section id="CD011889-sec-0120"> <h5 class="title">Pain intensity difference at two hours</h5> <p>Three studies reported no significant difference in pain intensity at two hours between paracetamol 1000 mg and ketoprofen 25 mg. </p> </section> <section id="CD011889-sec-0121"> <h5 class="title">Pain‐free or mild pain at two hours</h5> <p>Two studies (276 attacks or participants) reported pain‐free or mild pain at two hours (<a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>). </p> <p> <ul id="CD011889-list-0023"> <li> <p>The proportion of attacks/participants who were pain‐free or had only mild pain at two hours with paracetamol was 57% (83/145; range 41% to 61%). </p> </li> <li> <p>The proportion of attacks/participants who were pain‐free or had only mild pain at two hours with ketoprofen was 66% (86/131; range 52% to 70%). </p> </li> <li> <p>The RR for paracetamol 1000 mg compared with ketoprofen 25 mg was 0.87 (95% CI 0.72 to 1.04) (<a href="./references#CD011889-fig-0018" title="">Analysis 4.2</a>). The NNT was not calculated. </p> </li> </ul> </p> <p>We downgraded the evidence for this outcome from high to very low quality because of small numbers of studies and events. </p> </section> <section id="CD011889-sec-0122"> <h5 class="title">Use of rescue medication</h5> <p><a href="./references#CD011889-bbs2-0009" title="MehlischDR , WeaverM , FladungB . Ketoprofen, acetaminophen, and placebo in the treatment of tension headache. Headache1998;38(8):576‐89. [DOI: 10.1046/j.1526‐4610.1998.3808579.x] ">Mehlisch 1998</a> reported that 16/166 participants used rescue medication over four hours with paracetamol, and 7/156 with ketoprofen 25 mg. <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a> reported that 53/116 participants used rescue medication over two to 24 hours with paracetamol, and 44/102 with ketoprofen 25 mg. </p> </section> <section id="CD011889-sec-0123"> <h5 class="title">Adverse events</h5> <section id="CD011889-sec-0124"> <h6 class="title">Any adverse event</h6> <p>Two studies (558 participants) contributed data for any adverse event (<a href="./references#CD011889-bbs2-0009" title="MehlischDR , WeaverM , FladungB . Ketoprofen, acetaminophen, and placebo in the treatment of tension headache. Headache1998;38(8):576‐89. [DOI: 10.1046/j.1526‐4610.1998.3808579.x] ">Mehlisch 1998</a>; <a href="./references#CD011889-bbs2-0020" title="SteinerTJ , LangeR . Ketoprofen (25 mg) in the symptomatic treatment of episodic tension‐type headache: double‐blind placebo‐controlled comparison with acetaminophen (1000 mg). Cephalgia1998;18(1):38‐43. [PUBMED: 9601623] ">Steiner 1998</a>). </p> <p> <ul id="CD011889-list-0024"> <li> <p>The proportion of participants who experienced any adverse event with paracetamol was 9.3% (26/280; range 9.2% to 9.4%). </p> </li> <li> <p>The proportion of participants who experienced any adverse event with ketoprofen was 15% (42/278; range 14.7% to 15.3%). </p> </li> <li> <p>The RR for paracetamol 1000 mg compared to ketoprofen 25 mg was 0.61 (95% CI 0.39 to 0.97); the NNTp was 17 (8.9 to 240) (<a href="./references#CD011889-fig-0019" title="">Analysis 4.3</a>). For every 17 participants treated, one would not experience an adverse event with paracetamol who would have done with ketoprofen. </p> </li> </ul> </p> <p>We downgraded the evidence for this outcome from high to very low quality because of small numbers of studies and events. </p> <p>There were insufficient data for any analysis of individual adverse events.</p> </section> <section id="CD011889-sec-0125"> <h6 class="title">Serious adverse events</h6> <p>None of the studies reported any serious adverse events.</p> </section> <section id="CD011889-sec-0126"> <h6 class="title">Adverse event withdrawals</h6> <p><a href="./references#CD011889-bbs2-0001" title="DahlöfCG , JacobsLD . Ketoprofen, paracetamol and placebo in the treatment of episodic tension‐type headache. Cephalalgia1996;16(2):117‐23. [PUBMED: 8665578] ">Dahlöf 1996</a> reported one adverse event withdrawal with paracetamol 1000 mg (tinnitus and indigestion). There were no other adverse event withdrawals in these studies. </p> </section> </section> </section> <section id="CD011889-sec-0127"> <h4 class="title">Paracetamol 1000 mg versus ibuprofen 400 mg</h4> <section id="CD011889-sec-0128"> <h5 class="title">Pain‐free at two hours</h5> <p>Three studies (778 attacks or participants) contributed data for pain‐free at two hours (<a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a>; <a href="./references#CD011889-bbs2-0013" title="Daniels SE (Study investigator). A randomised, double‐blind, placebo‐controlled, double‐dummy, parallel group comparison of commercial ibuprofen (single dose of 400 mg) versus commercial paracetamol (single dose of 1000 mg) in patients with tension type headache. Supplied by Reckitt Benckiser2001. ">NL9701</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>). </p> <p> <ul id="CD011889-list-0025"> <li> <p>The proportion of attacks/participants who were pain‐free at two hours with paracetamol was 33% (125/384; range 8.6% to 56%). </p> </li> <li> <p>The proportion of attacks/participants who were pain‐free at two hours with ibuprofen was 38% (151/394; range 25% to 60%). </p> </li> <li> <p>The RR for paracetamol 1000 mg compared with ibuprofen 400 mg was 0.86 (95% CI 0.71 to 1.03); the NNH was not calculated (<a href="./references#CD011889-fig-0020" title="">Analysis 5.1</a>). </p> </li> </ul> </p> <p>These three studies showed a high degree of variability in response rates, between 9% and 53% for paracetamol 1000 mg, and between 25% and 60% for ibuprofen 400 mg. Placebo response rates in the same studies ranged between 1% and 53%. There was clear statistical heterogeneity between these three studies; the I<sup>2</sup> for this analysis was 85%. There was no obvious clinical heterogeneity, other than the mean age of the participants being 20 years, 30 years, and 40 years, though this factor is unlikely in itself to be the source of any heterogeneity. </p> <p>We downgraded the evidence for this outcome from high to low quality because, although there was a modest number of attacks or participants, there were few studies and events and there was inconsistency in response. </p> </section> <section id="CD011889-sec-0129"> <h5 class="title">Pain‐free at one hour</h5> <p>Two studies contributed data for pain‐free at one hour. In <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a>, 4/45 participants were pain‐free at two hours with paracetamol 1000 mg, and 7/50 with ibuprofen 400 mg, while in <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>, the numbers were 0/151 with paracetamol and 4/153 with ibuprofen (estimated from a graph). There were too few events for sensible analysis. </p> </section> <section id="CD011889-sec-0130"> <h5 class="title">Pain‐free at four hours</h5> <p><a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a> reported that 51/151 participants were pain‐free at four hours with paracetamol 1000 mg, and 96/153 participants with ibuprofen 400 mg. <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a> did not report this outcome and there were insufficient data for analysis. </p> <p>Two studies (683 participants) contributed data for pain‐free at four hours (<a href="./references#CD011889-bbs2-0013" title="Daniels SE (Study investigator). A randomised, double‐blind, placebo‐controlled, double‐dummy, parallel group comparison of commercial ibuprofen (single dose of 400 mg) versus commercial paracetamol (single dose of 1000 mg) in patients with tension type headache. Supplied by Reckitt Benckiser2001. ">NL9701</a>; <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a>). </p> <p> <ul id="CD011889-list-0026"> <li> <p>The proportion of attacks/participants who were pain‐free at four hours with paracetamol was 58% (195/339; range 34% to 77%). </p> </li> <li> <p>The proportion of participants who were pain‐free at two hours with ibuprofen was 69% (238/344; range 63% to 74%). </p> </li> <li> <p>The RR for paracetamol 1000 mg compared with ibuprofen 400 mg was 0.83 (95% CI 0.74 to 0.93); the NNH was 8.6 (5.3 to 22) (<a href="./references#CD011889-fig-0021" title="">Analysis 5.2</a>). </p> </li> </ul> </p> <p>As with the outcome of pain‐free at two hours, there was clear statistical heterogeneity between these studies, with no obvious clinical cause: the I<sup>2</sup> statistic was 96%. We downgraded the evidence for this outcome from high to very low quality because, although there was a modest number of attacks or participants, there were few studies and events and there was inconsistency in response. </p> </section> <section id="CD011889-sec-0131"> <h5 class="title">Pain‐free at 24 hours</h5> <p>No studies reported pain‐free at 24 hours.</p> </section> <section id="CD011889-sec-0132"> <h5 class="title">Pain intensity difference at two hours</h5> <p>No studies reported PID at two hours.</p> </section> <section id="CD011889-sec-0133"> <h5 class="title">Pain‐free or mild pain at two hours</h5> <p>No studies reported pain‐free or mild pain at two hours.</p> </section> <section id="CD011889-sec-0134"> <h5 class="title">Use of rescue medication</h5> <p><a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a> reported a slightly shorter median time to use of rescue medication with paracetamol 1000 mg (130 minutes) than with ibuprofen 400 mg (150 minutes). <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a> did not report any information on use of rescue medication. </p> </section> <section id="CD011889-sec-0135"> <h5 class="title">Adverse events</h5> <section id="CD011889-sec-0136"> <h6 class="title">Any adverse event</h6> <p>Two studies contributed data for any adverse event. <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a> reported 0/45 participants experiencing adverse events with paracetamol 1000 mg, and 4/50 with ibuprofen 400 mg, while <a href="./references#CD011889-bbs2-0019" title="SchachtelBP , FureySA , ThodenWR . Nonprescription ibuprofen and acetaminophen in the treatment of tension‐type headache. Journal of Clinical Pharmacology1996;36(12):1120‐5. [DOI: 10.1002/j.1552‐4604.1996.tb04165.x] ">Schachtel 1996</a> reported no adverse events in 151 participants with paracetamol 1000 mg and 153 participants with ibuprofen 400 mg. There were too few events for sensible analysis. </p> </section> <section id="CD011889-sec-0137"> <h6 class="title">Serious adverse events</h6> <p>Neither study reported serious adverse events.</p> </section> <section id="CD011889-sec-0138"> <h6 class="title">Adverse event withdrawals</h6> <p>There were no adverse event withdrawals during treatment periods in either of the studies. </p> </section> </section> </section> <section id="CD011889-sec-0139"> <h4 class="title">Paracetamol used in combination with other medications</h4> <p>Studies used paracetamol in combination with codeine (<a href="./references#CD011889-bbs2-0003" title="FriedmanAP , DiSerioF . Symptomatic treatment of chronically recurring tension headache: a placebo‐controlled, multicenter investigation of Fioricet® and acetaminophen with codeine. Clinical Therapeutics1987;10(1):69‐81. [PUBMED: 3329967] ">Friedman 1987</a>; <a href="./references#CD011889-bbs2-0004" title="GatoulisSC , VoelkerM , FisherM . Assessment of the efficacy and safety profiles of aspirin and acetaminophen with codeine: results from 2 randomized, controlled trials in individuals with tension‐type headache and postoperative dental pain. Clinical Therapeutics2012;34(1):138‐48. [PUBMED: 22169050] ">Gatoulis 2012</a>), with phenyltoloxamine citrate (Percogesic; <a href="./references#CD011889-bbs2-0005" title="GilbertMM , DeSola PoolN , SchecterC . Analgesic/calmative effects of acetaminophen and phenyltoloxamine in treatment of simple nervous tension accompanied by headache. Current Therapeutic Research, Clinical and Experimental1976;20(1):53‐8. [PUBMED: 821705] ">Gilbert 1976</a>), with peppermint oil (<a href="./references#CD011889-bbs2-0006" title="GöbelH , FreseniusJ , HeinzeA , DworschakM , SoykaD . Effectiveness of oleum menthae piperitae and paracetamol in therapy of headache of the tension type [in German] [Effektivität von oleum menthae piperitae und von Paracetamol in der Therapie des Kopfschmerzes vom Spannungstyp]. Nervenarzt1996;67(8):672‐81. [PUBMED: 8805113] ">Göbel 1996</a>; <a href="./references#CD011889-bbs2-0008" title="GöbelH , HeinzeA , DworschakM , Heinze‐KuhnK , StolzeH . Analgesic efficacy and tolerability of locally applied Oleum menthae piperitae preparation LI 170 in patients with migraine or tension‐type headache [German] [Wirksamkeit und verträglichkeit von oleum‐menthaepiperitae‐lösung LI 170 bei kopfschmerz vom spannungstyp und migräne]. Zeitschrift fur Allgemeinmedizin2001;77(6):287‐295. ">Göbel 2001</a>), with caffeine (<a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a>; <a href="./references#CD011889-bbs2-0012" title="GlaxoSmithKline . A study to assess the efficacy of paracetamol taken in combination with caffeine for the treatment of episodic tension type headache, 2015. www.clinicaltrials.gov/ct2/show/NCT01755702 (accessed 22 December 2015). ">NCT01755702</a>; <a href="./references#CD011889-bbs2-0016" title="PiniLA , DelBeneE , ZanchinG , SarchielliP , DiTrapaniG , PrudenzanoMP , et al. Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension‐type headache: a randomised, double‐blind, double‐dummy, cross‐over study versus placebo and naproxen sodium. Journal of Headache and Pain2008;9(6):367‐73. [PUBMED: 18815727] ">Pini 2008</a>; <a href="./references#CD011889-bbs2-0023" title="WardN , WhitneyC , AveryD , DunnerD . The analgesic effects of caffeine in headache. Pain1991;44(2):151‐5. [DOI: 10.1016/0304‐3959(91)90129‐L] ">Ward 1991</a>), with aspirin and caffeine (<a href="./references#CD011889-bbs2-0010" title="MigliardiJR , ArmellinoJJ , FriedmanM , GillingsDB , BeaverWT . Caffeine as an analgesic adjuvant in tension headache (studies 5 and 6). Clinical Pharmacology &amp; Therapeutics1994;56(5):576‐86. [DOI: 10.1038/clpt.1994.179] ">Migliardi 1994</a>), and as Fiorinal‐Pa (aspirin, caffeine, isobutylallylbarbituric acid, paracetamol; <a href="./references#CD011889-bbs2-0022" title='ThorpeP . Controlled and uncontrolled studies on "Fiorinal‐PA" for symptomatic relief in tension headache. Medical Journal of Australia1970;2(4):180‐1. [PUBMED: 4917129] '>Thorpe 1970</a>). However, none of these studies provided sufficient data to do any analyses. </p> <p><a href="./appendices#CD011889-sec-0163">Appendix 5</a> and <a href="./appendices#CD011889-sec-0164">Appendix 6</a> present results for individual studies. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011889-sec-0140" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011889-sec-0140"></div> <section id="CD011889-sec-0141"> <h3 class="title" id="CD011889-sec-0141">Summary of main results</h3> <p>The primary outcome of this review was pain‐free at two hours using any standard method of pain assessment and without the use of rescue medication, reflecting the updated guidelines for controlled trials of drugs in TTH issued by the IHS (<a href="./references#CD011889-bbs2-0065" title="BendtsenL , BigalME , CerboR , DienerHC , HolroydK , LamplC , et al. on behalf of the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in tension‐type headache: second edition. Cephalalgia2010;30(1):1‐16. [DOI: 10.1111/j.1468‐2982.2009.01948.x] ">IHS 2010</a>). We included 23 studies, with over 8000 participants, of which about 6000 were in comparisons of paracetamol 1000 mg versus placebo. Participants had moderate or severe pain at the start of treatment, and took just one treatment dose per headache episode. </p> <p>The NNT for the outcome pain‐free at two hours for paracetamol 1000 mg compared with placebo was 22 (95% CI 15 to 40) (high quality evidence). There was no significant difference from placebo at the earlier time point of one hour (RR 1.2 (0.90 to 1.5)) (moderate quality evidence). There was a better (lower) NNT for the outcome pain‐free or mild pain at two hours (10 (7.9 to 14); high quality evidence), and also for pain‐free at four hours (8.2 (6.6 to 11); moderate quality evidence). Pain‐free or mild pain at two hours is easier to achieve than pain‐free at two hours, and is an outcome regarded as useful by most people with acute or chronic pain (<a href="./references#CD011889-bbs2-0081" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013</a>), but even this result might be regarded as being on the borderline of what is generally considered clinically useful as few more people attain this outcome with paracetamol than with placebo. There were insufficient data for any analysis of outcomes assessing mean pain intensity differences (PID and SPID), but where information was reported, paracetamol was usually numerically or statistically significantly better than placebo. Overall differences between paracetamol 1000 mg and placebo were not great (between 4/100 and 15/100). There was clearly some small benefit from paracetamol in this condition, but the clinical significance of the benefit was difficult to assess. There is growing evidence of small or absent benefit and growing evidence about risks for paracetamol generally (<a href="./references#CD011889-bbs2-0085" title="MooreRA , MooreN . Paracetamol and pain: the kiloton problem. European Journal of Hospital Pharmacy2016;April. [DOI: 10.1136/ejhpharm‐2016‐000952] ">Moore 2016</a>). </p> <p>Fewer participants used rescue medication with paracetamol 1000 mg than with placebo, giving an NNTp of 7.7 (6.0 to 11) (moderate quality evidence). There was no significant difference in the number of participants who experienced adverse events with paracetamol 1000 mg compared with placebo (high quality evidence). Analysis of gastrointestinal adverse events (moderate quality evidence) and dizziness (low quality evidence) showed no significant differences between paracetamol 1000 mg and placebo (see <a href="./full#CD011889-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Data were combined for analysis for the small number of studies using paracetamol doses between 500 and 650 mg. No significant difference was found between paracetamol 500 mg to 650 mg and placebo for the outcomes of pain‐free or mild pain at two hours, use of rescue medication, or participants with adverse events (low quality evidence). There were insufficient data for analysis for any other outcomes (see <a href="./full#CD011889-tbl-0002">summary of findings Table 2</a>). </p> <p>Direct comparison of paracetamol 1000 mg and 500 mg within studies did not show a significant difference between the doses for pain‐free or mild pain at two hours (low quality evidence), and neither did indirect comparisons with placebo (P value = 0.43). This is not unexpected as a dose‐response curve for paracetamol is known to be difficult to demonstrate in a clinical setting, although it has been done in large data sets (<a href="./references#CD011889-bbs2-0077" title="McQuayHJ , MooreRA . Dose‐response in direct comparisons of different doses of aspirin, ibuprofen and paracetamol (acetaminophen) in analgesic studies. British Journal of Clinical Pharmacology2007;63(3):271‐8. [DOI: 10.1111/j.1365‐2125.2006.02723.x] ">McQuay 2007</a>; <a href="./references#CD011889-bbs2-0084" title="MooreRA , DerryS , AldingtonD , WiffenPJ . Single dose oral analgesics for acute postoperative pain in adults ‐ an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD008659.pub3] ">Moore 2015</a>). </p> <p>A small number of studies included sufficient data to compare paracetamol 1000 mg with the active comparators ketoprofen 25 mg and ibuprofen 400 mg. Based on this very limited information, there was no difference between paracetamol and ketoprofen for the outcome of pain‐free at two hours, or for pain‐free or mild pain at two hours, but fewer participants experienced adverse events with paracetamol than with ketoprofen (NNTp 17(8.9 to 240) (all low quality evidence). Again, based on very limited information, there was no difference between paracetamol and ibuprofen for pain‐free at two hours (low quality evidence), but a statistical difference was found for pain‐free at four hours (very low quality evidence). There were very variable response rates in the three trials comparing these two drugs. There was a broader observation that, at standard doses, ibuprofen is a more effective analgesic than paracetamol in a wide range of conditions (<a href="./references#CD011889-bbs2-0082" title="MooreRA , DerryS , WiffenPJ , StraubeS , AldingtonDJ . Overview review: comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions. European Journal of Pain2014;19(9):1213‐23. [DOI: 10.1002/ejp.649] ">Moore 2014a</a>). There were no data, or insufficient data for sensible analysis, for any other outcomes for these two comparators, or for any other active comparators. </p> </section> <section id="CD011889-sec-0142"> <h3 class="title" id="CD011889-sec-0142">Overall completeness and applicability of evidence</h3> <p>IHS recommendations regarding outcomes of headache trials are well regarded (<a href="./references#CD011889-bbs2-0065" title="BendtsenL , BigalME , CerboR , DienerHC , HolroydK , LamplC , et al. on behalf of the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in tension‐type headache: second edition. Cephalalgia2010;30(1):1‐16. [DOI: 10.1111/j.1468‐2982.2009.01948.x] ">IHS 2010</a>), and often, if not always, followed (<a href="./references#CD011889-bbs2-0033" title="BendtsenL , EversS , LindeM , MitsikostasDD , SandriniG , SchoenenJ . EFNS guideline on the treatment of tension‐type headache ‐ report of an EFNS taskforce. European Journal of Neurology2010;17(11):1318‐25. [DOI: 10.1111/j.1468‐1331.2010.03070.x] ">Bendtsen 2010</a>; <a href="./references#CD011889-bbs2-0083" title="MooreRA , DerryS , WiffenPJ , StraubeS , BendtsenL . Evidence for efficacy of acute treatment of episodic tension‐type headache: methodological critique of randomised trials for oral treatments. Pain2014;155(11):2220‐8. [DOI: 10.1016/j.pain.2014.08.009] ">Moore 2014b</a>). Studies included in this review largely predated those recommendations and were inconsistent in reporting them, which limited the ability to draw useful conclusions about the efficacy of paracetamol, either alone or in combination with other agents, compared with placebo or active comparators. Of the 23 included studies, only 15 reported the IHS preferred outcome of pain‐free rate at two hours (<a href="./references#CD011889-bbs2-0065" title="BendtsenL , BigalME , CerboR , DienerHC , HolroydK , LamplC , et al. on behalf of the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in tension‐type headache: second edition. Cephalalgia2010;30(1):1‐16. [DOI: 10.1111/j.1468‐2982.2009.01948.x] ">IHS 2010</a>). In our results, there was a lower (better) NNT for the secondary outcome of pain‐free at four hours, suggesting the beneficial effects of paracetamol extend beyond this preferred time point, but only four studies contributed data to this analysis, which was dominated by one large cross‐over study, limiting confidence in this result. </p> <p>Although two doses of paracetamol were considered in this review, most of the information was for the higher dose of 1000 mg, which is the standard dose for adult pain relief in most circumstances. More information on different doses, use of paracetamol in combination with another agent, and different formulations, would improve our understanding of the role of paracetamol in TTH. </p> <p>None of the included studies provided information on the mean number of headaches experienced by participants before study entry, although all studies required participants to have frequent episodic TTH. This is defined as anywhere between two and 14 headache days month. We do not know whether the participants in these studies were typically experiencing two to five, or 10 to 14 headaches a month. This might influence the efficacy of treatments tested in these TTH studies, but we do not know because the information was missing. Nor do we know if these results are applicable to people with infrequent episodic TTH (one headache per month or less), which may represent a large proportion of people experiencing this type of headache, who do not consult their doctors or need medical management, but who use simple analgesics for pain relief. </p> <p>The overwhelming majority of participants in the included studies had moderate or severe baseline pain. There is good reason for this in clinical trials, because it gives sensitivity to demonstrate a reduction in pain. However, the pain of TTH is usually described as being of mild to moderate intensity (<a href="./references#CD011889-bbs2-0065" title="BendtsenL , BigalME , CerboR , DienerHC , HolroydK , LamplC , et al. on behalf of the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in tension‐type headache: second edition. Cephalalgia2010;30(1):1‐16. [DOI: 10.1111/j.1468‐2982.2009.01948.x] ">IHS 2010</a>), so the participants in these trials may represent a population with headaches that are more severe and possibly more difficult to treat than is the norm. </p> <p>To understand these important methodological points, analysis of clinical trials at the level of the individual participant is required, using substantial amounts of data. Such an analysis seems unlikely at present, but would probably be highly informative for the development of existing IHS guidance (<a href="./references#CD011889-bbs2-0033" title="BendtsenL , EversS , LindeM , MitsikostasDD , SandriniG , SchoenenJ . EFNS guideline on the treatment of tension‐type headache ‐ report of an EFNS taskforce. European Journal of Neurology2010;17(11):1318‐25. [DOI: 10.1111/j.1468‐1331.2010.03070.x] ">Bendtsen 2010</a>). </p> </section> <section id="CD011889-sec-0143"> <h3 class="title" id="CD011889-sec-0143">Quality of the evidence</h3> <p>The quality of findings ranks from moderate to high for paracetamol 1000 mg compared with placebo, and from very low to low for paracetamol 500 mg to 650 mg compared with placebo, and for paracetamol 1000 mg compared with other active interventions. </p> <p>All included studies were both randomised and double‐blind; none were considered at high risk of bias for study conduct. Inconsistent reporting of outcomes, the small number of studies for the lower dose and for active comparators, and the small size of some studies were the major problems that limited analyses and downgraded our assessments of the quality of the results. For the most part, the direction of results was consistent within analyses. </p> </section> <section id="CD011889-sec-0144"> <h3 class="title" id="CD011889-sec-0144">Potential biases in the review process</h3> <p>Ten of the included studies (four contributed to analyses) were cross‐over studies, and in the absence of first period data we included data from all treatment periods. TTH is a suitable condition to study with cross‐over trials, and washout periods were appropriate for the treatments investigated. While this may introduce unknown biases (<a href="./references#CD011889-bbs2-0045" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. [DOI: 10.1093/ije/31.1.140] ">Elbourne 2002</a>), the data from these studies were consistent with data from others for both beneficial and harmful outcomes. </p> <p>We carried out extensive searches to identify relevant studies, and consulted widely and internationally for an earlier review (<a href="./references#CD011889-bbs2-0083" title="MooreRA , DerryS , WiffenPJ , StraubeS , BendtsenL . Evidence for efficacy of acute treatment of episodic tension‐type headache: methodological critique of randomised trials for oral treatments. Pain2014;155(11):2220‐8. [DOI: 10.1016/j.pain.2014.08.009] ">Moore 2014b</a>). We think it unlikely that there is a substantial number of studies that we have missed or are unpublished, and estimate that even if a similar number of participants existed in studies with no effect, there would still be a small beneficial effect overall for paracetamol 1000 mg relative to placebo. In the circumstance of the limited efficacy from the results of this review, the potential effects of unpublished data with no treatment effect are largely irrelevant. </p> </section> <section id="CD011889-sec-0145"> <h3 class="title" id="CD011889-sec-0145">Agreements and disagreements with other studies or reviews</h3> <p>These results are broadly in agreement with previous reviews that concluded that ibuprofen, paracetamol, and ketoprofen were better than placebo (<a href="./references#CD011889-bbs2-0083" title="MooreRA , DerryS , WiffenPJ , StraubeS , BendtsenL . Evidence for efficacy of acute treatment of episodic tension‐type headache: methodological critique of randomised trials for oral treatments. Pain2014;155(11):2220‐8. [DOI: 10.1016/j.pain.2014.08.009] ">Moore 2014b</a>; <a href="./references#CD011889-bbs2-0103" title="VerhagenAP , DamenL , BergerMY , PasschierJ , MerlinV , KoesBW . Is any one analgesic superior for episodic tension‐type headache?. Journal of Family Practice2006;55(12):1064‐72. [PUBMED: 17137543] ">Verhagen 2006</a>), as well as the guideline from the EFNS, which recommends ibuprofen as drug of choice among NSAIDs or paracetamol or aspirin for acute treatment of TTH (<a href="./references#CD011889-bbs2-0033" title="BendtsenL , EversS , LindeM , MitsikostasDD , SandriniG , SchoenenJ . EFNS guideline on the treatment of tension‐type headache ‐ report of an EFNS taskforce. European Journal of Neurology2010;17(11):1318‐25. [DOI: 10.1111/j.1468‐1331.2010.03070.x] ">Bendtsen 2010</a>). That guideline was not based on a systematic review. The German evidence‐based recommendations for self medication of migraine and TTH were based on systematic reviews (<a href="./references#CD011889-bbs2-0057" title="HaagG , DienerHC , MayA , MeyerC , MorckH , StraubeA , et al. Self‐medication of migraine and tension‐type headache: summary of the evidence‐based recommendations of the Deutsche Migräne und Kopfschmerzgesellschaft (DMKG), the Deutsche Gesellschaft für Neurologie (DGN), the Österreichische Kopfschmerzgesellschaft (ÖKSG) and the Schweizerische Kopfwehgesellschaft (SKG). Journal of Headache and Pain2011;12(2):201‐17. [DOI: 10.1007/s10194‐010‐0266‐4] ">Haag 2011</a>), and included only seven studies that recruited at least some people with TTH. For self medication of TTH, it recommended paracetamol in combination with other analgesics or caffeine, but not paracetamol alone. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011889-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011889-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/full#CD011889-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011889-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/full#CD011889-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Paracetamol 1000 mg versus placebo, outcome: 1.1 Pain‐free at 2 hours." data-id="CD011889-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Paracetamol 1000 mg versus placebo, outcome: 1.1 Pain‐free at 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/full#CD011889-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Paracetamol 1000 mg versus placebo, outcome: 1.4 Pain‐free or mild pain at 2 hours." data-id="CD011889-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Paracetamol 1000 mg versus placebo, outcome: 1.4 Pain‐free or mild pain at 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/full#CD011889-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 1 Pain‐free at 2 hours." data-id="CD011889-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 1 Pain‐free at 2 hours.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 2 Pain‐free at 1 hour." data-id="CD011889-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 2 Pain‐free at 1 hour.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 3 Pain‐free at 4 hours." data-id="CD011889-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 3 Pain‐free at 4 hours.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 4 Pain‐free or mild pain at 2 hours." data-id="CD011889-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 4 Pain‐free or mild pain at 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 5 Use of rescue medication." data-id="CD011889-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 5 Use of rescue medication.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 6 Any adverse event." data-id="CD011889-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 6 Any adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 7 Gastrointestinal adverse events." data-id="CD011889-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 7 Gastrointestinal adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 8 Dizziness adverse events." data-id="CD011889-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Paracetamol 1000 mg versus placebo, Outcome 8 Dizziness adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Paracetamol 500 mg to 650 mg versus placebo, Outcome 1 Pain‐free or mild pain at 2 hours." data-id="CD011889-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Paracetamol 500 mg to 650 mg versus placebo, Outcome 1 Pain‐free or mild pain at 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Paracetamol 500 mg to 650 mg versus placebo, Outcome 2 Use of rescue medication." data-id="CD011889-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Paracetamol 500 mg to 650 mg versus placebo, Outcome 2 Use of rescue medication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Paracetamol 500 mg to 650 mg versus placebo, Outcome 3 Any adverse event." data-id="CD011889-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Paracetamol 500 mg to 650 mg versus placebo, Outcome 3 Any adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Paracetamol 1000 mg versus paracetamol 500 mg, Outcome 1 Pain‐free or mild pain at 2 hours." data-id="CD011889-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Paracetamol 1000 mg versus paracetamol 500 mg, Outcome 1 Pain‐free or mild pain at 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Paracetamol 1000 mg versus ketoprofen 25 mg, Outcome 1 Pain‐free at 2 hours." data-id="CD011889-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Paracetamol 1000 mg versus ketoprofen 25 mg, Outcome 1 Pain‐free at 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Paracetamol 1000 mg versus ketoprofen 25 mg, Outcome 2 Pain‐free or mild pain at 2 hours." data-id="CD011889-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Paracetamol 1000 mg versus ketoprofen 25 mg, Outcome 2 Pain‐free or mild pain at 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Paracetamol 1000 mg versus ketoprofen 25 mg, Outcome 3 Adverse events." data-id="CD011889-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Paracetamol 1000 mg versus ketoprofen 25 mg, Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Paracetamol 1000 mg versus ibuprofen 400 mg, Outcome 1 Pain‐free at 2 hours." data-id="CD011889-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Paracetamol 1000 mg versus ibuprofen 400 mg, Outcome 1 Pain‐free at 2 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011889-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/urn:x-wiley:14651858:media:CD011889:CD011889-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_t/tCD011889-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Paracetamol 1000 mg versus ibuprofen 400 mg, Outcome 2 Pain‐free at 4 hours." data-id="CD011889-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Paracetamol 1000 mg versus ibuprofen 400 mg, Outcome 2 Pain‐free at 4 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/media/CDSR/CD011889/image_n/nCD011889-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011889-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Paracetamol 1000 mg compared with placebo for episodic tension‐type headache</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Paracetamol 1000 mg compared with placebo for episodic tension‐type headache</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with episodic tension‐type headache </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> paracetamol 1000 mg </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> comparator</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> intervention</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>RR<br/> (95% CI)</b> </p> <p><b>NNT or NNH (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No. of studies, attacks, events</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain‐free at 2 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>240 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.3 (1.1 to 1.4)</p> <p>NNT 22 (15 to 40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 studies</p> <p>5890 attacks</p> <p>1285 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and events</p> <p>Consistent direction of results</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain‐free at 1 hour</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.2 (0.90 to 1.5)</p> <p>NNT not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>4717 attacks</p> <p>269 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because few studies reported, and modest number of events</p> <p>Some inconsistency in direction of response</p> <p>Dominated by 1 study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain‐free at 4 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>440 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>560 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.2 (1.16 to 1.3)</p> <p>NNT 8.2 (6.6 to 11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies</p> <p>4909 attacks</p> <p>2577 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because few studies reported, but large number of events, tight CIs</p> <p>Consistent direction of results</p> <p>Dominated by 1 study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of rescue medication</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>170 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.58 (0.50 to 0.69)</p> <p>NNTp 7.7 (6.0 to 11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 studies</p> <p>1856 attacks</p> <p>422 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because few studies reported, and modest number of events</p> <p>Consistent direction of results</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain‐free or mild pain at 2 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>490 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>590 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.2 (1.15 to 1.3)</p> <p>NNT 10 (7.9 to 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 studies</p> <p>5238 attacks</p> <p>2910 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Few studies reported, but large number of events, tight CIs</p> <p>1 small study showed different direction of response</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse event</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.1 (0.94 to 1.3)</p> <p>NNH not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 studies</p> <p>5605 attacks</p> <p>528 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and events</p> <p>Consistent direction of results (no effect)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 studies, estimated 5147 participants in comparisons</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because no events reported in 5147 comparisons</p> <p>Rate of serious adverse events unlikely to be &gt; 1 in 1700 (<a href="./references#CD011889-bbs2-0046" title="EypaschE , LeferingR , KumCK , TroidlH . Probability of adverse events that have not yet occurred: a statistical reminder. BMJ1995;311(7005):619‐20. [DOI: 10.1136/bmj.311.7005.619] ">Eypasch 1995</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>NNTH:</b> number needed to treat for one additional harmful outcome; <b>NNT:</b> number needed to treat for one additional beneficial outcome; <b>NNTp:</b> number needed to treat to prevent one harmful outcome; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Paracetamol 1000 mg compared with placebo for episodic tension‐type headache</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/full#CD011889-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011889-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Paracetamol 500 mg to 650 mg compared with placebo for episodic tension‐type headache</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Paracetamol 500 mg to 650 mg compared with placebo for episodic tension‐type headache</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with episodic tension‐type headache </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> paracetamol 500 mg to 650 mg </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> comparator</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> intervention</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>RR<br/> (95% CI)</b> </p> <p><b>NNT or NNH (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No. of studies, attacks, events</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain‐free at 2 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain‐free at 1 hour</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain‐free at 4 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of rescue medication</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.76 (0.55 to 1.1)</p> <p>NNTp not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>301 attacks</p> <p>99 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Few studies and events</p> <p>Consistent direction of results (no effect)</p> <p>1 study had high attrition</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain‐free or mild pain at 2 hours</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>530 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>590 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.1 (0.90 to 1.4)</p> <p>NNT not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>275 attacks</p> <p>154 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Few studies and events</p> <p>Consistent direction of results (no effect)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse event</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 in 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>140 in 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.3 (0.71 to 2.5)</p> <p>NNH not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies</p> <p>301 attacks</p> <p>38 events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Few studies and events</p> <p>Consistent direction of results (no effect)</p> <p>1 study had high attrition</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 studies</p> <p>estimated 463 participants in comparisons</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 events reported in only 463 comparisons</p> <p>Rate of serious adverse events unlikely to be &gt; 1 in 155 (<a href="./references#CD011889-bbs2-0046" title="EypaschE , LeferingR , KumCK , TroidlH . Probability of adverse events that have not yet occurred: a statistical reminder. BMJ1995;311(7005):619‐20. [DOI: 10.1136/bmj.311.7005.619] ">Eypasch 1995</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>NNH:</b> number needed to treat for one additional harmful outcome; <b>NNT:</b> number needed to treat for one additional beneficial outcome; <b>NNTp:</b> number needed to treat to prevent one harmful outcome; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Paracetamol 500 mg to 650 mg compared with placebo for episodic tension‐type headache</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/full#CD011889-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011889-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Paracetamol 1000 mg versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain‐free at 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [1.14, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pain‐free at 1 hour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.90, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Pain‐free at 4 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.16, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Pain‐free or mild pain at 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.15, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Use of rescue medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.50, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.94, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Gastrointestinal adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.86, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Dizziness adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.83, 2.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Paracetamol 1000 mg versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011889-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Paracetamol 500 mg to 650 mg versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain‐free or mild pain at 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.90, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Use of rescue medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.55, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.71, 2.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Paracetamol 500 mg to 650 mg versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011889-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Paracetamol 1000 mg versus paracetamol 500 mg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain‐free or mild pain at 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.90, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Paracetamol 1000 mg versus paracetamol 500 mg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011889-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Paracetamol 1000 mg versus ketoprofen 25 mg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain‐free at 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.49, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pain‐free or mild pain at 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.72, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.39, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Paracetamol 1000 mg versus ketoprofen 25 mg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011889-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Paracetamol 1000 mg versus ibuprofen 400 mg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain‐free at 2 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>778</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.71, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pain‐free at 4 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.74, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Paracetamol 1000 mg versus ibuprofen 400 mg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011889.pub2/references#CD011889-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011889.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011889-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011889-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011889-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011889-note-0008">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011889-note-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD011889-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD011889-note-0004">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD011889-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011889-note-0002">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011889-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011889\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011889\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011889\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011889\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011889\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011889\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011889\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011889\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011889\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011889\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011889\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011889\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011889\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011889\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011889\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011889\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011889\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011889\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011889.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011889.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011889.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011889.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011889.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715225121"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011889.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715225125"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011889.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d81e17a51f446',t:'MTc0MDcxNTIyNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 